CN109563491B - 新颖的副粘病毒及其用途 - Google Patents

新颖的副粘病毒及其用途 Download PDF

Info

Publication number
CN109563491B
CN109563491B CN201780050005.7A CN201780050005A CN109563491B CN 109563491 B CN109563491 B CN 109563491B CN 201780050005 A CN201780050005 A CN 201780050005A CN 109563491 B CN109563491 B CN 109563491B
Authority
CN
China
Prior art keywords
leu
ile
ser
asn
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780050005.7A
Other languages
English (en)
Other versions
CN109563491A (zh
Inventor
T·W·瓦伦坎普
M·西格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH filed Critical Boehringer Ingelheim Vetmedica GmbH
Publication of CN109563491A publication Critical patent/CN109563491A/zh
Application granted granted Critical
Publication of CN109563491B publication Critical patent/CN109563491B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/115Paramyxoviridae, e.g. parainfluenza virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027Paramyxoviridae, e.g. respiratory syncytial virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/115Paramyxoviridae, e.g. parainfluenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

本发明是关于一种新颖的猫副粘病毒。本发明的副粘病毒是(‑)ssRNA病毒且在一个方面中具有与根据SEQ ID NO:1或SEQ ID NO:8的核酸互补的基因组。本发明进一步关于对应核酸及多肽、抗体及疫苗。此外,本发明是关于与本发明副粘病毒相关的医学用途及诊断方法。

Description

新颖的副粘病毒及其用途
技术领域
本发明是关于一种新颖的猫副粘病毒及针对该新颖的副粘病毒的疫苗及治疗。本发明进一步关于该副粘病毒的检测及感染该副粘病毒的诊断。
背景技术
副粘病毒是已与人类及动物的多种传染病关联的包膜的反义单链RNA((-)ssRNA)病毒。存在两个副粘病毒亚科-副粘病毒亚科及肺病毒亚科,且亚科副粘病毒亚科内存在至少五个属,亦即呼吸道病毒属(Respirovirus)、腮腺炎病毒属(Rubulavirus)、麻疹病毒属(Morbillivirus)、亨尼帕病毒属(Henipavirus)及禽腮腺炎病毒属(Avulavirus)。副粘病毒的实施例包括犬瘟热病毒、麻疹病毒、牛瘟病毒、腮腺炎病毒及人类副流行性感冒病毒。副粘病毒具有编码7种病毒多肽的线性基因组:核衣壳蛋白、磷蛋白、基质蛋白、融合蛋白、血细胞凝集素蛋白及聚合酶。副粘病毒的病毒粒子经包膜包覆且可为球形、丝状或多形,直径为约150nm。融合蛋白及附着蛋白质(血细胞凝集素,“H”)呈尖峰呈现在病毒粒子表面。包膜内部的基质蛋白(“M”)稳定病毒结构。核衣壳核心由基因组RNA、核衣壳蛋白(“N”)、磷蛋白(“P”)及聚合酶蛋白质(“大蛋白质”的“L”)组成。融合蛋白(“F”)呈三聚体自包膜表面突起,且由诱导病毒包膜与细胞膜之间的融合来介导细胞进入。
已从例如包括猫、啮齿动物及蝙蝠的野生动物及家畜以及人类分离副粘病毒。副粘病毒感染,尤其副粘病毒亚科的副粘病毒感染已由于不同物种中所展示的肾脏组织损伤而与肾脏病相关联。例如肾脏病,尤其慢性肾脏病(CKD)是最常见疾病且是家猫、尤其年老个体死亡的最常见病因之一。Lulich等人(Compendium on continuing education forthe practicing veterinarian(1992)14(2):127-125)报导总家猫群体中慢性肾脏病的发病率为约1.5%且年龄超过10年的家猫的慢性肾脏病的发病率为约7.5%。此等疾病的病因可极其不同。在许多情况下,无法确定确切病因。另一方面,已知慢性肾脏病最常由于肾小管及肾脏间质组织发炎而发生。此称作特发性肾小管间质性肾炎(TIN)。
本领域中已描述若干猫副粘病毒。US2013/0230529 A1及Woo等人(Proc.Nat.Acad.Sci.(2012)109(14):5435-5440)描述一种在中国香港分离的猫麻疹病毒(FmoPV),其与家猫的TIN相关联。来自日本(Sakaguchi等人(2014)General Virology,95(7),1464-1468;Furuya等人(2014)Archives of virology,159(2),371-373)、意大利(Lorusso等人(2013)Vet Ital.51(3):235-237)及美国(Sharp等人(2016)EmergingInfectious Diseases 22(4):760)的其他研究小组亦在猫的尿样品中检测到副粘病毒。Sieg等人(Virus Genes(2015)51(2):294-297)描述在患有慢性肾脏病的家猫体内发现猫副粘病毒。
然而,此等副粘病毒在基因上不同且需要鉴别相关副粘病毒且提供对抗该等副粘病毒的疫苗及治疗。
发明内容
本发明提供一种称为猫副粘病毒-2型(FPaV-2)的新颖猫副粘病毒。本发明的副粘病毒是(-)ssRNA病毒且在一个方面中具有与根据SEQ ID NO:1或SEQ ID NO:8的核酸互补的基因组。此两个序列表示由本发明者分离的FPaV-2的两个病毒株,“Gordon”病毒株(SEQID NO:1)及病毒株“TV25”(SEQ ID NO:8)的基因组的互补DNA序列。SEQ ID NO:1及SEQ IDNO:8以对应于负RNA链病毒基因组所转录的正RNA链的DNA序列给出,亦即该等序列如mRNA一般在5'至3'方向上包含ORF。本领域技术人员清楚本发明的副粘病毒的病毒基因组是(-)ssRNA基因组。因此,在一个方面中,本发明亦关于根据SEQ ID NO:1或SEQ ID NO:8或与SEQID NO:1或SEQ ID NO:8至少80%、至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%、至少99%相同的序列的核酸。SEQ IDNO:1或SEQ ID NO:8的核酸序列包含副粘病毒的六个病毒多肽的六个开放阅读框架(ORF)。SEQ ID NO:1或SEQ ID NO:8的核酸上的组件的序列为(自5'至3'):病毒基因组的3'非翻译区(UTR)、核衣壳蛋白(“N”)ORF、磷蛋白(“P”)ORF、基质蛋白(“M”)ORF、融合蛋白(“F”)ORF、血细胞凝集素(“H”)ORF、RNA依赖性RNA聚合酶(“L”用于“大蛋白质”)ORF、5'UTR。下表1描述SEQ ID NO:1及SEQ ID NO:8的核酸结构:
表1:根据本发明的副粘病毒的基因组的概述
SEQ ID NO:2至SEQ ID NO:7表示SEQ ID NO:1的开放阅读框架的多肽序列(Gordon病毒株)且SEQ ID NO:9至SEQ ID NO:14表示SEQ ID NO:8的开放阅读框架的多肽序列(病毒株TV25)。
因此在一个方面中,本发明是关于一种包含多核苷酸的核酸,该多核苷酸具有选自由以下组成的群的核苷酸序列:
(a)根据SEQ ID NO:1或SEQ ID NO:8的核苷酸序列;
(b)与SEQ ID NO:1或SEQ ID NO:8至少80%、至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%、至少99%相同的核苷酸序列;
(c)编码具有选自由以下组成的群的氨基酸序列的多肽的核苷酸序列:SEQ IDNO:2、SEQ ID NO:9(亦即核衣壳蛋白)、SEQ ID NO:3、SEQ ID NO:10(亦即磷蛋白)、SEQ IDNO:4、SEQ ID NO:11(亦即基质蛋白)、SEQ ID NO:5、SEQ ID NO:12(亦即融合蛋白)、SEQ IDNO:6、SEQ ID NO:13(亦即血细胞凝集素)、SEQ ID NO:7及SEQ ID NO:14(亦即聚合酶);
(d)编码具有如下氨基酸序列的多肽的核苷酸序列,该氨基酸序列是:
(i)与SEQ ID NO:2至少90%,优选至少95%,更优选至少98%相同,
(ii)与SEQ ID NO:3至少76%,优选至少80%,更优选至少90%,更优选至少95%且最优选至少98%相同,
(iii)与SEQ ID NO:4至少92%,优选至少95%,更优选至少98%相同,
(iv)与SEQ ID NO:5至少89%,优选至少90%,更优选至少95%,更优选至少98%相同,
(v)与SEQ ID NO:6至少86%,优选至少90%,更优选至少95%,最优选至少98%相同,及/或
(vi)与SEQ ID NO:7至少91%,优选至少95%,更优选至少98%相同;以及
(e)(a)至(d)的核苷酸序列中的任一者的互补链。
本发明的核酸编码猫副粘病毒的基因组。在一个实施方式中,该副粘病毒能够诱发人类或非人类哺乳动物,优选猫科动物、犬科动物、啮齿动物或人类,最优选家猫(家猫(Felis silvestris catus)有时亦称为家猫(Felis catus))的感染,尤其泌尿生殖系统感染,更尤其泌尿系统感染;或肾病,尤其慢性肾病。SEQ ID NO:2至SEQ ID NO:7是关于SEQID NO:1中的六个开放阅读框架(ORF)的多肽基因产物。SEQ ID NO:9至SEQ ID NO:14是关于SEQ ID NO:8中的六个开放阅读框架(ORF)的多肽基因产物。因此,由第(d)(i)项的核酸编码的多肽为病毒核衣壳蛋白,由第(d)(ii)项的核酸编码的多肽为病毒磷蛋白,由第(d)(iii)项的核酸编码的多肽为病毒基质蛋白,由第(d)(iv)项的核酸编码的多肽为病毒融合蛋白,由第(d)(v)项的核酸编码的多肽为病毒血细胞凝集素,且由第(d)(vi)项的核酸编码的多肽为病毒聚合酶。
在本文中,本发明的核酸优选包含
(i)编码具有与SEQ ID NO:2至少90%相同的氨基酸序列的多肽的核酸序列,
(ii)编码具有与SEQ ID NO:3至少76%相同的氨基酸序列的多肽的核酸序列,
(iii)编码具有与SEQ ID NO:4至少92%相同的氨基酸序列的多肽的核酸序列,
(vi)编码具有与SEQ ID NO:5至少89%相同的氨基酸序列的多肽的核酸序列,
(v)编码具有与SEQ ID NO:6至少86%相同的氨基酸序列的多肽的核酸序列,及/或
(vi)编码具有与SEQ ID NO:7至少91%相同的氨基酸序列的多肽的核酸序列。
此外,本发明的部分是具有如下氨基酸序列的多肽,该氨基酸:
(a)选自由以下氨基酸序列组成的群:SEQ ID NO:2、SEQ ID NO:3、SEQ ID NO:4、SEQ ID NO:5、SEQ ID NO:6、SEQ ID NO:7、SEQ ID NO:9、SEQ ID NO:10、SEQ ID NO:11、SEQID NO:12、SEQ ID NO:13及SEQ ID NO:14;或
(b)与SEQ ID NO:2至少90%,优选至少95%,更优选至少97%,最优选至少98%相同的氨基酸序列,
(c)与SEQ ID NO:3至少76%,优选至少80%,更优选至少85%,更优选至少90%,更优选至少95%,更优选至少97%,最优选至少98%相同的氨基酸序列,
(d)与SEQ ID NO:4至少92%,优选至少95%,更优选至少97%,最优选至少98%相同的氨基酸序列,
(e)与SEQ ID NO:5至少89%,优选至少90%,更优选至少95%,更优选至少97%,最优选至少98%相同的氨基酸序列,
(f)与SEQ ID NO:6至少86%,优选至少90%,更优选至少95%,更优选至少97%,最优选至少98%相同的氨基酸序列,或
(g)与SEQ ID NO:7至少91%,优选至少95%,更优选至少97%,最优选至少98%相同的氨基酸序列。
在一些实施方式中,多肽可包含诸如糖基化的一或多个翻译后修饰。
本发明亦关于一种猫副粘病毒,该猫副粘病毒的基因组包含与如上所陈述的本发明的核酸互补的核糖核酸。详言的,本发明是关于已在2016年8月16日以保藏编号CNCM I-5123保藏于法国国家微生物培养物保藏中心(Collection Nationalede Cultures deMicroorganismes,CNCM)(Institut Pasteur,25Rue du Docteur Roux,F-75724ParisCedex 15,France)的副粘病毒。此病毒株在本文中称为“Gordon”病毒株。本发明进一步关于保藏为CNCM I-5123的副粘病毒的任何后代,其中该后代可减毒或未减毒。因此,本发明的副粘病毒可选自由以下组成的群:保藏为CNCM I-5123的副粘病毒、保藏为CNCM I-5123的副粘病毒的后代、保藏为CNCM I-5123的副粘病毒的减毒后代及具有与保藏为CNCM I-5123的副粘病毒相同特征的副粘病毒株。
本发明的副粘病毒优选包含具有如下氨基酸序列的一或多个多肽,该氨基酸序列:
(a)选自由以下氨基酸序列组成的群:SEQ ID NO:2、SEQ ID NO:3、SEQ ID NO:4、SEQ ID NO:5、SEQ ID NO:6、SEQ ID NO:7、SEQ ID NO:9、SEQ ID NO:10、SEQ ID NO:11、SEQID NO:12、SEQ ID NO:13及SEQ ID NO:14;或
(b)与SEQ ID NO:2至少90%,优选至少95%,更优选至少97%,最优选至少98%相同的氨基酸序列,
(c)与SEQ ID NO:3至少76%,优选至少80%,更优选至少85%,更优选至少90%,更优选至少95%,更优选至少97%,最优选至少98%相同的氨基酸序列,
(d)与SEQ ID NO:4至少92%,优选至少95%,更优选至少97%,最优选至少98%相同的氨基酸序列,
(e)与SEQ ID NO:5至少89%,优选至少90%,更优选至少95%,更优选至少97%,最优选至少98%相同的氨基酸序列,
(f)与SEQ ID NO:6至少86%,优选至少90%,更优选至少95%,更优选至少97%,最优选至少98%相同的氨基酸序列,及/或
(g)与SEQ ID NO:7至少91%,优选至少95%,更优选至少97%,最优选至少98%相同的氨基酸序列。
优选地,本发明的副粘病毒包含SEQ ID NO:2、SEQ ID NO:3、SEQ ID NO:4、SEQ IDNO:5、SEQ ID NO:6及SEQ ID NO:7的多肽,或SEQ ID NO:9、SEQ ID NO:10、SEQ ID NO:11、SEQ ID NO:12、SEQ ID NO:13及SEQ ID NO:14的多肽,或第(b)项至第(g)项的所有多肽。
根据本发明,与核酸序列或氨基酸序列有关的术语“与……至少%相同”描述相比于构成整个序列长度(或其整个比较部分)的残基数目,两个或超过两个比对序列的相同核酸或氨基酸的匹配(“命中”)数目。换言,当在比较窗上或在如使用本领域已知的序列比较算法所量测的指定区上比较及比对(子)序列以获得最大相同性时,或当人工比对及目测时,针对两个或超过两个序列或子序列,使用比对,可确定相同残基的百分比(例如至少84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%相同性)。
本领域中熟知如何使用例如算法,诸如基于CLUSTALW计算机程序(ThompsonNucl.Acids Res.2(1994),4673-4680)或FASTA(Pearson及Lipman,Proc.Natl.Acad.Sci.,1988,85;2444)的彼等算法确定序列之间/当中的序列相同性百分比。尽管FASTA算法在其计算时通常不考虑序列中的内部非匹配缺失或添加,亦即间隙,但此可经人工校正以避免过高估计序列相同性%。然而,CLUSTALW在其相同性计算时未将序列间隙考虑在内。本领域技术人员亦可使用BLAST及BLAST 2.0算法(Altschul,Nucl.Acids Res.,25(1977),3389)。对于核酸序列,BLASTN程序使用以下作为默认值:字长(W)为11,期望值(E)为10,M=5,N=4及比较两个链。对于氨基酸序列,BLASTN程序使用以下作为默认值:字长(W)为3,且期望值(E)为10。BLOSUM62计分矩阵(Henikoff,Proc.Natl.Acad.Sci.,89(1989),10915)使用50的比对值(B),10的期望值(E),M=5,N=4及比较两个链。所有彼等程序均可用于达成本发明的目的。然而,优选使用BLAST程序。因此,具有规定功能且进一步如用上述程序中的任一者或本领域技术人员可使用的其他程序及优选用BLAST程序确定,具有至少84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列相同性的所有核酸分子或氨基酸序列均属于本发明的范畴。
在一个方面中,该副粘病毒能够诱发个体,优选哺乳动物,更优选猫,甚至更优选家猫(Felis silvestris catus)的感染,尤其泌尿生殖系统感染,更尤其泌尿系统感染;或肾病/肾脏病,尤其人类或非人类哺乳动物的慢性肾病,最优选肾小管间质性肾炎(TIN)。
然而,本发明的副粘病毒相对于已在2016年8月16日以保藏编号CNCM I-5123保藏于法国国家微生物培养物保藏中心(CNCM)(Institut Pasteur,25Rue du Docteur Roux,F-75724Paris Cedex 15,France)的副粘病毒亦可减毒,例如以用于免疫原性组合物或疫苗。
用于将本发明的副粘病毒减毒的方法为本领域技术人员所知。将病毒减毒的传统方法可例如包含在胚胎鸡蛋及鸡胚胎及/或鸡胚胎细胞培养物中使临床上分离的病毒连续传代(例如参见Buynak等人(1966),Experimental Biology and Medicine,123(3),768-775)或野生型病毒对外来物种细胞株的适应及连续传代以降低毒力及致病性(例如参见Enders等人(1960),New England Journal of Medicine,263(4),153-159)。更新近的方法例如是基于由对野生型病毒的密码子对偏好进行工程改造来限制毒力(例如参见Coleman等人(2008),Science,320(5884),1784-1787)或由负责毒力及致病性的一些病毒蛋白的缺失对临床上分离的病毒株进行基因修饰(例如参见Xu等人(2014)Journal of virology,88(5),2600-2610)。
因此,本发明进一步关于根据本发明的核酸分子(尤其根据SEQ ID NO:1或SEQ IDNO:8的核酸或与SEQ ID NO:1或SEQ ID NO:8至少80%相同的核酸)用于产生减毒猫副粘病毒的用途,其中将一或多个突变引入至该核酸分子中。因此,本发明亦提供一种产生减毒猫副粘病毒的方法,该方法包含以下步骤:将一或多个突变引入至根据本发明的核酸分子中,尤其引入至根据SEQ ID NO:1或SEQ ID NO:8的核酸或与SEQ ID NO:1或SEQ ID NO:8至少80%相同的核酸。
如本文所述的术语“减毒”副粘病毒尤其是针对在活体外及/或活体内减毒,尤其在易感细胞株及/或宿主内减毒的副粘病毒。
如本文中所提及,“减毒”尤其是指病原体、尤其副粘病毒的毒力降低,其中“毒力”理解为致病程度,且其中“致病性”是针对病原体诱发宿主或宿主后代的临床征象的能力。感染本发明的副粘病毒的可能临床征象包含例如个体口渴增加、排尿增多、体重减轻、食欲下降、嗜睡及呕吐。与个体感染本发明的副粘病毒相关联的可能实验室发现包含例如肌酸酐及对称性二甲基精氨酸(SDMA)含量增加。与个体感染本发明的副粘病毒相关联的可能组织学发现包含例如由于主要淋巴细胞、浆细胞、巨噬细胞及粒细胞的浸润而引起的皮层及髓质瘢痕形成、肾小管退化、间质发炎。
如本文所用的术语“宿主”尤其是针对感染本发明的猫副粘病毒的哺乳动物,尤其如下所定义的个体,优选猫,更优选家猫。
在本发明的情形下,术语“个体(subject)”(例如易感染本发明的副粘病毒或用本发明的疫苗治疗或在本发明的情形下经诊断的个体)是动物,优选哺乳动物,尤其选自由以下组成的群的哺乳动物:食肉目(优选)、啮齿目、翼手目及灵长目的成员,更优选猫科、犬科、仓鼠科、鼠科或人科的成员。优选地,个体是猫科成员,尤其猫属(其在本文中优选)、大山猫属、豹属、云豹属、波斯野猫属、美洲豹猫属、美洲狮属、猎豹属、豹猫属及兔狲属的成员。犬科包括例如犬属及狐属,例如灰狼,优选家犬(Canis lupus familiaris)(家犬(domestic dog))。然而,本发明不限于此等物种、目及科。
猫属包括例如野猫物种,例如欧洲野猫(Felis silvestris silvestris)(欧洲野猫(European wildcat))、街猫,优选家猫(Felis silvestris catus)(亦称为家猫(Feliscatus),亦即家猫(domestic cat))、丛林猫(Felis chaus)、黑足猫(Felis nigripes)、沙漠猫(Felis margarita)及荒漠猫(Felis bieti)。
豹属例如包括虎(Tiger)(虎(Panthera tigris))、狮(Lion)(狮(Pantheraleo))、美洲豹(Jaguar)(美洲豹(Panthera onca))、豹(Leopard)(豹(Panthera pardus))、雪豹(Snow leopard)(雪豹(Panthera uncial))及狮虎。
其他猫科动物包括但不限于猞猁(Lynx lynx)、短尾猫(Lynx rufus)、猎豹(Acinonyx jubatus)(猎豹(Cheetah))、美洲山狮(Puma concolor)(美洲山狮(Cougar))、美洲豹猫(Leopardus pardalis)(美洲豹猫(Ocelot))。
人科的哺乳动物包括婆罗洲猩猩(Bornean orangutan)(婆罗洲猩猩(Pongopygmaeus))、苏门答腊猩猩(Sumatran orangutan)(苏门答腊猩猩(Pongo abelii))、大猩猩(Gorilla gorilla)、黑猩猩(Chimpanzee)(黑猩猩(Pan troglodytes))、倭黑猩猩(Bonobo)(倭黑猩猩(Pan paniscus))及现代人(Homo sapiens sapiens)(人(human))。
翼手目(蝙蝠)包括大蝙蝠亚目(狐蝠科)及小蝙蝠亚目(微型蝙蝠)。
哺乳动物亦可为典型宠物物种,例如天竺鼠(guinea pig)(天竺鼠(Caviaporcellus))、家兔(domestic rabbit)(家兔(Oryctolagus cuniculus))、小家鼠(fancymouse)(小家鼠(Mus musculus))、褐家鼠(fancy rat)(褐家鼠(Rattus norvegicus))、雪貂(ferret)(雪貂(Mustela putorius furo))或叙利亚仓鼠(Syrian hamster)(金仓鼠(Mesocricetus auratus))。哺乳动物宠物及动物园动物在本文中是优选。哺乳动物优选是猫科动物、犬科动物、啮齿动物、人类或蝙蝠,更优选猫科动物(“猫”),最优选家猫。
本发明进一步提供一种包含根据本发明的核酸分子的DNA构建体,其中该DNA构建体尤其为诸如质粒的DNA载体。本领域技术人员将认识本发明的核苷酸分子可插入其中的DNA载体或质粒。如本文所述的DNA构建体优选为分离的DNA构建体。如本文所用,分别地,术语“包含核酸分子”或“包含DNA分子”尤其理解为分别等效于术语“包含核酸分子的序列”或“包含DNA分子的序列”。因此,本发明亦关于一种包含该本发明的核酸的载体及一种包含该载体的宿主细胞。
此外,本发明提供一种本文所述的DNA构建体的RNA转录物,其中该RNA转录物优选是分离的RNA转录物。本发明亦提供一种经本文所述的DNA构建体转染的细胞,其中该细胞优选是分离的细胞。因此,本发明亦提供一种由前述细胞产生的猫副粘病毒,其中该猫副粘病毒优选是分离的猫副粘病毒。此外,本发明提供一种经本文中提及的RNA转录物转染的细胞,其中该细胞优选是分离的细胞。因此,本发明亦提供一种由前述细胞产生的猫副粘病毒,其中该猫副粘病毒优选是分离的猫副粘病毒。其中可产生本发明的副粘病毒或本发明的多肽的宿主细胞包括但不限于选自HEK293、HEK293T、Vero、CrFK、LLC-MK2、BHK21、CHO、BSR-T7/5、MA-104及HELA细胞的细胞。
本发明进一步提供一种基因组包含本发明的核酸分子或基因组包含由本发明的核酸分子编码的RNA分子的猫副粘病毒,其中该猫副粘病毒优选是分离的猫副粘病毒。在另一方面中,本发明提供一种用于产生猫副粘病毒的方法,该方法包含用本文所述的DNA构建体或本发明的核酸转染细胞。
根据本发明的副粘病毒亦可为嵌合病毒,亦即基因组包含异源核酸序列的本发明的副粘病毒。嵌合病毒可例如由进一步包含异源核苷酸序列的载体编码。根据本发明,因此嵌合病毒可由异源核苷酸序列已添加、插入或取代天然或非天然序列的病毒载体编码。嵌合病毒可例如用于产生保护避免两种或超过两种病毒,例如副粘病毒的两种或超过两种病毒株的重组疫苗。减毒及复制缺陷病毒可用于实现用活疫苗进行疫苗接种的目的。异源序列可编码任何感染性病原体的抗原或能够引发免疫反应的与任何疾病相关联的抗原。
本发明进一步关于一种对本发明的副粘病毒及/或本发明的多肽具有特异性的抗体。除非另外指明,否则如本文所用的术语“抗体”广泛用于意指抗体分子与多种抗体衍生分子。此类抗体衍生分子包含至少一个可变区(重链或轻链可变区),以及单个抗体轻链、单个抗体重链、抗体链与其他分子之间的嵌合融合物及其类似物。根据本发明的功能性免疫球蛋白片段可为Fv、scFv、二硫键连接的Fv、Fab及F(ab')2。抗体可为例如IgM、IgD、IgE、IgA或IgG(例如IgG1、IgG2、IgG2b、IgG3或IgG4或各别物种中的各别IgG子类)。术语“抗体”亦涵盖多克隆抗体、单克隆抗体(“mAb”)、嵌合单克隆抗体;人类化抗体、经基因工程改造的单克隆抗体。举例而言,此类抗体可由向诸如小鼠或兔的非人类哺乳动物施用本发明的(完整)副粘病毒或其部分(例如本发明的多肽或其抗原片段)且随后分离抗体或产生抗体的细胞而获得。可替代地,可针对此类抗体筛选抗体文库。用于产生人类(或猫或犬或任何其他所需物种)、人类化(或犬类化、猫类化或任何其他物种)或嵌合抗体的方法为本领域所熟知。举例而言,噬菌体呈现及基于转基因鼠的技术可用于产生基于人类、猫、犬或其他物种的单克隆抗体。可使用(包括)本领域已知的生物分析,测试根据上文所述的方法所产生或所鉴别的抗体对本发明的猫副粘病毒的抗原的特异性及/或中和本发明的猫副粘病毒的能力。本文中优选是对本发明的猫副粘病毒的表面表位具有特异性的抗体,尤其针对血细胞凝集素蛋白质(根据SEQ ID NO:6或SEQ ID NO:13的多肽)或融合蛋白(根据SEQ ID NO:5或SEQID NO:12的多肽)的抗体。在本发明的抗体的情形下,术语“对……具有特异性”及“特异性结合”是指针对相关分子或其片段而产生的抗体。若抗体对相关分子或其前述片段的亲和力比其对含有相关分子的样品中所含的其他分子的亲和力高至少10倍,优选高50倍,更优选高100倍,最优选高至少1000倍,则认为抗体具有特异性。本发明的抗体可用于检测样品中的本发明的猫副粘病毒及/或用于达成诊断目的,例如以监测疗法的疗效及/或疾病进展。
在另一方面中,本发明是关于针对本发明的副粘病毒的免疫原性组合物及疫苗。该等疫苗可例如包含
(a)根据本发明的副粘病毒;
(b)根据本发明的核酸;
(c)根据本发明的多肽;或
(d)根据本发明的抗体;
及医药学上可接受的载剂或赋形剂,优选地,该载剂适合于皮内或肌内施用,可选地该疫苗进一步包含佐剂。
该免疫原性组合物可例如包含
(a)如权利要求5、6或7中任一项的副粘病毒;
(b)如权利要求1或2中任一项的核酸;
(c)如权利要求10的多肽;
(d)如权利要求11的抗体;
(e)如权利要求10的多肽,其融合至异源或自体(多)肽
及可选地医药学上可接受的载剂或赋形剂,优选地,该载剂适合于皮内或肌内施用,可选地该疫苗进一步包含佐剂。
如本文所用的“免疫原性组合物”是指包含根据本发明的至少一种副粘病毒、核酸、多肽或抗体的物质组合物,其在宿主内引发对组合物的免疫反应(细胞或抗体介导的免疫反应)。在一特定方面中,免疫原性组合物诱导免疫反应且更优选地,赋予对副粘病毒感染的一或多个临床征象的保护性免疫。
如本发明的特定方面中使用的术语“疫苗”是指一种医药组合物,其包含至少一种诱导动物中的免疫反应的免疫活性组份且可能(但不一定)包含一或多种提高活性组份的免疫活性的其他组分。疫苗可另外包含医药组合物典型的其他组份。作为区别,疫苗的免疫活性组份可包含呈原始形式的完整病毒粒子,或在所谓经修饰的活疫苗(MLV)中呈减毒粒子,或在所谓死疫苗(KV)中呈由适当方法灭活的粒子。在另一形式中,疫苗的免疫活性组份可包含生物体的适当要素(亚单位疫苗),其中此等要素由以下产生:破坏整个粒子或含有此类粒子的生长培养基且可选地随后进行纯化步骤,产生所需结构;或由合成过程,包括由使用基于例如细菌、昆虫、哺乳动物或其他物种的合适系统进行适当操纵,可选地加上随后分离及纯化程序;或使用合适医药组合物直接并入遗传物质,在需要疫苗的动物中诱发合成过程(多核苷酸疫苗接种)。疫苗可包含一种或同时超过一种上述要素。如本发明的特定方面中使用的术语“疫苗”描述一种用于兽医用途的包含抗原物质的经修饰的活减毒疫苗,且施用用于诱导针对由副粘病毒感染,优选由猫副粘病毒感染引起的疾病的特异性及主动免疫。在本发明的其他特定方面中,疫苗可尤其为活疫苗、活减毒疫苗、灭活疫苗或缀合物疫苗。
本领域已知灭活的各种物理及化学方法。术语“灭活”是指先前有毒或无毒病毒已经过辐射(紫外线(UV)、X射线、电子束或γ辐射)、加热(例如在55℃与65℃之间的温度下持续30分钟至若干小时,例如在56℃下持续3h)或经化学处理,以使此类病毒灭活、杀死此类病毒,同时保持此类病毒的免疫原性。在一个方面中,本文揭示的灭活副粘病毒可由用灭活剂处理而灭活。合适灭活剂包括β-丙内酯、二元或β-或乙酰基-乙撑亚胺(acetyl-ethyleneimine)、戊二醛、臭氧及福尔马林(formalin)(甲醛)。
对于由福尔马林或甲醛进行灭活,甲醛通常与水及甲醇混合以产生福尔马林。添加甲醇防止在活化过程期间降解或交叉反应。一个实施方式使用约0.1%至1%的37%甲醛溶液以使病毒灭活。关键是调节福尔马林的量以确保使物质灭活,但不会高至由高剂量引起副作用的程度。
更具体而言,在病毒的情形下术语“灭活”意谓病毒不能在活体内或活体外复制。举例而言,术语“灭活”意指病毒已在活体外繁殖,且随后已使用化学或物理方式去活化,从而使得其不再能够复制。在另一实施方式中,“灭活”意指病毒已繁殖且随后使用化学或物理方式去活化,从而产生病毒、病毒的片段或组份的悬浮液,其可用作疫苗组份。如本文所用,术语“灭活”、“死”或“KV”可互换使用。
术语“活疫苗”是指包含活的,尤其活病毒活性组份的疫苗。
如本文中所提及的可选地一或多种医药学上可接受的载剂或赋形剂包括任何及所有溶剂、分散介质、涂层、佐剂、稳定剂、稀释剂、防腐剂、抗菌及抗真菌剂、等渗剂、吸收延迟剂及其类似试剂。在一些方面中,且尤其包括冻干免疫原性组合物的方面中,稳定剂包括用于冻干或冷冻干燥的稳定剂。
在一优选方面中,本发明的免疫原性组合物每剂包含101至107个病毒粒子的量的本文所述的减毒副粘病毒,优选每剂103至106个粒子,更优选每剂104至106个粒子。
在另一优选方面中,本发明的免疫原性组合物包含每剂相当于至少约103TCID50/mL,优选每剂在103至105TCID50/ml之间的病毒滴度的量的根据本发明的副粘病毒。
如本文所用,术语“疫苗”及“疫苗组合物”可互换使用且尤其是指将在已暴露于组合物的个体中引发保护性免疫反应的组合物。免疫反应可包括抗体的诱导及/或T细胞反应的诱导。
本发明的疫苗亦可为标记疫苗,亦即允许免疫学上区分或分开感染动物与接种疫苗的动物的疫苗。举例而言,标记疫苗可缺乏疫苗接种所针对的病原体中存在的免疫原性抗原(亦即本发明的副粘病毒),因此产生疫苗接种的阴性标记。此类标记疫苗在兽医学中亦称为DIVA或SIVA疫苗(“区分/分开感染动物与接种疫苗的动物”)且尤其适用于诸如农畜的生产性牲畜。
通常,“免疫反应”包括但不限于一或多个以下作用:产生或活化特异性针对相关组合物或疫苗中所包括的抗原的抗体、B细胞、辅助T细胞、抑制T细胞及/或细胞毒性T细胞。优选地,宿主将呈现治疗性或保护性免疫(记忆)反应,使得对新感染的抗性将增强及/或疾病的临床严重程度将降低。此保护将由以下证实:与病原体感染相关联的一或多个临床征象的次数或严重程度降低,或缺乏与病原体感染相关联的一或多个临床征象,病毒血症发作延迟,病毒续存降低,整体病毒负荷降低及/或病毒分泌减少。
因此,“免疫反应”尤其意谓但不限于在子组中产生对相关组合物或疫苗的细胞及/或抗体介导的免疫反应。
在一个方面中疫苗可包含本发明的多肽与另一肽或多肽的融合蛋白。融合搭配物可为异源多肽/肽或自体多肽/肽。可融合至本发明的多肽的异源多肽包括但不限于金丝雀痘病毒的多肽(尤其用于猫中的疫苗)、黏液瘤病毒的多肽(尤其用于兔中的疫苗)或疱疹病毒的多肽。
在另一方面中,本发明是关于一种检测来自个体的样品中的本发明副粘病毒的方法。在本发明的情形下样品是生物样品,尤其出于诊断、预后或评估个体的目的而获得的体液或组织样品。就本发明而言的“个体”包括人类与其他哺乳动物。因此,该等方法适用于人类诊断学及兽医学应用二者。优选测试样品包括全血、血清、血浆、尿、唾液、痰、抽吸物、穿刺液及黏膜拭子。此外,本领域技术人员将认识到一些测试样品在部分分离或纯化程序,例如全血分离为血清或血浆组份的后将更容易分析。因此,在本发明的一优选实施方式中,样品选自包含以下的群:血液样品、血清样品、血浆样品、唾液样品、抽吸物样品、穿刺液样品、黏膜拭子及尿样品或任一前述样品的提取物。亦可使用石蜡组织切片样品。优选地,样品为血液或尿样品,最优选血清样品或血浆样品。适当时,样品在用于本发明的前可能需要均质化,或用溶剂萃取以获得液体样品。液体样品在此可为溶液或悬浮液。液体样品在用于本发明的前可经受一或多次预处理。此类预处理包括但不限于稀释、过滤、离心、浓缩、沉降、沉淀、渗析。预处理亦可包括向溶液中添加化学或生物化学物质,诸如酸、碱、缓冲液、盐、溶剂、反应性染料、清洁剂、乳化剂、螯合剂。在本发明的情形下“血浆”是在离心的后所获得的含有抗凝血剂的实质上不含细胞的血液上清液。例示性抗凝血剂包括诸如EDTA或柠檬酸盐的钙离子结合化合物及诸如肝素盐或水蛭素的凝血酶抑制剂。不含细胞的血浆可由在2000g至3000g下离心抗凝血液(例如柠檬酸化、EDTA或肝素化血液)至少15分钟而获得。
检测可在核酸层面下,亦即在样品中检测病毒的基因组RNA,或在病毒蛋白的层面下,例如使用免疫分析。本领域已知的任何免疫分析系统可用于达成此目的,包括但不限于:使用诸如放射免疫分析的技术的竞争性及非竞争性分析系统、ELISA(酶联免疫吸附分析)、“夹心”免疫分析、沉淀素反应、凝胶扩散沉淀素反应、免疫扩散分析、凝集分析、补体结合分析、免疫放射分析、荧光免疫分析、蛋白A免疫分析及免疫电泳分析。亦可使用免疫印迹法分析或侧流免疫分析。可例如用使用特异性引物及/或探针的逆转录及聚合酶链反应(RT-PCR)检测病毒核酸。例如,核酸检测可直接在个体的尿样品中进行。亦可使用诸如NASBA的基于核酸的其他样品。PCR分析可例如包含诸如巢式PCR、半巢式PCR及定量PCR的格式。
详言的,本发明是关于一种检测样品中的根据本发明的副粘病毒的方法,其包含以下步骤:
(i)使样品与对根据本发明的核酸具有特异性的一或多个寡核苷酸引物及/或探针(亦即,优选在严格条件下与该核酸杂交的引物及/或探针)接触,及
(ii)检测该副粘病毒与该一或多个寡核苷酸引物及/或探针之间的结合。
在另一特定方面中,本发明是关于一种检测样品中的根据本发明的副粘病毒的方法,其包含以下步骤:
(i)使样品与根据本发明的抗体接触,及
(ii)检测该副粘病毒与该抗体之间的结合。
因此,检测本发明的副粘病毒的方法可基于样品中副粘病毒的直接检测。然而,其亦可基于更加间接的方法,亦即由检测样品中针对该副粘病毒的抗体的存在。针对该副粘病毒的抗体的存在表明个体免疫系统已与副粘病毒接触,使得相应免疫反应起始。在此情形下,由检测样品中自标记疫苗缺失的抗原(亦即本发明的多肽或其抗原片段),可区别真正感染副粘病毒与免疫接种标记疫苗(DIVA,参见上文)的个体。
因此,本发明亦关于一种用于检测样品中的根据本发明的副粘病毒的方法,其包含检测该样品中针对该副粘病毒的抗体是否存在。检测样品中的抗体的合适方法包括如上所述的免疫分析(例如ELISA,尤其夹心ELISA及侧流分析)。因此,本发明亦关于用于检测样品中的本发明的副粘病毒的方法(及对应试剂盒),其包含使样品与副粘病毒的抗原接触及检测样品中针对该副粘病毒的抗体(若存在)与该抗原的结合。该抗原优选固定在表面上。结合于该抗原的抗体可例如由使用二级检测抗体,例如在猫样品的情况下针对猫免疫球蛋白(Ig)的抗体(诸如小鼠-抗-猫Ig抗体)检测。本发明的多肽的例示性抗原表位列于以下表2中:
此等表位(或含有该等表位中的一或多者的本发明的多肽的片段)可例如用于产生针对本发明的副粘病毒的抗体。
在另一方面中,本发明是关于一种诊断个体感染本发明的副粘病毒的方法。详言的,本发明亦关于一种诊断来自个体、优选猫、更优选家猫的样品中感染根据本发明的副粘病毒的方法,其包含如上文所述的检测副粘病毒的方法,其中该副粘病毒的存在指示感染。在另一方面中,本发明是关于一种用于在来自个体,优选为家猫的样品中诊断感染根据本发明的副粘病毒的方法,其包括检测针对该本发明的副粘病毒的抗体的方法,其中该抗体的存在表示已感染该副粘病毒。
在本发明的检测方法及诊断方法的情形下,优选是检测副粘病毒的融合蛋白或血细胞凝集素。在一个方面中,亦优选为未检测到病毒聚合酶或至少未检测到对应于病毒基因组(SEQ ID NO:1或SEQ ID NO:8)的核苷酸残基10055至10560的表位或区域。
在另一方面中,本发明是关于一种用于检测本发明的副粘病毒的试剂盒。在一个实施方式中,该试剂盒可包含一或多种对本发明的副粘病毒具有特异性的抗体。在另一实施方式中,试剂盒可包含用于检测本发明的副粘病毒的寡核苷酸引物及/或探针。
最后,本发明是关于本发明的疫苗、核酸、多肽、抗体及免疫原性组合物的医学用途及治疗及/或预防个体的副粘病毒感染的方法。举例而言,本发明的疫苗或免疫原性组合物可用于减少副粘病毒感染的临床征象,优选是泌尿生殖系统感染,更尤其泌尿系统感染,或肾病/肾脏病,尤其人类或非人类哺乳动物的慢性肾病,最优选是肾小管间质性肾炎(TIN)的临床征象。详言的,本发明是关于本发明的疫苗或免疫原性组合物,其用于治疗或预防本发明的副粘病毒、尤其猫副粘病毒的感染。
本发明进一步关于本发明的疫苗或免疫原性组合物,其用于治疗或预防哺乳动物,优选是猫,更优选是家猫的感染,尤其泌尿生殖系统感染,更尤其泌尿系统感染,或肾病/肾脏病,尤其人类或非人类哺乳动物的慢性肾病,最优选是肾小管间质性肾炎(TIN)。
本发明亦关于一种治疗或预防个体、优选家猫的根据本发明的副粘病毒、尤其猫副粘病毒的感染的方法,其包含向该个体施用疫苗或免疫原性组合物的步骤。
本发明亦关于一种治疗或预防个体、优选猫、更优选家猫的肾脏病,优选慢性肾脏病,最优选肾小管间质性肾炎(TIN)的方法,其包含向该个体施用本发明的疫苗或免疫原性组合物的步骤。
在一优选方面中,本发明的疫苗或免疫原性组合物用于预防个体的本发明副粘病毒的感染。
本发明亦关于本发明的免疫原性组合物或疫苗,其用于减少或预防个体的由病原性副粘病毒、优选本发明副粘病毒的感染引起的临床征象或疾病的方法中,或用于治疗或预防个体的病原性副粘病毒、优选本发明副粘病毒的感染的方法中,其中该个体优选是猫。本发明进一步关于本发明的免疫原性组合物或疫苗,其用于保护个体、优选猫免遭副粘病毒、优选根据本发明的副粘病毒感染,或避免由病原性副粘病毒、优选本发明副粘病毒的感染引起的临床征象或疾病的方法。
本发明进一步关于一种对个体、优选猫进行免疫接种以抵抗个体的由副粘病毒、优选本发明副粘病毒引起的临床疾病或临床征象的方法,该方法包含向个体、优选猫施用根据本发明的免疫原性组合物或疫苗的步骤,其中该病毒不会引起副粘病毒感染的临床征象,但能够诱导使个体、优选猫对副粘病毒、优选本发明的副粘病毒的病原形式具免疫性的免疫反应。
因此,本发明亦关于一种预防或减少个体、优选猫的副粘病毒(优选本发明的副粘病毒)感染的临床征象,预防个体的由副粘病毒、优选本发明的副粘病毒引起的临床疾病或临床征象的方法,该方法包含向个体、优选猫施用根据本发明的免疫原性组合物或疫苗的步骤,其中该病毒不会引起副粘病毒感染的临床征象,但能够诱导使个体、优选猫对副粘病毒、优选本发明的副粘病毒的病原形式具免疫性的免疫反应。
本发明进一步关于一种用于对个体、优选猫进行疫苗接种以抵抗个体的与副粘病毒、优选根据本发明的副粘病毒相关联的疾病及/或用于降低个体的与副粘病毒、优选根据本发明副粘病毒相关联或由其引起的一或多个临床征象的发病率或严重程度的试剂盒,该试剂盒包含:
(a)能够向个体、优选猫施用疫苗的配送器;及
(b)根据本发明的免疫原性组合物或疫苗,及
(c)可选地说明书小册子。
所引用的所有专利及非专利文献在此均以全文引用的方式并入本文中。
附图说明
图1:细胞培养上清液中猫副粘病毒(FPaV-2)的检测。
展示在感染FPaV-2“Gordon”病毒株的后,分别来自CrFK及LLC-MK2细胞的第3传代的细胞培养上清液的分析。M:DNA尺寸标准;1:CrFK细胞的细胞培养上清液;2:LLC-MK2细胞的细胞培养上清液;3:水;4:阳性对照。
图2:感染FPaV-2“Gordon”分离株的LLC-MK2细胞的免疫荧光。
细胞核用DAPI染色。感染FPaV-2的细胞展示绿色荧光。放大倍数:200×;在感染5天后染色。
图3:猫初级肾脏细胞的分离。放大倍数:100×,在接种48小时后。
图4:猫初级肾脏细胞的FPaV-2感染。
细胞核用DAPI染色。感染FPaV-2的细胞展示绿色荧光。放大倍数:200×;在感染5天后染色。
图5:感染FPaV-2的猫的抗体多样性。
由SDS-PAGE分离且转印至硝化纤维素膜上的半纯化全FPaV-2的免疫印迹分析。
A.=与来自FPaV-2阳性的猫“TV25”的1:100稀释的血清样品一起培育。
B.=与来自副粘病毒阴性的猫的1:100稀释的样品一起培育。
C.=与1:200稀释的抗核衣壳抗体一起培育。
对病毒蛋白的特异性反应基于其与标靶抗体的反应性(核衣壳蛋白及磷蛋白)或基于其预测分子量(聚合酶蛋白质及血细胞凝集素蛋白质)注释在右下角。
图6:检测猫血清样品中的FPaV-2抗体的ELISA的显色。
针对特异性抗体的存在,在FPaV-2-IFA中筛选猫血清样品。IFA结果设定为最高准则且与OD值比较。OD值低于0.5的样品定义为FPaV-2阴性,而OD值高于0.7的样品定义为FPaV-2阳性。灰色框指示需要在IFA中检查以评估ELISA结果的“边界”样品。
图7:FPaV-2的主要免疫标靶细胞。
以0.1的MOI感染FPaV-2 48小时后的PBMC的流动式细胞测量分析。针对T细胞(CD4)或B细胞(CD20)的表面标记及针对FPaV-2的胞内存在,使用多克隆核衣壳抗体,将细胞染色。
A.及C.=模拟感染的PBMC
B.及D.=感染FPaV-2的PBMC
图8:FPaV-2免疫接种的兔的免疫印迹分析。
半纯化全FPaV-2经由SDS-PAGE分离且转印至硝化纤维素膜上。
A.=与来自免疫接种前的2号兔的血清样品(1:100稀释)(免疫前血清)一起培育。
B.=与来自用加热灭活FPaV-2免疫接种5周后的2号兔的血清样品(1:100稀释)一起培育。
对病毒蛋白的特异性反应基于图5中所示的反应性注释在右下角。
相比于免疫前血清,在免疫接种5周后检测FPaV-2特异性抗体。
实施例
实施例1:FPaV-2的检测
样品收集:
自患有慢性肾脏病的13岁雄性猫收集尿且储存于冰上。
RNA分离:
使用“QIAamp病毒RNA微型试剂盒”(Qiagen,Hilden)自300μl尿中分离RNA,在50μl缓冲液AVE中溶离且储存在-80℃下。
RT-PCR:
如Tong等人(2008)(J Clin Microbiol.46(8):2652-8)所述,使用“具有PlatinumTaq高保真的SuperScript III单步RT-PCR系统”(Life Technologies)在单一步骤中进行RT-PCR,进行一些微小修改:将9微升RNA与12.5μl反应缓冲液(2倍,各0.4mM dNTP及2.4mMMgSO4)、2μl硫酸镁(5mM)、0.25μl引物RES-MOR-HEN-R(100μM)、0.25μl引物RES-MOR-HEN-F1(100μM)、0.5μl RNA酶抑制剂(40U/μl,Life Technologies)及0.5μl“SuperScript III/Platinum Taq高保真酶混合物”混合。样品随后根据以下热分布处理:在60℃下1分钟,在45℃下30分钟及在94℃下2分钟。在此处理的后,样品如下加热:在94℃下持续15秒,在48℃下持续30秒及在68℃下持续30秒的45次循环,及在68℃下持续5分钟的最终伸长步骤。在包括0.2μg/ml溴化乙锭的Tris-乙酸盐-EDTA-缓冲液(40mM Tris-乙酸盐,1mM EDTA,pH=8.3)中使用琼脂糖凝胶电泳观察PCR产物。自凝胶切割尺寸为约611bp的特定PCR片段且使用“凝胶/PCR DNA片段提取试剂盒”(Geneaid,Taiwan)纯化。
测序:
使用RES-MOR-HEN-R(10μM)及RES-MOR-HEN-F1(10μM)作为测序引物,由应用桑格双脱氧(Sanger didesoxy)方法将PCR片段测序。所得层析图使用软件“BioEdit”(7.2.4版)编辑且用NCBI网站的“基本局部比对检索工具”比对。
实施例2:FPaV-2的分离
对于病毒培养,在包括5%二氧化碳的氛围中在37℃及90%湿度下,LLC-MK2及CrFK细胞于75cm2细胞培养烧瓶中具有5% FBS的DMEM(具有丙酮酸钠及非必需氨基酸)中接种。在70-80%汇合时,细胞在37℃、5% CO2及90%湿度下用1毫升尿与5ml DMEM(具有青霉素及链霉素)的混合物感染隔夜。
在24小时的后,感染培养基替换成8ml培养用培养基(DMEM、丙酮酸钠、非必需氨基酸、5% FBS、青霉素及链霉素)且在指定条件下另外培养6天。来自此感染的细胞培养上清液再传代3次。然后,针对猫副粘病毒的存在,如实施例1中所述测试600μl细胞培养上清液。图1展示此类实验的结果。
实施例3:FPaV-2的免疫荧光检测
为检测FPaV-2感染,如实施例2中所述感染LLC-MK2细胞且使用免疫荧光技术用FPaV-2特异性抗体染色。
出于此目的,在感染5天的时段后用PBS洗涤黏附细胞且随后在-20℃下用80%丙酮固定10分钟。细胞用PBS洗涤两次且由在37℃下与含5% BSA的PBS一起培育一小时来阻断非特异性结合。
此后为在37℃下与于含1% BSA的PBS中最终浓度为1μg/ml的抗FPaV-2抗体(抗FPaV-2核衣壳,多克隆,兔)一起培育一小时的步骤。细胞用PBS洗涤三次,随后施加在含1%BSA的PBS中1:1000最终稀释的“山羊抗兔IgG(H+L)二级抗体,Alexa 488缀合物”(Thermo Fisher Scientific)。在37℃下培育一小时的时间后,细胞用PBS洗涤两次且针对FPaV-2的存在使用荧光显微镜筛选细胞。结果展示于图2中。
实施例4:FPaV-2的感染谱
为分析FPaV-2的活体外易感性,感染不同细胞株且随后使用如实施例3中所述的免疫荧光技术分析。表3反映此类实验的结果。
细胞株 组织 物种 FPaV-2的感染
CrFK 肾脏、上皮 阳性
CrFK/CatSLAM 肾脏、上皮,用猫CD150转染 阳性
FE 胚胎、上皮及纤维母细胞 阳性
Vero(CCL-81) 肾脏、上皮 绿色猴 阳性
LLC-MK2 肾脏、上皮 恒河猴 阳性
BHK-21 肾脏、纤维母细胞 叙利亚金仓鼠 阳性
表3:FPaV-2感染的活体外谱
实施例5:猫初级肾脏细胞的FPaV-2感染
为调查初级细胞是否亦易感染FPaV-2,分离初级猫肾脏细胞。出于此目的,在无菌条件下自经安乐死的猫移除肾脏且立即储存于冰上。随后将肾囊剥离且将皮层切割为小块且在HBSS中冲洗5次。此等组织块随后在垂直震荡器中在37℃下用含0.1百分比胰蛋白酶的HBSS处理20分钟。细胞悬浮液经由100μm尼龙过滤器过滤且滤液在400×g下离心10分钟。细胞沉淀粒再悬浮于完全肾脏培养基(DMEM与Hams-F12培养基的1:1混合物,补充有“胰岛素-运铁蛋白-硒-乙醇胺”[Thermo Fisher Scientific]、丙酮酸钠、非必需氨基酸、10% FBS、青霉素及链霉素)中,在组织烧瓶中接种且在37℃、5% CO2及90%湿度下培育。图3展示此类实验的典型结果。
如实施例2中所述使上述初级猫肾脏细胞感染FPaV-2,且如实施例3中所述针对FPaV-2的存在进行染色。
图4展示此类实验的结果。
实施例6:全长FPaV-2基因组的测定及分析
为获得FPaV-2-细胞培养分离株的全基因组序列,如实施例1中所述将“Gordon”RNA自细胞培养上清液中分离。FPaV-2特异性PCR产物随后由使用实施例1中描述的单步PCR系统及引物步移策略产生。借助于“凝胶/PCR DNA片段提取试剂盒”(Geneaid)自琼脂糖凝胶中分离扩增产物且使用对应扩增引物由桑格双脱氧方法测序。各PCR片段测序两次。表4中展示所得FPaV-2序列与FmoPV-分离株M252A(Woo等人(2012),Proc.Nat.Acad.Sci.109(14):5435-5440;保藏编号:JQ411016.1)的比对结果。
表4:FPaV-2(病毒株“Gordon”)的全基因组序列的分析
Nt's:核苷酸aa:氨基酸
实施例7:尿样品中的FPaV-2盛行率(prevalence)
为阐明家猫中的FPaV-2盛行率,由膀胱穿刺来收集尿样品,立即储存在-20℃下且如实施例1中所述分析FPaV-2-RNA的存在。结果展示于表5中。
表5:家猫尿样品中的FPaV-2盛行率
实施例8:FPaV-2病毒株的异质性
使用实施例1中描述的程序,将FPaV-2的第二病毒株自患有猫泌尿道症候群的雄性猫中分离。使用引物步移策略及桑格双脱氧DNA测序方法,对病毒分离株(称为“TV25”)进行全基因组测序。结果概括于表6中,核苷酸序列展示于SEQ ID NO:8中。
/>
表6:两个FPaV-2分离株『Gordon』与『TV25』的全基因组序列比较
实施例9:FPaV-2的电子显微术
15ml FPaV-2-细胞培养上清液(描述于实施例2中)在4℃下在3.000×g下离心10分钟,随后由0.45μm硝化纤维素过滤器过滤。滤液覆盖在20%(w/v)蔗糖垫上且在4℃下在100.000×g下离心90分钟。沉淀粒随后悬浮于100μl PBS中且在室温下使病毒吸附至formvar/碳涂布的300网目铜网,历时5分钟。在使用蒸馏水的三个洗涤步骤的后,病毒粒子使用2%(w/v)乙酸铀酰染色30秒。使用透射电子显微镜分析此样品,显示典型副粘病毒形态:尺寸为100-150纳米的多形性包膜病毒粒子。
实施例10:感染FPaV-2的猫的抗体多样性
为调查自然感染FPaV-2的猫的抗体多样性,将半纯化病毒粒子(如实施例9中所示)与等体积的SDS-加样缓冲液(100mM Tris-HCl,pH 6.8;4%(w/v)十二烷基硫酸钠;0.2%(w/v)溴酚蓝;20%(v/v)甘油;200mMβ-巯基乙醇)混合,在95℃下加热5分钟且装载至8%聚丙烯酰胺凝胶上。在SDS-PAGE电泳缓冲液(25 mM Tris、192 mM甘氨酸、0.1%SDS)中在130 V下由电泳90分钟使病毒蛋白分离,随后转印至硝化纤维素膜。
在室温下用含5%(w/v)脱脂乳粉的PBS-T(0.05%吐温20(tween 20))阻断30分钟的后,膜与在阻断缓冲液中1:100稀释的猫血清样品一起在4℃下培育隔夜。膜用PBS-T洗涤3次且在室温下与在阻断缓冲液中1:1.000稀释的缀合辣根过氧化酶的α-猫-IgG抗体一起培育一小时。3,3'-二氨基联苯胺用于信号形成。如图5A中所示,感染FPaV-2的猫可产生针对广泛范围的病毒结构蛋白,例如聚合酶蛋白质、磷蛋白、核衣壳蛋白及血细胞凝集素蛋白质的抗体。如对于核衣壳蛋白所示(图5C),对病毒蛋白的特异性反应基于其与标靶抗体的反应性注释。
证明磷蛋白使用磷丝氨酸抗体(来自QIAGEN N.V.的Q5)重度磷酸化,使计算的分子量自53 kDa改变至约75 kDa。此分子量改变现象自其他麻疹病毒属,如麻疹病毒(磷蛋白=70 kDa)及犬瘟热病毒(磷蛋白=73 kDa)已知。针对聚合酶蛋白质及血细胞凝集素蛋白质的特异性反应的注释是基于自其氨基酸序列预测的分子量进行。
实施例11:针对FPaV-2的血清中和测试的显色
为检测针对FPaV-2的中和抗体,建立血清中和分析(SNT)。因此,在56℃下处理猫血清样品30分钟以使补体因子灭活。将50μl此等热灭活血清样品与含有100荧光形成单位(FFU)FPaV-2(分离株“Gordon”)的50μl DMEM混合且随后在4℃下培育一小时。混合物用于在96孔细胞培养盘中在37℃下感染LLC-MK2-细胞,历时两小时。随后移除血清/病毒-混合物且替换成含有2%(v/v)热灭活FBS、丙酮酸钠、非必需氨基酸、青霉素及链霉素的DMEM。细胞在37℃、5%CO2及90%湿度下培育5天,随后如实施例3中所述,进行免疫荧光染色。测试血清样品的中和滴度定义为与无血清培育的病毒对照相比,使病毒感染力降低50%的最高测试血清稀释度的倒数。
实施例12:感染FPaV-2的猫中的中和抗体的筛选
使用实施例11中描述的SNT,针对中和抗体的存在,筛选自然感染FPaV-2的猫的血清样品。此等实验的结果展示于表7中。其明确展示FPaV-2感染可诱导高滴度的针对病毒的中和抗体(参见表7中的猫血清样品98450及TV25的FPaV-2-SNT结果)。相比的下,来自感染犬瘟热病毒的猫(表7中的样品CDV)及猫副粘病毒阴性的猫(表7中的样品TV26)的血清样品未展示中和抗体,突出显示检测抗体滴度为FPaV-2特异性的。
表7:FPaV-2血清中和测试的结果
IFA:免疫荧光分析,CDV:犬瘟热病毒阳性样品
实施例13:筛选猫血清样品中的FPaV-2抗体的ELISA显色
为阐明德国猫群体中FPaV-2感染的盛行率,建立基于重组表达的核衣壳的ELISA系统。因此,FPaV-2-核衣壳(SEQ ID NO:2)的完整开放阅读框架使用限制酶BamHI及XhoI克隆至表达载体“pGEX-4T-1”。所得重组表达质粒(“pGEX-Gordon-NC”)由标准技术转型至化学感受态大肠杆菌(E.coli)BL21(DE3)且在LB琼脂上用100μg/ml氨比西林(Ampicillin)选择重组细菌,从而产生称为“大肠杆菌-Gordon-NC”的大肠杆菌-克隆。此克隆经接种至具有0.2%葡萄糖及100μl/ml氨比西林的1.000ml LB培养基中且在37℃下以200rpm震荡直至培养物达至A600nm=1.0的光学密度。彼时,培养物冷却至22℃且重组蛋白表现使用最终浓度为0.1mM的异丙基β-D-1-硫代吡喃半乳糖苷(IPTG)诱导。在22℃及220rpm下培育20小时后,培养物在3.000×g、4℃下离心20分钟且所得沉淀粒经超声处理以破坏大肠杆菌细胞。如由制造商所描述,使用谷胱甘肽琼脂糖凝胶4B(GE Healthcare Life Science)纯化重组GST融合蛋白。
在4℃下在Nunc MaxiSorp ELISA盘中的每一孔涂布200ng所得GST-Gordon-NC-蛋白质隔夜,接着使用PBS-T(0.05%吐温20)的三个洗涤步骤。在37℃下使用含5%(w/v)脱脂乳粉的PBS-T(阻断缓冲液)阻断游离蛋白质结合位点30分钟。血清样品在阻断缓冲液中1:100稀释且在预致敏ELISA盘上在37℃下培育两小时。在使用PBS-T的三个洗涤步骤的后,孔在37℃下与二级抗体(山羊抗猫IgG(Fc):HRP,Bio-Rad,在阻断缓冲液中1:10.000稀释)一起培育一小时。未结合抗体由三次PBS-T洗涤循环而洗去且将底物溶液(OPD SubstrateTable,Thermo Fisher Scientific)施加至各孔,在22℃下培育5分钟,接着由2.5M硫酸停止酶反应。量测490nm下的吸亮度。为界定此ELISA-系统的截止值,应用描述于实施例3中的免疫荧光测试,针对FPaV-2-特异性反应筛选来自猫的血清样品。
结果展示于图6中。IFA结果设定为最高准则且与OD值比较。OD值低于0.5的样品定义为FPaV-2阴性,而OD值高于0.7的样品定义为FPaV-2阳性。OD值在0.5与0.7之间的“边界”样品需要在IFA中检查以评估ELISA结果。
使用此方法,来自家猫的230份血清样品中的13份(=5.6%)对FPaV-2呈阳性。此结果反映在德国猫群体中相对较高的FPaV-2盛行率。
实施例14:FPaV-2的初级标靶细胞
猫PBMC在活体外感染FPaV-2以揭示猫免疫细胞是否亦为FPaV-2的标靶。出于此目的,使用标准Ficoll密度梯度离心将外周血液单核细胞(PBMC)自健康雄性猫中分离。在37℃下PBMC用含2%(v/v)植物血细胞凝集素(M形式,粗提物,Thermo Fisher Scientific)的RPMI处理四小时,随后以0.1的MOI感染FPaV-2或在37℃下模拟感染两小时。PBMC用PBS洗涤一次且随后在37℃、5% CO2及90%湿度下培育48小时。针对CD4及CD20表面标记,使用标准流动式细胞测量术方案对细胞进行染色。在4℃下用2%(w/v)三聚甲醛进行10分钟的固定步骤的后,细胞在22℃下在具有0.5(w/v)皂素的facs缓冲液(PBS,pH=7.4;3% FBS;0.1%叠氮化钠)中使用抗-FPaV-2-核衣壳抗体(参见实施例2)胞内染色30分钟。染色细胞用facs缓冲液洗涤3次且使用LSRFortessaTM(Becton Dickinson)细胞分析器分析。如图7中所示,猫CD4阳性T细胞以及猫CD20阳性B细胞是FPaV-2的标靶细胞。此等结果明确表明可能出现FPaV-2的全身状态。
实施例15:用灭活FPaV-2对兔进行免疫接种
此“概念验证”实验旨在阐明使用灭活FPaV-2的免疫接种是否将诱导中和抗体且因此可充当潜在候选疫苗。雄性兔用1ml热灭活(在56℃下3小时)FPaV-2病毒株“Gordon”(1×105FFU/ml,参见实施例2)与2ml佐剂(92.8%矿物油;3.48%吐温80(Tween80);3.48%司盘80(Span 80);23%脂多醣)的疫苗混合物进行免疫接种。对于阴性对照动物而言,使用相同体积的来自仿真感染(无病毒)的细胞培养上清液与佐剂混合代替FPaV-2。
免疫接种根据以下方案进行:
-第1次免疫接种:收集免疫前血清,随后接种1ml皮下及1ml肌内疫苗混合物。
-在第1次免疫接种14天后的第2次免疫接种:接种1ml皮下及1ml肌内的疫苗混合物。
-在第2次免疫接种7天后的第3次免疫接种:接种1ml皮下及1ml肌内的疫苗混合物。
-最终放血(杀死兔):在第3次免疫接种14天的后
如实施例10中所描述,最初在免疫印迹法分析中使用全病毒制剂测试最终血清样品。此实验展示在免疫接种5周的后,在FPaV-2免疫接种的动物中检测到针对聚合酶蛋白质、磷蛋白、血细胞凝集素蛋白质及核衣壳蛋白的特异性抗体(参见图8B)。由分析此兔的免疫前血清确认观测到的反应的特异性。如图8A中所示,在免疫接种前不存在病毒特异性抗体。此外,免疫接种后血清样品的染色图案(图8B)与自然感染FPaV-2的猫中的结果(参见图5a)相同,证明在提供的免疫印迹分析中观测到的亮带的病毒特异性性质。因此,所应用的FPaV-2疫苗接种配方能够在动物中诱导广泛范围的抗FPaV-2抗体。
为阐明此等抗体是否具有中和特性,使用在用FPaV-2免疫接种或用来自模拟感染的细胞培养上清液免疫接种5周的后收集的血清样品进行FPaV-2-SNT(描述于实施例11中)。结果展示于表8中。
表8:免疫接种兔的FPaV-2-SNT结果。
兔用热灭活FPaV-2病毒株“Gordon”(2号兔)或用作为阴性对照(1号兔)的细胞培养上清液免疫接种,如实施例15中所述。在免疫接种5周的后,针对抗FPaV-2的中和抗体的存在测试此等兔的血清样品。表8中的”阳性”意谓无病毒生长,亦即存在病毒中和活性。病毒生长藉助于根据实施例3的免疫荧光染色量测。
此等实验明确展示热灭活FPaV-2配方可诱导高滴度的能够抑制病毒感染的中和抗体。尽管在兔中测试,但可假定相似疫苗接种策略将在如家猫的其他动物中有效。
序列表
<110> 勃林格殷格翰动物保健有限公司
<120> 新颖的副粘病毒及其用途
<130> Z1938 EP S3
<150> EP 16 18 5761.0
<151> 2016-08-25
<160> 14
<170> BiSSAP 1.3
<210> 1
<211> 16047
<212> DNA
<213> Feline Paramyxovirus-Type 2
<220>
<223> complementary sequence of the genome of Feline Paramyxovirus-Type
2 (FPaV-2), Strain Gordon
<400> 1
accagacaaa gatgtctgtg acctattcta acggttagat tattacttga tatttaggaa 60
taacgattcc attagtcagg taagggagag gaatcagtta ttctataatg gctagtttac 120
tcaggtcact tgcggcattc aagaaacaca gagaacaacc aactgttcct tctgggtcag 180
gagggacgat caaaggatta aaaaatacaa ttattgtgcc tgttcctgga gatacagtca 240
tcactaccag atcgaactta ctgttcagat tagtctacat aattggtaat ccagatacac 300
ctttaagcac ttcaacaggg gcaataatat cattgttgac attatttgtt gaatctccag 360
gtcaattaat tcaaagaatc gctgatgatc ctgatgctgt ttttaaatta gtagaggtgg 420
ttcctgaggt tggtaatcct ggagaattaa cttttgcatc tagaggaatt aacttggata 480
aacaagctca acaatacttt agattggctg agaaaaatga tcaaggatat tatgtaagtt 540
tggggtttga aaatccacca aatgatgatg atataacgtc aagtcctgaa atctttaatt 600
atattttagc atctgtactt gcacagatct ggattctcct agctaaggct gtaactgctc 660
cagacacagc tgctgaggct gaaaaccgta ggtggattaa attgatgcaa caacgcagag 720
tggatggtga gcttagatta agtaaaggat ggttggactt agtgaggaat aaaatcgcat 780
cggatatcac aattagaagg tttatggtag cattagttct tgacattaaa cgttctcctg 840
gaacaagacc aagaattgct gaaatgattt gtgatataga caattatatt gtggaggccg 900
gactggcaag ttttctgtta actatcaaat ttggtataga aacacgttac ccggcattag 960
cgttacatga gttttcgggg gaattagcca ctattgaagg actcatgaaa ttgtaccagt 1020
ctatgggaga aatggcacca tacatggtca ttctagagaa ttcgatccag actaggttta 1080
gtgctgggtc ttatccgtta ctctggagct atgctatggg tgttggtgta gaacttgaaa 1140
gatcaatgag tggattaaac ttcacaagaa gtttctttga tcctacgtac ttcaggttgg 1200
gtcaggagat ggtaagaagg tcttcaggaa tggttaatag ctcatttgcc aaagaacttg 1260
gactatctga acatgaaaca caacttgtta gccagatcat taactcaggt ggtgagtcag 1320
gtataccgaa atttgatgga tttagagcaa acccaacaac atttctaggg gctaaggaca 1380
acatcactga taggagtgaa gatccattga ttgcaattcc agggtcatca ggacaaccat 1440
tgccaggtta tgaccccaat atctcaggtg actcatatag aattgatagt agcactaaag 1500
acacaaacaa tatatcagat ggaggaacaa atccaagtca tgatgtttcc aattctgcta 1560
tggaagagct gagaagattg gtagagtcta ccaacaagat tgatacaaag aaatctgaaa 1620
gcccaggcat cgttaatcat tacaacgata ctgaccttct gagataataa ggatatattc 1680
aggtagatct ttacagaatt taaattaaga aaaacttagg acctcaaggt tcacactcct 1740
ctggccttta tcagaattcg gccaattcct cactcactcc atgtcagcag aacaaatcca 1800
acaagttaga catggccttg aatccttgca agagatcaaa aacaaccctc caccctctca 1860
agatgtcaat cttgccaggg aaatttacga atccattaaa caaacaggaa caccttcaac 1920
acaaggaggg accattacag gaaataatac tgcgtcaggg tgtgacaatt actcaatgca 1980
tagccaggga tcaggtcctt ctgtttcagg tgctgacaag aatatcgaga gacttactgg 2040
acccgattat tcagaattat gggatccaga aggtaacctc tgcatgctat tcgaaagcga 2100
tgatgatgac aacaattatt cagagattaa tggccggtct accgctatcg aaggattgga 2160
tgaacagaat aataaggacc caggtattaa acaatcagga gatcagtgtt ctgaaggagt 2220
gtctaagatt aattcatctt ctagtcccca agaagctaca ttatcttctg ggagatctga 2280
tatatctggg acaggagtat ctccctgtgc ctctttggat ataactgtta atgaattaga 2340
agatgcaact gttaagaata gtaataatat gaaaggaaat tggccaatcc caaagttgct 2400
tgtcaaacca ccaccaagaa tgaaatcact ttctgactct gttacaccat taaaaggggc 2460
caccgacggg aaatcagtct tacctgggat ggagattaca ttgtccggga agaatggtgc 2520
aaccctacct gtacacccat ttacacaacc tataaaagac tcaaatgcag atgtaagcaa 2580
tgtccgtcaa catgtcccaa gtgtgactga tggtcatagt gatgataatg aggaagtacc 2640
cggtttgcat aaagaaacta tagacaaagc tgatctatct atgcaggaca tatacaattt 2700
aattcttgga tttaaggatg attacaggaa actatcaaat aaattggata tgatactaga 2760
gatgaaacaa gatattgata atcttaaaaa gagtagtgca aaaatacaac ttgcattatc 2820
aacaattgaa ggacatctgt ccagtgttat gattgctatt ccaggttcag gtattgatat 2880
aaatcaagat gagaagaagg atcaattaaa ctctgactta aagccattac tagggaggga 2940
ccattgccgt gcatttcgtg aagtcactaa tcctttagat gaaacgtcat tgaccaacgc 3000
tccgaccaaa catgttgcta agatcaacaa aaattgcact cttcagaaaa tcaataacaa 3060
tgagacatct gcaattaagt ttgtacctaa tgatagccat gcaagtatct cgactatcaa 3120
gtctattgtc aaatcctcaa accttaatca agagcttaaa gtcaagttac tgacaattct 3180
atctcaaatt aaaggggtag acaatattaa ggagttttat gagaaagtta tgatattgat 3240
caagaataat aactgatctt gactaatcaa tagatactac ttatcaaatc tcgctctgac 3300
atcaagtgaa ttcatcttta ttaacaagta ttaatcttaa ataattataa aaaacttagg 3360
agttcaggat tagtgggtca tatacaatat gactgagata ttcaatctgg atgaaagttc 3420
atggtcagtc aagggaacac tggacccatt gacgcctgat acttatcctg atgggcgcct 3480
agtacccaag attcgggtta ttgatcccgg tctaggtgat cgtaaaagtg gaggatatat 3540
gtacttactc cttcacggtg tcatcgagga cagtgagacc gtcataaatc cgaaagggag 3600
agcatttgga gctttccctt taggcgtagg gcaatcaacc gagaacccag aagacttatt 3660
taaggaaata ttaaccctca acattgttac tcgcaggact gctggcttca atgaaaaatt 3720
ggtgtattat aatactacac ctctaaatct actaacccct tggaaaaaag tactagcata 3780
tggaagtatc tttactgcta atcaggtctg caataataca agttctatcc ctatagacat 3840
tcctcagaaa tttcgacctg tctatttaac tgttaccaag ttatcggatg atggatatta 3900
tcagatacct aaaatgatac aggatttcaa atcatcaaac tctgttgcat ttaacatcct 3960
tgtgcatcta tcaatgggaa caattttact tgactcatct aaaggctctc gagtaggaaa 4020
ccctgcagaa aatttgatca cattcatgat tcatattggg aatttcaaac ggaagaataa 4080
taaagcttat tctcccgaat attgtaagag gaaaataatg aggcttggat taattttctc 4140
actaggagcc attggtggaa caagtttgca tattcgatgc acaggcaaaa tgagtaagag 4200
attacaagcc tacttagggt ttaaaagaac tttatgttat cctctgatgt atgtcaatga 4260
gggtctaaat aaaaccttat ggagaaatga atgcaaaatt gagaaggttc aagcagtatt 4320
acagccatca gttccgaatg aatttaagat ttatgatgat ataatcattg ataacacgaa 4380
tggcctcttt aaggttaagt aagctgtgac tagtatcagg agttactagt caaaatcatg 4440
tgttgatatc cgaattaata gctttaagtt gaatatatta aacctgtgat aatttaaatt 4500
tgaaacataa ttagtatgta gtattgtatt aatcagttta taatcttgtt tgaggatcca 4560
aattataacc ctattaggta ttgccactcc agtcttacag gtaaatctaa gcgaatatac 4620
aaataattga tattcgggat taaacaatac ttgtatatta atccataggt atattagatt 4680
ttactatatt caattattat aatgtttatt gagttaagct ctcatgatta taaaaaacta 4740
aggattccac ataatcacag tttgattgcc aattgatgtg tttagtatta gttgtgtgaa 4800
atattgatat taataaggtt aatcaacttt tgtacagaag tgaaagtgta attagataga 4860
aatagattaa tccttagtag ccgttttgat aattgaattg attcttgttt taattctgaa 4920
ttgagattat taatcaccag ctcggcataa tgtataagat taaggttgta atcatgggtt 4980
ttttactgtt atcagatatt acatttgcac aggtaggttg ggataattta acctcaattg 5040
gagttataag tactaaacaa tataactata agataactac tttgaatact aatcaactca 5100
tggtgatcaa aatggtaccc aatatatcat caattattaa ctgtactaaa cttgaattag 5160
caaaatatag ggaactgatt acaggaatac tgagaccaat taatgaatca ttagaattga 5220
tgaattcata tatcaacatg agaacaggtt cagagagatt cataggggct gttatagcag 5280
gagtagctct aggggttgca actgcggcgc agataacatc gggaattgcc ttacataatt 5340
cgattatgaa taaaaaacag atacaggaat taaggaaagc ccttagtact acaaataagg 5400
caattgatga gataaggatt gcaggtgaaa gaactctgat agctgtccaa ggtgtgcaag 5460
attacattaa caatgttatt atccctatgc aagagaaact ccagtgcgat attttagcct 5520
cacagctatc tattgcccta ctcagatact atactaatat actgactgtt tttggaccaa 5580
gtataagaga tcctattact agtacaattt ctatacaagc tctcagtcaa gcattcaatg 5640
gtaatctaca ggcattgctt gatggattag ggtatactgg acaagactta catgatctca 5700
tagaaagtag atctatcact ggtcaaatta ttcacgctga tatgactgat ttattccttg 5760
tattgagaat caattatcca tctattacgg atatgcaagg agtggtaata tatgagctga 5820
attctatcac atatcatatt ggacctgaag agtggtacac tattatgcct aatttcatag 5880
ctgttcaggg atttctggta tctaatttcg atgaacgtaa atgttcaatt actaaaacaa 5940
gtatactgtg tcaacagaat tcaatttatc ctatgtcaac cgaaatgcaa agatgtataa 6000
aaggtgagat taaattctgt ccaaggtcca aagcaattgg gacattagtt aatcgattta 6060
tattaattaa tgggaatcta atggccaatt gtttgggtat tatctgtaga tgttatacct 6120
caggtcaaat tataacgcaa gacccaaata aattaatcac aattatatca caagaagaat 6180
gtagagaggt tggtgttgat gggattcgta taatggtggg gcctaaaaaa ttaccggatg 6240
ttatctttaa tgccagacta gaaataggtg tacctatctc attaagcaag ctggatgttg 6300
ggaccgactt ggcaattgct tcagctaaac tcaataactc taaggcactt ttggagcagt 6360
ctgataaaat cttaaattct atgtctaagt tggattcttt aaattcacgt atcttaggat 6420
ctgtctttat aattatgata atcttcgtga ctgtaattgt gattatttgg attatttgta 6480
aaaagtgtag aaataagagg aacaaattaa gtgcttctat tgaacccctc tacatacctc 6540
cctcttataa ttcaccccat agcatagtta aatctatttg aaatataagt gtataatctg 6600
atataacaga tgcagtagaa ttattaatca atgataatat tattatgata atgattcagt 6660
tagatgttca ttgtatctca taacttaata ttgacaaatt tcaattagtt aaatttattc 6720
tcttcataat atgtatttgt ttaattatcc tagattcatg tactgttatt aaattggtca 6780
tctttaataa ctaactcagc aatactatcc tatacacatg tattagctaa taacgatgta 6840
atattgccat ttaataataa gtacctagta gaatgggaag cattagctgt agtcaatgaa 6900
ccattacctg ctcaattaga aaaaacttag gaatccatgt taatgggagc tggccatcat 6960
ggaatctaat aacaacaagt actataaaga ttcaaaccgg tattttagca agatactaga 7020
tgagaacaag acggtaaata atcatctgta tagtcttagt ataaggataa ttaccgttat 7080
agctattgtt gtgagtctaa ttgcaacaac aataaccatc attaatgcta taagcggaag 7140
gactactctt aataataata tggacatgct actcaaccaa caagacaaga ttaataatat 7200
caaggaaatg atatttgatc gtatctatcc cctgataaat gccatgagta cagagcttgg 7260
tcttcacatt ccaactttat tggatgagct gactaaatca attgatcaaa aaatcaagat 7320
aatgactcca ccacttgaaa ctacaacatc taatctcaat tggtgtatca accccccaaa 7380
tggcattatt gtagatccta aaggttattg tgaaggcttg gaactgtcaa aaacttataa 7440
gttattactt gatcaattag atatgttaag aaagaaatca cttattatta ataagaaaag 7500
tattaatcag tgtagacttg ttgatagttc gaatatcgtc tttgcaacag ttaatataca 7560
atctacaccg agattcttaa atcttggtca cacagttagt aaccaacgta taacattcgg 7620
tcaaggaaca tatagtagca cttatattat aactatacaa gaggatggat taactgatgt 7680
tcagtaccga gtatttgaaa taggatatat ctcagatcaa tttggaacct tcccttctct 7740
aatcgtttcc agagtactac ctgtgcgaat ggtacttgga atggaatctt gtacactgac 7800
cagtgacaag tttgggggtt attttttatg catgaacatt ccgacacgct ctatatatga 7860
ttatgtcaac ataagagact taaagtcact atacgtcaca atccctcatt atggcaaaat 7920
taattacact tactttaatt ttgggaaagt cagaagccca catgaaattg ataagatttg 7980
gcttacatca gaaaggggac agatgatttc aggttacttt gcagcatttg ttacgattac 8040
aattagaaat tataacaatt atccctataa atgcttacat aacccgtgtc ttgaaagatc 8100
tgagagttat tgcaaaggat ggtacaaaaa tattacaggt actgatgatg ttccaatatt 8160
agcatatcta ttagttgaaa tgaatgatga ggaaggaccc ttaattacat tggttgagat 8220
accaccttac aattatacgg ctccttctca taattccctt tactatgatg ataaaattaa 8280
caaattaata atgacaacat ctcatatagg atacattcaa atcaatgaag tgcatgaagt 8340
cattgtcggg gataatctta aggctattct cttaaacaga ttatctgatg aacaccctac 8400
tcttactgct tgtagattta atcaggaaat taaagagcga catatatctg atggattaat 8460
aatatctaac tctgctctta ttgatataca agaacgtatg tatgttacag ttaaggctgt 8520
tccacccata ggaaattata acttcacggt agagttgcat tcacggtcaa atacatctta 8580
cgtagggttg ccaaggcagt tcaatgctag gtatgacaaa ctgcatctcg aatgctttgc 8640
ctgggatagg tcttggtggt gcgctttgat acctcaattt tcattaagtt ggaatgaatc 8700
tctttcagta gatactgcca ttttcaactt aataaactgt aattaagttt gtggcttgtt 8760
ctagattgat catttgaata acagttgatt aagccaaagt tagtaaatac atacattaac 8820
ctgttcttga ccaagtatat atcccaatcc aattataaaa aacttaggac tcaaggtgtt 8880
gatggcaatg gagcaatcag attatcaaga tattttatat ccagaggtac atctcaacag 8940
tcctatagtt atctctaaat tagtgggtat tttggagtat tctaaggttg ttcacaatca 9000
gcagttatct gatcacacaa tagtcaagaa tatacaattt agattgagaa atggattcaa 9060
tagtccaaga atacaaacac tgttagttat gggtgaaatt atcaataaaa tcaaaaataa 9120
atacccaaat tatttgcaca taccttatcc tgaatgtaat caaaagttat ttaggatagc 9180
tgacccggag ttaacatcta aactagaagc cctcttggac aaaggtgaca cattatatct 9240
taagattaag acagagatca tagcttgttt cgataagtta aaaactaaaa tgagcataac 9300
caatgatctg attagtgaca ataggcagct aatttcagat ctacctataa ttgtcaaggg 9360
atctcaatgg tttttccctt ttttgctctg gttctctgtt aaaactgaga ctaggaactg 9420
tattcgacaa aatcaaaaaa ctcgtgttag gtcacaatac cgacctcatt tgtcagaaac 9480
taaaagaatt acgctggtcg ttactcatga cttgatcaca atatttgacc acgtcaacaa 9540
atgtatatat catctgactt ttgagatgtt gttgatgtat tgtgatgtag tagaagggag 9600
gttaatgacc gaagcatcta tgagtctaga tcacagattt attaacctat tgtcgagggt 9660
ccagtatatg tgggatctat tagatgggat gtttgagagt ctaggaaatc agctatattc 9720
aatcattgca ctcttagaac ctctctctct tgcctatcta cagttgatgg atgcagaccc 9780
acagatacgg ggtacatttt tacaccattg cctttcagag ttggaagaac tcttatttag 9840
taaattccct tttgatcctg taatttatga aaatctaatt agtggacttg attacatcta 9900
tttaacagac gatattcatt taactgctga gatattttct ttctttagaa gttttggtca 9960
tccttattta gaagcacaaa atgcagctag caatgttagg aaatatatga atcaacctaa 10020
agttatctca taccagactc taatgcaagg acatgcaatt ttttgtggca ttataataaa 10080
tgggttcaga gatcgtcacg gagggacatg gccacccgta gagctaccac atcatgcatc 10140
cgctgtaatt agaaatgctc agttatctgg agaaggatta acacctgagc agtgtgctca 10200
atactggagg tcattttgtg gatttaaatt taaatgtttt atgccattaa gtttagatag 10260
cgacctcacc atgtacctta gagacaaggc attatcacct attaagaatg agtgggactc 10320
tgtgtatgct aaagagtatt taagatacaa ccctggctta ccgactagct ctcgaagatt 10380
agtcaatgta tttcttgaag atgataaatt tgatccgtac gaaatgatta tgtacgtaat 10440
aaacggtgat tatttaaggg ataatgagtt caatctctca tatagtctta aagaaaagga 10500
gatcaaggag gtaggccgat tgttcgctaa aatgacttat aaaatgagag cttgtcaggt 10560
aatagcagaa aatttaattg caaatggagt tgggaaattt tttaaagaca atgggatggc 10620
gaaggatgaa cataaattaa ccaaaacatt acataagctg gccatttctg gtgtacctaa 10680
agataatttt caactctatt taagtgaatg ttgggaacaa gtggtagaac aatgcgtaac 10740
cagtacgcaa acaaaaaatc aaattatcag ttcacactca agaaaatcag ttgcatcaaa 10800
gtttccaaga tcaaatccca atgatagggg tattctaaat agtggcagac atttgaataa 10860
acatccaaaa catccttcaa acaccgaata ctatgaaact gtcagtagtt ttataactac 10920
tgatctcaag aaatattgcc tcaactggcg ctatgaatca agtagtgtgt ttgcagaaag 10980
actcaatgag atttatgggt taccaggatt ttttcattgg cttcatagaa ttttggagaa 11040
atctgtatta tatgttagtg atccatccag tccacctgat tttgatcaac atgttgatat 11100
tgattcagtt ccaaatgatc atatttttat caaataccca atgggtggga tagaaggatt 11160
ttgtcaaaaa ttatggacaa tcagcacaat cccattttta tatttagcag cttttgatac 11220
aggggttaga atatcttcgt tggttcaagg tgataatcaa gcaattgcag tgaccaaaag 11280
agttccatcg tcctggagtt attcgagaaa aaaagaggag tcaactaaag ttacaacaca 11340
atatttttta aacttaagac aacgcttaca tgatataggt catgagttaa aggcaaatga 11400
gactattata tcttcacact tttttgttta ctctaagggt atttattatg atggtatact 11460
tctttcacaa tcccttaaaa gtattgcaag atgtgttttt tggtccgaga caattgtcga 11520
tgagactagg tcagcttgca gcaatatatc cactaccctt gctaaagcta ttgaacgggg 11580
ttatgataaa ttcgtggcat acgctattaa tatatataag actatacacc aggtcttaat 11640
tgcattatct tttactatta atcccactat gactccggac ataacagaac ctttttataa 11700
aagtttagat ttacttaaaa acctcattct gataccagca ccattgggtg ggatgaatta 11760
catgaatatg agcagattat ttgttagaaa cataggtgat cccattacag cttcatttgc 11820
tgacatcaag cgtatgatcg aatgcgggtt attagggcac aatgttctct cacaaataat 11880
gtatcagaaa tgtggtacct cgaaatactt agattgggct agtgaccctt attccataaa 11940
tcttccttat agtcaaagca tgaccaaagt attaaaaaat ataaccgcga gatatgttct 12000
catgcacagt cctaacccta tgctaaaaga tttattccat gagaagtcac aagaagaaga 12060
tgagattctt gctgaatttt tgctggatcg tcagttaata atccctagag ctgcacatga 12120
aattttatcg aattcagtaa caggagctag agagtcgatt gcagggatgc ttgatactac 12180
taaaggactt attcgagcca gtatgtcaag aggtggtctg acatcttcac ttgtgttgaa 12240
attgtcaaca tatgattatc aacaatttag aacatgcctt gaatggcttt atgcccctac 12300
cacaggaata gcagtaagtg ctgattcttg ttcagttttt ttagccagag ctattcgaaa 12360
aaggatgtgg gttcacctga ctaaaggaag agaaatttat ggcctagaag tgcctgatat 12420
attagaatgt atgcagagca atgtaattgt tgatcatgaa gattgttatt catgtattca 12480
aggatcaaga tactacacat ggttttttgt accttctaat tgtcagcttg atcagattaa 12540
caagtctaca aattctctac gggttcctta cattggctct actacagagg aaagaagtga 12600
catgaaatta tcatacgtca gatcccctag taggccactt aaggcagcag tccgaattgc 12660
agcagtctac acatgggcat acggtgatga cgatctgtct tggcgtgagg cttggtactt 12720
ggcaaggact agggcaaatg ttactttcga tgagcttaaa ttagtaacac ccatagctac 12780
ctctacgaac ttggcacata gattaaggga caggagtact caagttaagt attcaggaac 12840
ttcattagta agagtggcac gctatacaac aatatccaat gataatatgt catttgtcat 12900
taatgacaaa aaggtagata ctaattttgt ctatcaacag ggcatgttat tgggtttgag 12960
tatcctagaa tatatattta gatactgtaa aagtactggt caatcaaata ctgtagttca 13020
cttgcatgca gatgttaatt gttgcataat ccaaatgaca gatcaacctt atactccaag 13080
cttaacgaaa aaattacctg agattaaacc tattaataat aagttgattt atgatccagc 13140
tcctataatt gatactgatg cagctaggtt atattctcag aagtacttat cacacctgat 13200
agattttcca aattggtcaa tgaatcagct aaatgtagtt ttagcaaaag tagttgcaat 13260
atctattgtg gacttgataa ctaaagcgag taaagatcat ctcaatgaaa ttatggcagt 13320
tgttggagat gatgacatta atagctttat aacagaattt ttgctagttg atccgaggct 13380
atttacattg tacttaggtc aatacacgtc acttcaatgg gcatatgaaa ttcattatca 13440
ccgacccgta ggcaaatacc agatggcaga agtgttacac actttactgt caagagcaag 13500
taaaggtata tttaatatat taactaatgc ttttagtcat cctagagttt acaaaagatt 13560
ttgggaatgt ggattactgg agcctattta tggaccatac atagggagcc aaaatttata 13620
tagtacagta attgattacc tttacaatgc ttatataact tatttagatg cttatctatc 13680
tgatcatatc gaagatgcag acatagtaat atgtgagaca gaagaaactt gtctagctaa 13740
taggattgat aactatcaag gtaggcatct agccgtactt attgatcttt attgtgattc 13800
tactaggtgt cctaatataa aagggtcaga cacaatcatg cgaaactcaa ttctcaaatc 13860
ttttattgat aatgagagaa ggacaagtcc attaggtcta acatggaatc ttgatccatt 13920
actcatagat catttcagtt gttcaattac ttatctgagg agaggtatta ttaaacagat 13980
taggctaagg tttgatccaa acatatctat tgagttggtt aaattggcaa aacctgaagt 14040
gattcatcaa ggaccaaaaa taccgtcttc ttgggccctt atagatatta atcctgaggt 14100
caatgatctt aatacagttt tcggagaatt aaatagtaaa tggaaagata ttcctattgg 14160
acaaattaga attcaaaatt atgagatcca tgcttaccga agaattggag ttaattcaac 14220
tgcatgttat aaagcattgg aaatgctatc tgtactaacc cggtttatgt ctaacccagc 14280
aggagctttg tttttaggag agggtgcagg gtcaatgtta gttacctatc gtgcgtttat 14340
cccgttcaag agaatttatt ataatagtgg aatttctata caaaatattc aaagccaaag 14400
agaactaagt ctatacccat ctgaagtagc cttggttgat aataaaaatc gtttgaccag 14460
tgatcctgat atcaaagtct tatttaatgg caagccagaa tccacgtggg ttgggaatat 14520
agactgcttt gcttatattc tgagtcatat tgaaacttct agtttaacat taatccacag 14580
tgatattgaa tctagcttga gtaaaacaaa gaataagatt cttgaggagc tttgccatat 14640
tctatcaatg gcactgattt taggaaagat tggatctgta ttagttatta agctgttacc 14700
acgggttggt gactacacat attcattttg caagtatgcg tcagaattct accaacagaa 14760
tttttttatt ttacctagat ttagcaacat gtcatcatct gaaatttact acgttggagt 14820
tcatttaaat accaatagac tggttgatcc agataggatt gtgcaatata taatcaggaa 14880
tctccaatct actccagtta ctttcttatc ttacattttg gaaactaaat atagaaataa 14940
tatggttaca aattatgggc tctgcttgtc tgatggacat aaaagcgatt acttgtcatc 15000
aatcaccaag atagaaaatg ttcttttatc atgtggattg gaattgaatg gacctaagat 15060
tatacagcaa ttatctggac atgactacgc caatggagag attagcttag aatcaagtat 15120
aatggtactg gttagagaat atctaaatgc aactatccaa ggtcgggaaa cactaggtct 15180
tttttcacct taccctgtgt tacatgagag tcagttaaga gaaattaaca ggtgcattgc 15240
attgaagtat gttgtatatt tactttttta ctcaacctct gtaggatcta gtagacaaat 15300
catgagcaat ctcagaaaag gagtattaat gtatgactta agagatgagt ttttcatgga 15360
aaggttatca acaaatttca agaaaaaaat aatgtcacaa gaggttaaaa ctacatggat 15420
ctttaatatt gatgtaccaa caagaaaagc tctgtataaa ttagttggtt attcacttat 15480
cattaatcac gtataacaag tgtattgagt tggtaatatt ctagatgaac aagtataggt 15540
ttatgtacag taagtgatta aatattagat tcaggtagat aaacttccta atagtgtatc 15600
ctatagataa cctaaggcta tttaatgtta gattaattag aaaaaacttc ttgaattatg 15660
atagacttca acccctggct aagacttatc atttaaaatt ataaccaagt tgtcctgata 15720
atatcagatc tcattaatta cttgatagcg taatataaca ggtgcatgat gatcctttat 15780
tactcatata cctgttatta agctcctgtt caaattatcc cctatttaag ttgcctttta 15840
aattacctaa tatgttttgt aatgagaaac attgatacat acaaagctaa agaagcctga 15900
ttttatctaa ggttgtatct aattgttgtc aatttataat tcggaatatc tgggccctaa 15960
acctcctcca aatatactaa aaggttttaa aaaaacaaaa aaggtttctt acttattgta 16020
cggacctata gctttctttt gtctggt 16047
<210> 2
<211> 519
<212> PRT
<213> Feline Paramyxovirus-Type 2
<220>
<223> Nucleocapsid protein, Strain Gordon
<400> 2
Met Ala Ser Leu Leu Arg Ser Leu Ala Ala Phe Lys Lys His Arg Glu
1 5 10 15
Gln Pro Thr Val Pro Ser Gly Ser Gly Gly Thr Ile Lys Gly Leu Lys
20 25 30
Asn Thr Ile Ile Val Pro Val Pro Gly Asp Thr Val Ile Thr Thr Arg
35 40 45
Ser Asn Leu Leu Phe Arg Leu Val Tyr Ile Ile Gly Asn Pro Asp Thr
50 55 60
Pro Leu Ser Thr Ser Thr Gly Ala Ile Ile Ser Leu Leu Thr Leu Phe
65 70 75 80
Val Glu Ser Pro Gly Gln Leu Ile Gln Arg Ile Ala Asp Asp Pro Asp
85 90 95
Ala Val Phe Lys Leu Val Glu Val Val Pro Glu Val Gly Asn Pro Gly
100 105 110
Glu Leu Thr Phe Ala Ser Arg Gly Ile Asn Leu Asp Lys Gln Ala Gln
115 120 125
Gln Tyr Phe Arg Leu Ala Glu Lys Asn Asp Gln Gly Tyr Tyr Val Ser
130 135 140
Leu Gly Phe Glu Asn Pro Pro Asn Asp Asp Asp Ile Thr Ser Ser Pro
145 150 155 160
Glu Ile Phe Asn Tyr Ile Leu Ala Ser Val Leu Ala Gln Ile Trp Ile
165 170 175
Leu Leu Ala Lys Ala Val Thr Ala Pro Asp Thr Ala Ala Glu Ala Glu
180 185 190
Asn Arg Arg Trp Ile Lys Leu Met Gln Gln Arg Arg Val Asp Gly Glu
195 200 205
Leu Arg Leu Ser Lys Gly Trp Leu Asp Leu Val Arg Asn Lys Ile Ala
210 215 220
Ser Asp Ile Thr Ile Arg Arg Phe Met Val Ala Leu Val Leu Asp Ile
225 230 235 240
Lys Arg Ser Pro Gly Thr Arg Pro Arg Ile Ala Glu Met Ile Cys Asp
245 250 255
Ile Asp Asn Tyr Ile Val Glu Ala Gly Leu Ala Ser Phe Leu Leu Thr
260 265 270
Ile Lys Phe Gly Ile Glu Thr Arg Tyr Pro Ala Leu Ala Leu His Glu
275 280 285
Phe Ser Gly Glu Leu Ala Thr Ile Glu Gly Leu Met Lys Leu Tyr Gln
290 295 300
Ser Met Gly Glu Met Ala Pro Tyr Met Val Ile Leu Glu Asn Ser Ile
305 310 315 320
Gln Thr Arg Phe Ser Ala Gly Ser Tyr Pro Leu Leu Trp Ser Tyr Ala
325 330 335
Met Gly Val Gly Val Glu Leu Glu Arg Ser Met Ser Gly Leu Asn Phe
340 345 350
Thr Arg Ser Phe Phe Asp Pro Thr Tyr Phe Arg Leu Gly Gln Glu Met
355 360 365
Val Arg Arg Ser Ser Gly Met Val Asn Ser Ser Phe Ala Lys Glu Leu
370 375 380
Gly Leu Ser Glu His Glu Thr Gln Leu Val Ser Gln Ile Ile Asn Ser
385 390 395 400
Gly Gly Glu Ser Gly Ile Pro Lys Phe Asp Gly Phe Arg Ala Asn Pro
405 410 415
Thr Thr Phe Leu Gly Ala Lys Asp Asn Ile Thr Asp Arg Ser Glu Asp
420 425 430
Pro Leu Ile Ala Ile Pro Gly Ser Ser Gly Gln Pro Leu Pro Gly Tyr
435 440 445
Asp Pro Asn Ile Ser Gly Asp Ser Tyr Arg Ile Asp Ser Ser Thr Lys
450 455 460
Asp Thr Asn Asn Ile Ser Asp Gly Gly Thr Asn Pro Ser His Asp Val
465 470 475 480
Ser Asn Ser Ala Met Glu Glu Leu Arg Arg Leu Val Glu Ser Thr Asn
485 490 495
Lys Ile Asp Thr Lys Lys Ser Glu Ser Pro Gly Ile Val Asn His Tyr
500 505 510
Asn Asp Thr Asp Leu Leu Arg
515
<210> 3
<211> 491
<212> PRT
<213> Feline Paramyxovirus-Type 2
<220>
<223> Phosphoprotein, Strain Gordon
<400> 3
Met Ser Ala Glu Gln Ile Gln Gln Val Arg His Gly Leu Glu Ser Leu
1 5 10 15
Gln Glu Ile Lys Asn Asn Pro Pro Pro Ser Gln Asp Val Asn Leu Ala
20 25 30
Arg Glu Ile Tyr Glu Ser Ile Lys Gln Thr Gly Thr Pro Ser Thr Gln
35 40 45
Gly Gly Thr Ile Thr Gly Asn Asn Thr Ala Ser Gly Cys Asp Asn Tyr
50 55 60
Ser Met His Ser Gln Gly Ser Gly Pro Ser Val Ser Gly Ala Asp Lys
65 70 75 80
Asn Ile Glu Arg Leu Thr Gly Pro Asp Tyr Ser Glu Leu Trp Asp Pro
85 90 95
Glu Gly Asn Leu Cys Met Leu Phe Glu Ser Asp Asp Asp Asp Asn Asn
100 105 110
Tyr Ser Glu Ile Asn Gly Arg Ser Thr Ala Ile Glu Gly Leu Asp Glu
115 120 125
Gln Asn Asn Lys Asp Pro Gly Ile Lys Gln Ser Gly Asp Gln Cys Ser
130 135 140
Glu Gly Val Ser Lys Ile Asn Ser Ser Ser Ser Pro Gln Glu Ala Thr
145 150 155 160
Leu Ser Ser Gly Arg Ser Asp Ile Ser Gly Thr Gly Val Ser Pro Cys
165 170 175
Ala Ser Leu Asp Ile Thr Val Asn Glu Leu Glu Asp Ala Thr Val Lys
180 185 190
Asn Ser Asn Asn Met Lys Gly Asn Trp Pro Ile Pro Lys Leu Leu Val
195 200 205
Lys Pro Pro Pro Arg Met Lys Ser Leu Ser Asp Ser Val Thr Pro Leu
210 215 220
Lys Gly Ala Thr Asp Gly Lys Ser Val Leu Pro Gly Met Glu Ile Thr
225 230 235 240
Leu Ser Gly Lys Asn Gly Ala Thr Leu Pro Val His Pro Phe Thr Gln
245 250 255
Pro Ile Lys Asp Ser Asn Ala Asp Val Ser Asn Val Arg Gln His Val
260 265 270
Pro Ser Val Thr Asp Gly His Ser Asp Asp Asn Glu Glu Val Pro Gly
275 280 285
Leu His Lys Glu Thr Ile Asp Lys Ala Asp Leu Ser Met Gln Asp Ile
290 295 300
Tyr Asn Leu Ile Leu Gly Phe Lys Asp Asp Tyr Arg Lys Leu Ser Asn
305 310 315 320
Lys Leu Asp Met Ile Leu Glu Met Lys Gln Asp Ile Asp Asn Leu Lys
325 330 335
Lys Ser Ser Ala Lys Ile Gln Leu Ala Leu Ser Thr Ile Glu Gly His
340 345 350
Leu Ser Ser Val Met Ile Ala Ile Pro Gly Ser Gly Ile Asp Ile Asn
355 360 365
Gln Asp Glu Lys Lys Asp Gln Leu Asn Ser Asp Leu Lys Pro Leu Leu
370 375 380
Gly Arg Asp His Cys Arg Ala Phe Arg Glu Val Thr Asn Pro Leu Asp
385 390 395 400
Glu Thr Ser Leu Thr Asn Ala Pro Thr Lys His Val Ala Lys Ile Asn
405 410 415
Lys Asn Cys Thr Leu Gln Lys Ile Asn Asn Asn Glu Thr Ser Ala Ile
420 425 430
Lys Phe Val Pro Asn Asp Ser His Ala Ser Ile Ser Thr Ile Lys Ser
435 440 445
Ile Val Lys Ser Ser Asn Leu Asn Gln Glu Leu Lys Val Lys Leu Leu
450 455 460
Thr Ile Leu Ser Gln Ile Lys Gly Val Asp Asn Ile Lys Glu Phe Tyr
465 470 475 480
Glu Lys Val Met Ile Leu Ile Lys Asn Asn Asn
485 490
<210> 4
<211> 337
<212> PRT
<213> Feline Paramyxovirus-Type 2
<220>
<223> Matrix protein, Strain Gordon
<400> 4
Met Thr Glu Ile Phe Asn Leu Asp Glu Ser Ser Trp Ser Val Lys Gly
1 5 10 15
Thr Leu Asp Pro Leu Thr Pro Asp Thr Tyr Pro Asp Gly Arg Leu Val
20 25 30
Pro Lys Ile Arg Val Ile Asp Pro Gly Leu Gly Asp Arg Lys Ser Gly
35 40 45
Gly Tyr Met Tyr Leu Leu Leu His Gly Val Ile Glu Asp Ser Glu Thr
50 55 60
Val Ile Asn Pro Lys Gly Arg Ala Phe Gly Ala Phe Pro Leu Gly Val
65 70 75 80
Gly Gln Ser Thr Glu Asn Pro Glu Asp Leu Phe Lys Glu Ile Leu Thr
85 90 95
Leu Asn Ile Val Thr Arg Arg Thr Ala Gly Phe Asn Glu Lys Leu Val
100 105 110
Tyr Tyr Asn Thr Thr Pro Leu Asn Leu Leu Thr Pro Trp Lys Lys Val
115 120 125
Leu Ala Tyr Gly Ser Ile Phe Thr Ala Asn Gln Val Cys Asn Asn Thr
130 135 140
Ser Ser Ile Pro Ile Asp Ile Pro Gln Lys Phe Arg Pro Val Tyr Leu
145 150 155 160
Thr Val Thr Lys Leu Ser Asp Asp Gly Tyr Tyr Gln Ile Pro Lys Met
165 170 175
Ile Gln Asp Phe Lys Ser Ser Asn Ser Val Ala Phe Asn Ile Leu Val
180 185 190
His Leu Ser Met Gly Thr Ile Leu Leu Asp Ser Ser Lys Gly Ser Arg
195 200 205
Val Gly Asn Pro Ala Glu Asn Leu Ile Thr Phe Met Ile His Ile Gly
210 215 220
Asn Phe Lys Arg Lys Asn Asn Lys Ala Tyr Ser Pro Glu Tyr Cys Lys
225 230 235 240
Arg Lys Ile Met Arg Leu Gly Leu Ile Phe Ser Leu Gly Ala Ile Gly
245 250 255
Gly Thr Ser Leu His Ile Arg Cys Thr Gly Lys Met Ser Lys Arg Leu
260 265 270
Gln Ala Tyr Leu Gly Phe Lys Arg Thr Leu Cys Tyr Pro Leu Met Tyr
275 280 285
Val Asn Glu Gly Leu Asn Lys Thr Leu Trp Arg Asn Glu Cys Lys Ile
290 295 300
Glu Lys Val Gln Ala Val Leu Gln Pro Ser Val Pro Asn Glu Phe Lys
305 310 315 320
Ile Tyr Asp Asp Ile Ile Ile Asp Asn Thr Asn Gly Leu Phe Lys Val
325 330 335
Lys
<210> 5
<211> 541
<212> PRT
<213> Feline Paramyxovirus-Type 2
<220>
<223> Fusion protein, Strain Gordon
<400> 5
Met Tyr Lys Ile Lys Val Val Ile Met Gly Phe Leu Leu Leu Ser Asp
1 5 10 15
Ile Thr Phe Ala Gln Val Gly Trp Asp Asn Leu Thr Ser Ile Gly Val
20 25 30
Ile Ser Thr Lys Gln Tyr Asn Tyr Lys Ile Thr Thr Leu Asn Thr Asn
35 40 45
Gln Leu Met Val Ile Lys Met Val Pro Asn Ile Ser Ser Ile Ile Asn
50 55 60
Cys Thr Lys Leu Glu Leu Ala Lys Tyr Arg Glu Leu Ile Thr Gly Ile
65 70 75 80
Leu Arg Pro Ile Asn Glu Ser Leu Glu Leu Met Asn Ser Tyr Ile Asn
85 90 95
Met Arg Thr Gly Ser Glu Arg Phe Ile Gly Ala Val Ile Ala Gly Val
100 105 110
Ala Leu Gly Val Ala Thr Ala Ala Gln Ile Thr Ser Gly Ile Ala Leu
115 120 125
His Asn Ser Ile Met Asn Lys Lys Gln Ile Gln Glu Leu Arg Lys Ala
130 135 140
Leu Ser Thr Thr Asn Lys Ala Ile Asp Glu Ile Arg Ile Ala Gly Glu
145 150 155 160
Arg Thr Leu Ile Ala Val Gln Gly Val Gln Asp Tyr Ile Asn Asn Val
165 170 175
Ile Ile Pro Met Gln Glu Lys Leu Gln Cys Asp Ile Leu Ala Ser Gln
180 185 190
Leu Ser Ile Ala Leu Leu Arg Tyr Tyr Thr Asn Ile Leu Thr Val Phe
195 200 205
Gly Pro Ser Ile Arg Asp Pro Ile Thr Ser Thr Ile Ser Ile Gln Ala
210 215 220
Leu Ser Gln Ala Phe Asn Gly Asn Leu Gln Ala Leu Leu Asp Gly Leu
225 230 235 240
Gly Tyr Thr Gly Gln Asp Leu His Asp Leu Ile Glu Ser Arg Ser Ile
245 250 255
Thr Gly Gln Ile Ile His Ala Asp Met Thr Asp Leu Phe Leu Val Leu
260 265 270
Arg Ile Asn Tyr Pro Ser Ile Thr Asp Met Gln Gly Val Val Ile Tyr
275 280 285
Glu Leu Asn Ser Ile Thr Tyr His Ile Gly Pro Glu Glu Trp Tyr Thr
290 295 300
Ile Met Pro Asn Phe Ile Ala Val Gln Gly Phe Leu Val Ser Asn Phe
305 310 315 320
Asp Glu Arg Lys Cys Ser Ile Thr Lys Thr Ser Ile Leu Cys Gln Gln
325 330 335
Asn Ser Ile Tyr Pro Met Ser Thr Glu Met Gln Arg Cys Ile Lys Gly
340 345 350
Glu Ile Lys Phe Cys Pro Arg Ser Lys Ala Ile Gly Thr Leu Val Asn
355 360 365
Arg Phe Ile Leu Ile Asn Gly Asn Leu Met Ala Asn Cys Leu Gly Ile
370 375 380
Ile Cys Arg Cys Tyr Thr Ser Gly Gln Ile Ile Thr Gln Asp Pro Asn
385 390 395 400
Lys Leu Ile Thr Ile Ile Ser Gln Glu Glu Cys Arg Glu Val Gly Val
405 410 415
Asp Gly Ile Arg Ile Met Val Gly Pro Lys Lys Leu Pro Asp Val Ile
420 425 430
Phe Asn Ala Arg Leu Glu Ile Gly Val Pro Ile Ser Leu Ser Lys Leu
435 440 445
Asp Val Gly Thr Asp Leu Ala Ile Ala Ser Ala Lys Leu Asn Asn Ser
450 455 460
Lys Ala Leu Leu Glu Gln Ser Asp Lys Ile Leu Asn Ser Met Ser Lys
465 470 475 480
Leu Asp Ser Leu Asn Ser Arg Ile Leu Gly Ser Val Phe Ile Ile Met
485 490 495
Ile Ile Phe Val Thr Val Ile Val Ile Ile Trp Ile Ile Cys Lys Lys
500 505 510
Cys Arg Asn Lys Arg Asn Lys Leu Ser Ala Ser Ile Glu Pro Leu Tyr
515 520 525
Ile Pro Pro Ser Tyr Asn Ser Pro His Ser Ile Val Lys
530 535 540
<210> 6
<211> 595
<212> PRT
<213> Feline Paramyxovirus-Type 2
<220>
<223> Hemagglutinin, Strain Gordon
<400> 6
Met Glu Ser Asn Asn Asn Lys Tyr Tyr Lys Asp Ser Asn Arg Tyr Phe
1 5 10 15
Ser Lys Ile Leu Asp Glu Asn Lys Thr Val Asn Asn His Leu Tyr Ser
20 25 30
Leu Ser Ile Arg Ile Ile Thr Val Ile Ala Ile Val Val Ser Leu Ile
35 40 45
Ala Thr Thr Ile Thr Ile Ile Asn Ala Ile Ser Gly Arg Thr Thr Leu
50 55 60
Asn Asn Asn Met Asp Met Leu Leu Asn Gln Gln Asp Lys Ile Asn Asn
65 70 75 80
Ile Lys Glu Met Ile Phe Asp Arg Ile Tyr Pro Leu Ile Asn Ala Met
85 90 95
Ser Thr Glu Leu Gly Leu His Ile Pro Thr Leu Leu Asp Glu Leu Thr
100 105 110
Lys Ser Ile Asp Gln Lys Ile Lys Ile Met Thr Pro Pro Leu Glu Thr
115 120 125
Thr Thr Ser Asn Leu Asn Trp Cys Ile Asn Pro Pro Asn Gly Ile Ile
130 135 140
Val Asp Pro Lys Gly Tyr Cys Glu Gly Leu Glu Leu Ser Lys Thr Tyr
145 150 155 160
Lys Leu Leu Leu Asp Gln Leu Asp Met Leu Arg Lys Lys Ser Leu Ile
165 170 175
Ile Asn Lys Lys Ser Ile Asn Gln Cys Arg Leu Val Asp Ser Ser Asn
180 185 190
Ile Val Phe Ala Thr Val Asn Ile Gln Ser Thr Pro Arg Phe Leu Asn
195 200 205
Leu Gly His Thr Val Ser Asn Gln Arg Ile Thr Phe Gly Gln Gly Thr
210 215 220
Tyr Ser Ser Thr Tyr Ile Ile Thr Ile Gln Glu Asp Gly Leu Thr Asp
225 230 235 240
Val Gln Tyr Arg Val Phe Glu Ile Gly Tyr Ile Ser Asp Gln Phe Gly
245 250 255
Thr Phe Pro Ser Leu Ile Val Ser Arg Val Leu Pro Val Arg Met Val
260 265 270
Leu Gly Met Glu Ser Cys Thr Leu Thr Ser Asp Lys Phe Gly Gly Tyr
275 280 285
Phe Leu Cys Met Asn Ile Pro Thr Arg Ser Ile Tyr Asp Tyr Val Asn
290 295 300
Ile Arg Asp Leu Lys Ser Leu Tyr Val Thr Ile Pro His Tyr Gly Lys
305 310 315 320
Ile Asn Tyr Thr Tyr Phe Asn Phe Gly Lys Val Arg Ser Pro His Glu
325 330 335
Ile Asp Lys Ile Trp Leu Thr Ser Glu Arg Gly Gln Met Ile Ser Gly
340 345 350
Tyr Phe Ala Ala Phe Val Thr Ile Thr Ile Arg Asn Tyr Asn Asn Tyr
355 360 365
Pro Tyr Lys Cys Leu His Asn Pro Cys Leu Glu Arg Ser Glu Ser Tyr
370 375 380
Cys Lys Gly Trp Tyr Lys Asn Ile Thr Gly Thr Asp Asp Val Pro Ile
385 390 395 400
Leu Ala Tyr Leu Leu Val Glu Met Asn Asp Glu Glu Gly Pro Leu Ile
405 410 415
Thr Leu Val Glu Ile Pro Pro Tyr Asn Tyr Thr Ala Pro Ser His Asn
420 425 430
Ser Leu Tyr Tyr Asp Asp Lys Ile Asn Lys Leu Ile Met Thr Thr Ser
435 440 445
His Ile Gly Tyr Ile Gln Ile Asn Glu Val His Glu Val Ile Val Gly
450 455 460
Asp Asn Leu Lys Ala Ile Leu Leu Asn Arg Leu Ser Asp Glu His Pro
465 470 475 480
Thr Leu Thr Ala Cys Arg Phe Asn Gln Glu Ile Lys Glu Arg His Ile
485 490 495
Ser Asp Gly Leu Ile Ile Ser Asn Ser Ala Leu Ile Asp Ile Gln Glu
500 505 510
Arg Met Tyr Val Thr Val Lys Ala Val Pro Pro Ile Gly Asn Tyr Asn
515 520 525
Phe Thr Val Glu Leu His Ser Arg Ser Asn Thr Ser Tyr Val Gly Leu
530 535 540
Pro Arg Gln Phe Asn Ala Arg Tyr Asp Lys Leu His Leu Glu Cys Phe
545 550 555 560
Ala Trp Asp Arg Ser Trp Trp Cys Ala Leu Ile Pro Gln Phe Ser Leu
565 570 575
Ser Trp Asn Glu Ser Leu Ser Val Asp Thr Ala Ile Phe Asn Leu Ile
580 585 590
Asn Cys Asn
595
<210> 7
<211> 2202
<212> PRT
<213> Feline Paramyxovirus-Type 2
<220>
<223> Polymerase, Strain Gordon
<400> 7
Met Glu Gln Ser Asp Tyr Gln Asp Ile Leu Tyr Pro Glu Val His Leu
1 5 10 15
Asn Ser Pro Ile Val Ile Ser Lys Leu Val Gly Ile Leu Glu Tyr Ser
20 25 30
Lys Val Val His Asn Gln Gln Leu Ser Asp His Thr Ile Val Lys Asn
35 40 45
Ile Gln Phe Arg Leu Arg Asn Gly Phe Asn Ser Pro Arg Ile Gln Thr
50 55 60
Leu Leu Val Met Gly Glu Ile Ile Asn Lys Ile Lys Asn Lys Tyr Pro
65 70 75 80
Asn Tyr Leu His Ile Pro Tyr Pro Glu Cys Asn Gln Lys Leu Phe Arg
85 90 95
Ile Ala Asp Pro Glu Leu Thr Ser Lys Leu Glu Ala Leu Leu Asp Lys
100 105 110
Gly Asp Thr Leu Tyr Leu Lys Ile Lys Thr Glu Ile Ile Ala Cys Phe
115 120 125
Asp Lys Leu Lys Thr Lys Met Ser Ile Thr Asn Asp Leu Ile Ser Asp
130 135 140
Asn Arg Gln Leu Ile Ser Asp Leu Pro Ile Ile Val Lys Gly Ser Gln
145 150 155 160
Trp Phe Phe Pro Phe Leu Leu Trp Phe Ser Val Lys Thr Glu Thr Arg
165 170 175
Asn Cys Ile Arg Gln Asn Gln Lys Thr Arg Val Arg Ser Gln Tyr Arg
180 185 190
Pro His Leu Ser Glu Thr Lys Arg Ile Thr Leu Val Val Thr His Asp
195 200 205
Leu Ile Thr Ile Phe Asp His Val Asn Lys Cys Ile Tyr His Leu Thr
210 215 220
Phe Glu Met Leu Leu Met Tyr Cys Asp Val Val Glu Gly Arg Leu Met
225 230 235 240
Thr Glu Ala Ser Met Ser Leu Asp His Arg Phe Ile Asn Leu Leu Ser
245 250 255
Arg Val Gln Tyr Met Trp Asp Leu Leu Asp Gly Met Phe Glu Ser Leu
260 265 270
Gly Asn Gln Leu Tyr Ser Ile Ile Ala Leu Leu Glu Pro Leu Ser Leu
275 280 285
Ala Tyr Leu Gln Leu Met Asp Ala Asp Pro Gln Ile Arg Gly Thr Phe
290 295 300
Leu His His Cys Leu Ser Glu Leu Glu Glu Leu Leu Phe Ser Lys Phe
305 310 315 320
Pro Phe Asp Pro Val Ile Tyr Glu Asn Leu Ile Ser Gly Leu Asp Tyr
325 330 335
Ile Tyr Leu Thr Asp Asp Ile His Leu Thr Ala Glu Ile Phe Ser Phe
340 345 350
Phe Arg Ser Phe Gly His Pro Tyr Leu Glu Ala Gln Asn Ala Ala Ser
355 360 365
Asn Val Arg Lys Tyr Met Asn Gln Pro Lys Val Ile Ser Tyr Gln Thr
370 375 380
Leu Met Gln Gly His Ala Ile Phe Cys Gly Ile Ile Ile Asn Gly Phe
385 390 395 400
Arg Asp Arg His Gly Gly Thr Trp Pro Pro Val Glu Leu Pro His His
405 410 415
Ala Ser Ala Val Ile Arg Asn Ala Gln Leu Ser Gly Glu Gly Leu Thr
420 425 430
Pro Glu Gln Cys Ala Gln Tyr Trp Arg Ser Phe Cys Gly Phe Lys Phe
435 440 445
Lys Cys Phe Met Pro Leu Ser Leu Asp Ser Asp Leu Thr Met Tyr Leu
450 455 460
Arg Asp Lys Ala Leu Ser Pro Ile Lys Asn Glu Trp Asp Ser Val Tyr
465 470 475 480
Ala Lys Glu Tyr Leu Arg Tyr Asn Pro Gly Leu Pro Thr Ser Ser Arg
485 490 495
Arg Leu Val Asn Val Phe Leu Glu Asp Asp Lys Phe Asp Pro Tyr Glu
500 505 510
Met Ile Met Tyr Val Ile Asn Gly Asp Tyr Leu Arg Asp Asn Glu Phe
515 520 525
Asn Leu Ser Tyr Ser Leu Lys Glu Lys Glu Ile Lys Glu Val Gly Arg
530 535 540
Leu Phe Ala Lys Met Thr Tyr Lys Met Arg Ala Cys Gln Val Ile Ala
545 550 555 560
Glu Asn Leu Ile Ala Asn Gly Val Gly Lys Phe Phe Lys Asp Asn Gly
565 570 575
Met Ala Lys Asp Glu His Lys Leu Thr Lys Thr Leu His Lys Leu Ala
580 585 590
Ile Ser Gly Val Pro Lys Asp Asn Phe Gln Leu Tyr Leu Ser Glu Cys
595 600 605
Trp Glu Gln Val Val Glu Gln Cys Val Thr Ser Thr Gln Thr Lys Asn
610 615 620
Gln Ile Ile Ser Ser His Ser Arg Lys Ser Val Ala Ser Lys Phe Pro
625 630 635 640
Arg Ser Asn Pro Asn Asp Arg Gly Ile Leu Asn Ser Gly Arg His Leu
645 650 655
Asn Lys His Pro Lys His Pro Ser Asn Thr Glu Tyr Tyr Glu Thr Val
660 665 670
Ser Ser Phe Ile Thr Thr Asp Leu Lys Lys Tyr Cys Leu Asn Trp Arg
675 680 685
Tyr Glu Ser Ser Ser Val Phe Ala Glu Arg Leu Asn Glu Ile Tyr Gly
690 695 700
Leu Pro Gly Phe Phe His Trp Leu His Arg Ile Leu Glu Lys Ser Val
705 710 715 720
Leu Tyr Val Ser Asp Pro Ser Ser Pro Pro Asp Phe Asp Gln His Val
725 730 735
Asp Ile Asp Ser Val Pro Asn Asp His Ile Phe Ile Lys Tyr Pro Met
740 745 750
Gly Gly Ile Glu Gly Phe Cys Gln Lys Leu Trp Thr Ile Ser Thr Ile
755 760 765
Pro Phe Leu Tyr Leu Ala Ala Phe Asp Thr Gly Val Arg Ile Ser Ser
770 775 780
Leu Val Gln Gly Asp Asn Gln Ala Ile Ala Val Thr Lys Arg Val Pro
785 790 795 800
Ser Ser Trp Ser Tyr Ser Arg Lys Lys Glu Glu Ser Thr Lys Val Thr
805 810 815
Thr Gln Tyr Phe Leu Asn Leu Arg Gln Arg Leu His Asp Ile Gly His
820 825 830
Glu Leu Lys Ala Asn Glu Thr Ile Ile Ser Ser His Phe Phe Val Tyr
835 840 845
Ser Lys Gly Ile Tyr Tyr Asp Gly Ile Leu Leu Ser Gln Ser Leu Lys
850 855 860
Ser Ile Ala Arg Cys Val Phe Trp Ser Glu Thr Ile Val Asp Glu Thr
865 870 875 880
Arg Ser Ala Cys Ser Asn Ile Ser Thr Thr Leu Ala Lys Ala Ile Glu
885 890 895
Arg Gly Tyr Asp Lys Phe Val Ala Tyr Ala Ile Asn Ile Tyr Lys Thr
900 905 910
Ile His Gln Val Leu Ile Ala Leu Ser Phe Thr Ile Asn Pro Thr Met
915 920 925
Thr Pro Asp Ile Thr Glu Pro Phe Tyr Lys Ser Leu Asp Leu Leu Lys
930 935 940
Asn Leu Ile Leu Ile Pro Ala Pro Leu Gly Gly Met Asn Tyr Met Asn
945 950 955 960
Met Ser Arg Leu Phe Val Arg Asn Ile Gly Asp Pro Ile Thr Ala Ser
965 970 975
Phe Ala Asp Ile Lys Arg Met Ile Glu Cys Gly Leu Leu Gly His Asn
980 985 990
Val Leu Ser Gln Ile Met Tyr Gln Lys Cys Gly Thr Ser Lys Tyr Leu
995 1000 1005
Asp Trp Ala Ser Asp Pro Tyr Ser Ile Asn Leu Pro Tyr Ser Gln Ser
1010 1015 1020
Met Thr Lys Val Leu Lys Asn Ile Thr Ala Arg Tyr Val Leu Met His
1025 1030 1035 1040
Ser Pro Asn Pro Met Leu Lys Asp Leu Phe His Glu Lys Ser Gln Glu
1045 1050 1055
Glu Asp Glu Ile Leu Ala Glu Phe Leu Leu Asp Arg Gln Leu Ile Ile
1060 1065 1070
Pro Arg Ala Ala His Glu Ile Leu Ser Asn Ser Val Thr Gly Ala Arg
1075 1080 1085
Glu Ser Ile Ala Gly Met Leu Asp Thr Thr Lys Gly Leu Ile Arg Ala
1090 1095 1100
Ser Met Ser Arg Gly Gly Leu Thr Ser Ser Leu Val Leu Lys Leu Ser
1105 1110 1115 1120
Thr Tyr Asp Tyr Gln Gln Phe Arg Thr Cys Leu Glu Trp Leu Tyr Ala
1125 1130 1135
Pro Thr Thr Gly Ile Ala Val Ser Ala Asp Ser Cys Ser Val Phe Leu
1140 1145 1150
Ala Arg Ala Ile Arg Lys Arg Met Trp Val His Leu Thr Lys Gly Arg
1155 1160 1165
Glu Ile Tyr Gly Leu Glu Val Pro Asp Ile Leu Glu Cys Met Gln Ser
1170 1175 1180
Asn Val Ile Val Asp His Glu Asp Cys Tyr Ser Cys Ile Gln Gly Ser
1185 1190 1195 1200
Arg Tyr Tyr Thr Trp Phe Phe Val Pro Ser Asn Cys Gln Leu Asp Gln
1205 1210 1215
Ile Asn Lys Ser Thr Asn Ser Leu Arg Val Pro Tyr Ile Gly Ser Thr
1220 1225 1230
Thr Glu Glu Arg Ser Asp Met Lys Leu Ser Tyr Val Arg Ser Pro Ser
1235 1240 1245
Arg Pro Leu Lys Ala Ala Val Arg Ile Ala Ala Val Tyr Thr Trp Ala
1250 1255 1260
Tyr Gly Asp Asp Asp Leu Ser Trp Arg Glu Ala Trp Tyr Leu Ala Arg
1265 1270 1275 1280
Thr Arg Ala Asn Val Thr Phe Asp Glu Leu Lys Leu Val Thr Pro Ile
1285 1290 1295
Ala Thr Ser Thr Asn Leu Ala His Arg Leu Arg Asp Arg Ser Thr Gln
1300 1305 1310
Val Lys Tyr Ser Gly Thr Ser Leu Val Arg Val Ala Arg Tyr Thr Thr
1315 1320 1325
Ile Ser Asn Asp Asn Met Ser Phe Val Ile Asn Asp Lys Lys Val Asp
1330 1335 1340
Thr Asn Phe Val Tyr Gln Gln Gly Met Leu Leu Gly Leu Ser Ile Leu
1345 1350 1355 1360
Glu Tyr Ile Phe Arg Tyr Cys Lys Ser Thr Gly Gln Ser Asn Thr Val
1365 1370 1375
Val His Leu His Ala Asp Val Asn Cys Cys Ile Ile Gln Met Thr Asp
1380 1385 1390
Gln Pro Tyr Thr Pro Ser Leu Thr Lys Lys Leu Pro Glu Ile Lys Pro
1395 1400 1405
Ile Asn Asn Lys Leu Ile Tyr Asp Pro Ala Pro Ile Ile Asp Thr Asp
1410 1415 1420
Ala Ala Arg Leu Tyr Ser Gln Lys Tyr Leu Ser His Leu Ile Asp Phe
1425 1430 1435 1440
Pro Asn Trp Ser Met Asn Gln Leu Asn Val Val Leu Ala Lys Val Val
1445 1450 1455
Ala Ile Ser Ile Val Asp Leu Ile Thr Lys Ala Ser Lys Asp His Leu
1460 1465 1470
Asn Glu Ile Met Ala Val Val Gly Asp Asp Asp Ile Asn Ser Phe Ile
1475 1480 1485
Thr Glu Phe Leu Leu Val Asp Pro Arg Leu Phe Thr Leu Tyr Leu Gly
1490 1495 1500
Gln Tyr Thr Ser Leu Gln Trp Ala Tyr Glu Ile His Tyr His Arg Pro
1505 1510 1515 1520
Val Gly Lys Tyr Gln Met Ala Glu Val Leu His Thr Leu Leu Ser Arg
1525 1530 1535
Ala Ser Lys Gly Ile Phe Asn Ile Leu Thr Asn Ala Phe Ser His Pro
1540 1545 1550
Arg Val Tyr Lys Arg Phe Trp Glu Cys Gly Leu Leu Glu Pro Ile Tyr
1555 1560 1565
Gly Pro Tyr Ile Gly Ser Gln Asn Leu Tyr Ser Thr Val Ile Asp Tyr
1570 1575 1580
Leu Tyr Asn Ala Tyr Ile Thr Tyr Leu Asp Ala Tyr Leu Ser Asp His
1585 1590 1595 1600
Ile Glu Asp Ala Asp Ile Val Ile Cys Glu Thr Glu Glu Thr Cys Leu
1605 1610 1615
Ala Asn Arg Ile Asp Asn Tyr Gln Gly Arg His Leu Ala Val Leu Ile
1620 1625 1630
Asp Leu Tyr Cys Asp Ser Thr Arg Cys Pro Asn Ile Lys Gly Ser Asp
1635 1640 1645
Thr Ile Met Arg Asn Ser Ile Leu Lys Ser Phe Ile Asp Asn Glu Arg
1650 1655 1660
Arg Thr Ser Pro Leu Gly Leu Thr Trp Asn Leu Asp Pro Leu Leu Ile
1665 1670 1675 1680
Asp His Phe Ser Cys Ser Ile Thr Tyr Leu Arg Arg Gly Ile Ile Lys
1685 1690 1695
Gln Ile Arg Leu Arg Phe Asp Pro Asn Ile Ser Ile Glu Leu Val Lys
1700 1705 1710
Leu Ala Lys Pro Glu Val Ile His Gln Gly Pro Lys Ile Pro Ser Ser
1715 1720 1725
Trp Ala Leu Ile Asp Ile Asn Pro Glu Val Asn Asp Leu Asn Thr Val
1730 1735 1740
Phe Gly Glu Leu Asn Ser Lys Trp Lys Asp Ile Pro Ile Gly Gln Ile
1745 1750 1755 1760
Arg Ile Gln Asn Tyr Glu Ile His Ala Tyr Arg Arg Ile Gly Val Asn
1765 1770 1775
Ser Thr Ala Cys Tyr Lys Ala Leu Glu Met Leu Ser Val Leu Thr Arg
1780 1785 1790
Phe Met Ser Asn Pro Ala Gly Ala Leu Phe Leu Gly Glu Gly Ala Gly
1795 1800 1805
Ser Met Leu Val Thr Tyr Arg Ala Phe Ile Pro Phe Lys Arg Ile Tyr
1810 1815 1820
Tyr Asn Ser Gly Ile Ser Ile Gln Asn Ile Gln Ser Gln Arg Glu Leu
1825 1830 1835 1840
Ser Leu Tyr Pro Ser Glu Val Ala Leu Val Asp Asn Lys Asn Arg Leu
1845 1850 1855
Thr Ser Asp Pro Asp Ile Lys Val Leu Phe Asn Gly Lys Pro Glu Ser
1860 1865 1870
Thr Trp Val Gly Asn Ile Asp Cys Phe Ala Tyr Ile Leu Ser His Ile
1875 1880 1885
Glu Thr Ser Ser Leu Thr Leu Ile His Ser Asp Ile Glu Ser Ser Leu
1890 1895 1900
Ser Lys Thr Lys Asn Lys Ile Leu Glu Glu Leu Cys His Ile Leu Ser
1905 1910 1915 1920
Met Ala Leu Ile Leu Gly Lys Ile Gly Ser Val Leu Val Ile Lys Leu
1925 1930 1935
Leu Pro Arg Val Gly Asp Tyr Thr Tyr Ser Phe Cys Lys Tyr Ala Ser
1940 1945 1950
Glu Phe Tyr Gln Gln Asn Phe Phe Ile Leu Pro Arg Phe Ser Asn Met
1955 1960 1965
Ser Ser Ser Glu Ile Tyr Tyr Val Gly Val His Leu Asn Thr Asn Arg
1970 1975 1980
Leu Val Asp Pro Asp Arg Ile Val Gln Tyr Ile Ile Arg Asn Leu Gln
1985 1990 1995 2000
Ser Thr Pro Val Thr Phe Leu Ser Tyr Ile Leu Glu Thr Lys Tyr Arg
2005 2010 2015
Asn Asn Met Val Thr Asn Tyr Gly Leu Cys Leu Ser Asp Gly His Lys
2020 2025 2030
Ser Asp Tyr Leu Ser Ser Ile Thr Lys Ile Glu Asn Val Leu Leu Ser
2035 2040 2045
Cys Gly Leu Glu Leu Asn Gly Pro Lys Ile Ile Gln Gln Leu Ser Gly
2050 2055 2060
His Asp Tyr Ala Asn Gly Glu Ile Ser Leu Glu Ser Ser Ile Met Val
2065 2070 2075 2080
Leu Val Arg Glu Tyr Leu Asn Ala Thr Ile Gln Gly Arg Glu Thr Leu
2085 2090 2095
Gly Leu Phe Ser Pro Tyr Pro Val Leu His Glu Ser Gln Leu Arg Glu
2100 2105 2110
Ile Asn Arg Cys Ile Ala Leu Lys Tyr Val Val Tyr Leu Leu Phe Tyr
2115 2120 2125
Ser Thr Ser Val Gly Ser Ser Arg Gln Ile Met Ser Asn Leu Arg Lys
2130 2135 2140
Gly Val Leu Met Tyr Asp Leu Arg Asp Glu Phe Phe Met Glu Arg Leu
2145 2150 2155 2160
Ser Thr Asn Phe Lys Lys Lys Ile Met Ser Gln Glu Val Lys Thr Thr
2165 2170 2175
Trp Ile Phe Asn Ile Asp Val Pro Thr Arg Lys Ala Leu Tyr Lys Leu
2180 2185 2190
Val Gly Tyr Ser Leu Ile Ile Asn His Val
2195 2200
<210> 8
<211> 16045
<212> DNA
<213> Feline Paramyxovirus-Type 2
<220>
<223> complementary sequence of the genome of Feline Paramyxovirus-Type
2 (FPaV-2), Strain TV25
<400> 8
accagacaaa gatgtctgtg acctattcta acggttagat tattacttga tatttaggaa 60
taacgattcc attagtcagg taagggagag gaatcagtta ttctataatg gctagtttac 120
tcaggtcact tgcggcattc aagaaacaca gagaacaacc aactgttcct tctgggtcag 180
gagggacgat caaaggatta aaaaatacaa ttattgtgcc tgttcctgga gatacagtca 240
tcactaccag atcgaactta ctgttcagat tagtctacat aattggtaat ccagatacac 300
ctttaagcac ttcaacaggg gcaataatat cattgttgac attatttgtt gaatctccag 360
gtcaattaat tcaaagaatc gctgatgatc ctgatgctgt ttttaaatta gtagaggtgg 420
ttcctgaggt tggtaatcct ggagaattaa cttttgcatc tagaggaatt aacttggata 480
aacaagctca acaatacttt agattggctg agaaaaatga tcaaggatat tatgtaagtt 540
tggggtttga aaatccacca aatgatgatg atataacgtc aagtcctgaa atcttaaatt 600
atattttagc atctgtactt gcacagatct ggattctcct agctaaggct gtaactgctc 660
cagacacagg tggtgaggct gaaaatcgta ggtggattaa attgatgcaa caacgcagag 720
tggatggtga gcttagatta agtaaaggat ggttggactt agtgaggaat aaaatcgcat 780
cggatatcac aattagaagg tttatggtag cattagttct tgacattaaa cgttctcctg 840
gaacaagacc aagaattgct gaaatgattt gtgatataga caattatatt gtggaggccg 900
gactggcaag ttttctgtta actatcaaat ttggtataga aacacgttac ccagcattgg 960
cgttacatga gttttcgggg gaattagcca ctattgaagg actcatgaaa ttgtaccagt 1020
ctatgggaga aatggcacca tacatggtca ttctagagaa ttcgatccag actaggttta 1080
gtgctgggtc ttatccgtta ctctggagct atgctatggg tgttggtgta gaacttgaga 1140
gatcaatgag tggattaaac ttcacaagaa gtttctttga tcctacgtac ttcaggttgg 1200
gtcaggagat ggtaagaagg tcttcaggaa tggttaatag ctcatttgct aaagaacttg 1260
gactatctga acatgaaaca caacttgtta gccagatcat taactctggt ggtgaatcag 1320
gtataccgaa atttgatgga tttagagcaa acccaacaac atttctaggg gctaaggaca 1380
acatcactga taggagtgaa gatccattga ttgcaattcc agggtcatca ggacaaccat 1440
tgccaggtca tgaccccaat atctcaggtg actcatatag aattgatagt agcactaaag 1500
acacgaacaa tatatcagat ggaggaacaa atccaagtca tgatgtttcc aattctgcta 1560
tggaagagct gagaagattg gtagagtcta ccaacaagat tgatacaaag aaatctgaaa 1620
gcccaggcat tgttaatcat tacaacgata ctgaccttct gagataataa ggatatattc 1680
aggtagatct ttacagaatt taaattaaga aaaacttagg acctcaaggt tcacactcct 1740
ctggccttca tcagaactcg gccaattcct cactcactcc atgtcagcag aacaaatcca 1800
acaagttaga catggccttg aatccttgca agagatcaaa aacaaccctc caccctctca 1860
agatgtcaat cttgccaggg aaatttacga atccattaaa caaacaggaa caccttcaac 1920
acaaggaggg accattacag gaaataatac tacgtcaggg tgtgacaatt actcaatgca 1980
tagccaggga tcaggtcctt ctgtttcagg tgctgacaag aatatcgaga gacttactgg 2040
acccgattat tcagaattat gggatccaga aggtaacctc tgcatgctat tcgaaagcga 2100
tgatgatgac aacaattatt cagagattaa tggccggtct accgctatcg aaggattgga 2160
tgaacagaat aataaggacc caggtattaa acaatcagga gatcagtgtt ctgaaggagt 2220
gtctaagatt aattcatctt ctagtcccca agaagctaca ttatcttctg ggagatctga 2280
tatatctggg acaggagtat ctccctgtgc ctctttggat ataactgtta atgaattaga 2340
agatgcaact gttaagaata gtaataatat gaaaggaaat tggccaatcc caaagttgct 2400
tgtcaaacca ccaccaagaa tgaaatcact ttctgactct gttacaccat taaaaggggc 2460
caccgacggg aaatcagtct tacctgggat ggagattaca ttgtccggga agaatggtgc 2520
aaccctacct gtacacccat ttacacaacc tgtaaaagac tcaaatgcag atgtaagcaa 2580
tgtccgtcaa catgtcccaa gtgtgactga tggttatagt gatgataatg aggaagtacc 2640
cggtttgcat aaagaaacta tagacaaagc tgatctatct atgcaggaca tatacaattt 2700
aattcttgga tttaaggatg attacaggaa actatcaaat aaattggata tgatactaga 2760
gatgaaacaa gatattgata atcttaaaaa gagtagtgca aaaatacaac ttgcattatc 2820
aacaattgaa ggacatctgt ccagtgttat gattgctatt ccaggttcag gtattgatat 2880
gaatcaagat gagaagaagg atcaattaaa ctctgactta aagccattac tagggaggga 2940
ccattgccgt gcatttcgtg aagtcactaa tcctttagat gaaacgtcat tgaccaacgc 3000
tccgaccaaa catgttgcta agatcaacaa aaattgcact cttcagaaaa tcaataagaa 3060
tgagacatct gcaattaagt ttgtacctaa tgatagctat gcaagtatct cgactatcaa 3120
gtctattgtc aaatcctcaa accttaatca agagcttaaa gtcaagttac tgacaattct 3180
atctcaaatt aaaggggtag acaatattaa ggagttttat gagaaagtta tgatattgat 3240
caagaataat aactgatctt gactaatcaa tagatactac ttatcaaatc tagctctgac 3300
atcaagtgaa ttcatcttta ttaacaagta ttaatcttaa ataattataa aaaacttagg 3360
agttcaggat cagtgggtca tatacaatat gactgagata ttcaatctgg atgaaagttc 3420
atggtcagtc aagggaacac tggacccatt gacgcctgat acttatcctg atgggcgcct 3480
agtacccaag attcgggtta ttgatcccgg tctaggtgat cgtaaaagtg gaggatatat 3540
gtacttactc cttcacggtg tcatcgagga cagtgagacc gtcataaatc cgaaagggag 3600
agcatttgga gctttccctt taggtgtagg gcaatcaacc gagaacccag aagacttatt 3660
taaggaaata ttaaccctca acattgttac tcgcaggact gctggcttca atgaaaaatt 3720
ggtgtattat aatactacac ctctaaatct actaacccct tggaaaaaag tactagcata 3780
tggaagtatc tttactgcta atcaggtctg caataataca agttctatcc ctatagacat 3840
tcctcagaaa tttcgacctg tctatttaac tgttaccaag ttatcggatg atggatatta 3900
tcagatacct aaaatgatac aggatttcaa atcatcaaac tctgttgcat ttaacatcct 3960
tgtgcatcta tcaatgggaa caattttact tgactcatct aaaggctctc gagtaggaaa 4020
tcctgcagaa aatttgatca cattcatgat tcatattggg aatttcaaac ggaagaataa 4080
taaagcttat tctcccgaat attgtaagag gaaaataatg aggcttggat taatcttctc 4140
actaggagcc attggtggaa caagtttgca tattcgatgc acaggcaaaa tgagtaagcg 4200
attacaagcc tacttagggt ttaaaagaac tttatgttat cctctgatgt atgtcaatga 4260
gggtctaaac aaaaccttat ggagaaatga atgcagaatt gagaaggttc aagcagtatt 4320
acagccatca gttccgaatg aatttaagat ttatgatgat ataatcattg ataacacgaa 4380
tggcctcttt aaggttaagt aagctgtgac tagtatcagg agttactagt caaaatcatg 4440
tgttgatatc cgaattaata gctttaagtt gaatatatta aacctgtgat aattcaaatt 4500
tgaaacataa ttagtatgta gtattgtatt aatcagtttg taatcttgtt tgaggatcca 4560
aattataacc tattaggtat tgccactcca gcttacaggt aaatctaagc gaatatacaa 4620
ataattgata ttcgggatta aacaatactt gcatattaat ccataggtat attagatttt 4680
actatattca attattataa tgtttattga gttaagctct catgattata aaaaacttag 4740
gattccacat aatcacagtt tgattgccaa ttgatgtgtt tagtattagt tgtgtgaaat 4800
attgatatta ataaggttaa tcaacttttg tacagaagtg aaggtgtaat tagatagaaa 4860
tagattaatc cttagtagcc gttttgataa ttgaattgat tcttgtttta attctgaatt 4920
gagattatta atcaccagct cggcataatg tataagatta aggttgtaat catgggtttt 4980
ttactgttat cagatattac atttgcacag gtaggttggg ataatttaac ctcaattgga 5040
gttataagta ctaaacaata taactataag ataactactt tgaatactaa tcaactcatg 5100
gtgattaaaa tggtacccaa tatatcatca attattaact gtactaaact tgaattagca 5160
aaatataggg aactgattac aggaatactg agaccaatta atgaatcatt agaattgatg 5220
aattcatata tcaacatgag aacaggttca gagagattca taggggctgt tatagcagga 5280
gtagctctag gggttgcaac tgcggcgcag ataacatcgg gaattgcctt acataattcg 5340
attatgaata aaaaacagat acaggaatta aggaaagccc ttagtactac aaataaggca 5400
attgatgaga taaggattgc aggtgaaaga actctgatag ctgtccaagg tgtgcaagat 5460
tacattaaca atgttattat ccctatgcaa gagaaactcc agtgcgatat tttagcctca 5520
cagctatcta ttgccctact cagatactat actaatatac tgactgtttt tggaccaagt 5580
ataagagatc ctattactag tacaatttct atacaagctc tcagtcaagc attcaatggt 5640
aatctacagg cattgcttga tggattaggg tatactggac aagacttaca tgatctcata 5700
gaaagtagat ctatcactgg tcaaataatt cacgctgata tgactgattt attccttata 5760
ttgagaatca attatccatc tattacggat atgcaaggag tggtaatata tgagctgaat 5820
tctatcacat atcatattgg acctgaagag tggtacacta ttatgcctaa tttcatagct 5880
gttcagggat ttctggtatc taatttcgat gaacgtaaat gttcaattac taaaacaagt 5940
atactgtgtc aacagaattc aatttatcct atgtcaaccg aaatgcaaag atgtataaaa 6000
ggtgagatta aattctgtcc aaggtccaaa gcaattggga cattagttaa tcgatttata 6060
ttaattaatg ggaatctaat ggccaattgt ttgggtatta tttgtagatg ttatacctca 6120
ggtcaaatta taacgcaaga cccaaataaa ttaatcacaa ttatatcaca agaagaatgt 6180
agagaggttg gtgttgatgg gattcgtata atggtgggac ctaaaaaatt accggatgtt 6240
atctttaatg ccagactaga aataggtgta cctatctcat taagcaagct ggatgttggg 6300
accgatttgg caattgcttc agctaaactc aataactcta aggcactttt ggagcagtct 6360
gataaaatct taaattctat gtctaagttg gattctttaa attcacgtat cttaggatct 6420
gtctttataa tgatgataat ctttgtgatt gtaattgtga ttatttggat tatttgtaag 6480
aagtgtagaa ataagaggaa caaattaagt gcttctattg aacccctcta catacctccc 6540
tcttataatt caccccatag catagttaaa tctatttgaa atataagtgt ataatctgat 6600
ataacagatg cagtagaatt attaatcaat gataatatta ttatgataat gattcagtta 6660
gatgttcatt atatctcata acttaatatt gacaaatttc aattagttaa atttattctc 6720
ttcataatat gtatttgttt aattatccta gattaatgta ttgttattaa actggtcatc 6780
tttaatacct aactcagcaa tactatccta tacacatgta ttagctaata acgatgtaat 6840
attgccattt aataataagt acctagtaga atgggaagca ttagctgtag tcaatgaatc 6900
attatctgct caattagaaa aaayttagga atccatgtta atgggagttg gccatcatgg 6960
agtctaataa caacaagtac tataaagatt caaaccggta ttttagcaag atactagatg 7020
agaacaagac ggtaaataat catctgtata gtcttagtat aaggataatt accgttatag 7080
ctattgttgt gagtctaatt gcaacaacaa taaccatcat taatgctata agcggaagga 7140
ctactcttaa taataatatg gacatgctac tcaaccaaca agacaagatt aataatatca 7200
aggaaatgat atttgatcgt atctatcccc tgataaatgc catgagtaca gagcttggtc 7260
ttcacattcc aactttattg gatgagctga ctaaatcaat tgatcaaaaa atcaagataa 7320
tgactccacc acttgaaact acgacatcta atctcaattg gtgtatcaac cccccaaatg 7380
gcattattgt agatcctaaa ggttactgtg aaggcttgga actgtcaaaa acttataagt 7440
tattacttga tcaattagat atgttaagaa agaaatcact tattattaat aagaaaagta 7500
ttaatcagtg tagacttgtt gatagctcga atatcatctt tgcaacagtt aatatacaat 7560
ctacaccgag attcttaaat cttggtcaca cagttagtaa ccaacgtata acattcggtc 7620
aaggaacata tagtagcact tatattataa ctatacaaga ggatggatta actgatgttc 7680
agtaccgagt atttgaaata ggatatatct cagatcaatt tggaaccttc ccttctctaa 7740
tcgtttctag agtactacct gtgcgaatgg tacttggaat ggaatcttgt acactgacca 7800
gtgacaagtt cgggggttat tttttatgca tgaacattcc gacacgctct atatatgatt 7860
atgtcaacat aagagactta aagtcactat acgtcacaat ccctcattat ggcaaaatta 7920
attacactta ctttaatttt ggaaaagtca gaagcccaca tgaaattgat aagatttggc 7980
ttacatcaga aaggggacag atgatttcag gttactttgc agcatttgtt acgattacaa 8040
ttagaaatta taacaattat ccctataaat gcttacataa cccgtgtctt gaaagatctg 8100
agagttattg caaaggatgg tacaaaaata ttacaggtac tgatgatgtt ccaatattag 8160
catatctatt agttgaaatg aaggatgagg aaggaccttt aattacactg gttgaaatac 8220
caccttacaa ttatacggct ccttctcata attcccttta ctatgatgat aaaattaaca 8280
aattaataat gacaacatct catataggat acattcaaat caatgaagtg catgaagtca 8340
ttgtcgggga taatcttaag gctattctct taaacagatt atctgatgaa caccctactc 8400
ttactgcttg tagatttaat caggaaatta aagagcgaca tatatctgat gggttaataa 8460
tatctaactc tgctcttatt gatatacaag aacgtatgta tattacagtt aaggctgttc 8520
cacccatagg aaattataac ttcacggtag agttgcattc acggtcaaat acatcttacg 8580
tagggttgcc aaggcagttc aatgctaggt atgacaaact gcatctcgaa tgctttgcct 8640
gggataggtc ttggtggtgc gctttgatac ctcaattttc attaagttgg aatgaatctc 8700
tttcagtaga tactgccatt ttcaacttaa taaactgtaa ttaagtttgt ggcttgttct 8760
agattgatca tttgaataac agttgattaa gccgaagtta gtaaatacat acattaacct 8820
gttcttgacc aagtatgtat cctaatccaa ttataaaaaa cttaggactc aaggtgttga 8880
tggcaatgga gcaatcagat tatcaagata ttttatatcc agaggtacat ctcaacagtc 8940
ctatagttat ctctaaatta gtgggtattt tggagtattc taaggttgtt cacaatcagc 9000
agttatctga tcacacaata gtcaagaata tacaatttag attgagaaat ggattcaata 9060
gtccaagagt acaaacactg ttagttatgg gtgaaattat caataaaatc aaaaataaat 9120
acccaaatta tttgcacata ccttatcctg aatgtaatca aaagttattt aggatggctg 9180
acccggagtt aacatctaaa ctagaagccc tcttggacaa aggtgacaca ttatatctta 9240
agattaagac agagatcata gcttgtttcg ataagttaaa aactaaaatg agcataacca 9300
atgatctgat tagtgacaat aggcagctaa tttcagatct acctctaatt gtcaagggat 9360
ctcaatggtt tttccctttt ttgctctggt tttctgttaa aactgagact aggaactgta 9420
ttcgacaaaa tcaaaaaact cgtgttaggt cacaataccg acctcatttg tcagaaacta 9480
aaagaattac gctggtcgtt acccctgact tgatcacaat atttgaccac gtcaacaaat 9540
gtatatatca tctgactttt gagatgttgt tgatgtattg tgatgtagta gaagggaggt 9600
taatgaccga agcatctatg agtctagatc acagatttat taacctattg tcgagggtcc 9660
agtatatgtg ggatctatta gatgggatgt ttgagagtct aggaaatcag ctatattcaa 9720
tcattgcact cttagaacct ctctctcttg cctatctaca gttgatggat gcagacccac 9780
agatacgggg tacattttta caccattgcc tttcagagtt ggaagaactc ttatttagta 9840
aatccccttt tgatcctgtg atttatgaaa atctaattag tggacttgat tacatctatt 9900
taacagacga tattcattta actgctgaga tattttcttt ctttagaagt tttggtcatc 9960
cttatttaga agcacaaaat gcagctagca atgttaggaa atatatgaat caacctaaag 10020
ttatctcata ccagactcta atgcaaggac atgcaatttt ttgtggcatt ataataaatg 10080
ggttcagaga tcgtcacgga gggacatggc cacctgtaga gctaccacat catgcatccg 10140
ctgtaattag aaatgctcag ttatctggag aaggattaac acctgagcag tgtgctcaat 10200
actggaggtc attttgtgga tttaaattta aatgttttat gccattaagt ctagatagcg 10260
acctcaccat gtaccttaga gataaggcat tatcacctat taagaatgag tgggattctg 10320
tgtatgctaa agagtattta agatacaacc ctggcttacc gactagctct cgaagattag 10380
tcaatgtatt tctagaagat gataaatttg atccgtacga aatgattatg tacgtaataa 10440
acggtgatta tttaagggat aatgagttca atctctcata tagtcttaaa gaaaaggaga 10500
tcaaggaggt aggccgattg ttcgctaaaa tgacttataa gatgagagct tgtcaggtaa 10560
tagcagaaaa tttaattgca aatggagttg ggaaattttt taaagacaat gggatggcga 10620
aggatgaaca taaattaacc aaaacattac ataagctggc tatttctggt gtacctaaag 10680
ataattctca actctattta agtgaatgtt gggaacaagt ggtagaacaa tgcgtaacca 10740
gtacgcaaac aaaaaatcaa attatcagtt cacactcagg aaaatcagtt gcatcaaagt 10800
tttcaagatc aaatcccaat gataggggta ttctaaatag tggtagacat ttgaataaac 10860
atccaaaaca tccatcaaac accgaatact atgaaactgt cagtagtttt ataactactg 10920
atctcaagaa atattgcctc aactggcgct atgaatcaag tagtgtgttt gcagaaagac 10980
tcaatgagat ttatgggtta ccaggatttt tccattggct tcatagaatt ttggagaaat 11040
ctgtattata tgttagtgat ccatccagtc cacctgattt tgatcaacat gtcgatattg 11100
attcagttcc aaatgatcat atttttatca aatacccaat gggtgggata aaaggatttt 11160
gtcaaaaatt atggacaatc agcacaatcc catttttata tttagcagcc tttgatacag 11220
gggttagaat atcttcgttg gttcaaggtg ataatcaagc aattgcagtg accaaaagag 11280
ttccatcatc ctggagttat tcgagaaaaa aagaggagtc aactaaagtt acaacacaat 11340
attttttaaa cttgagacaa cgcttacatg atataggtca tgagttaaag gcaaatgaga 11400
ctattatatc ttcacacttt tttgtttact ctaagggtat ttattatgat ggtatacttc 11460
tttcacaatc ccttaaaagt attgcaagat gtgttttttg gtccgagaca attgtcgatg 11520
agactaggtc agcttgcagc aatatatcca ctacccttgc taaagctatt gaacggggtt 11580
atgataaatt tgtagcatac gctattaata tatataagac tatacaccag gtcttaattg 11640
cattatcttt tactattaat cccactatga ctccggacat aacagaacct ttttataaaa 11700
gtttagattt acttaaaaac ctcattctga taccagcacc attgggtggg atgaattaca 11760
tgaatatgag cagattattt gttaggaaca taggtgatcc cattacagct tcatttgctg 11820
acatcaagcg tatgatcgaa tgcgggttat tagggcacaa tgttctctca caaataatgt 11880
atcagaaatg tggtacctcg aaatacttag attgggctag tgacccttat tccataaatc 11940
ttccttatag tcaaagcatg accaaagtat taaaaaatat aaccgcgaga tatgttctca 12000
tgcatagtcc taaccctatg ctaaaagatt tattccatga gaagtcacaa gaagaggatg 12060
agattcttgc tgaatttttg ctggatcgtc agttaataat ccctagagct gcacatgaaa 12120
ttttatcgaa ttcagtaaca ggagctagag agtcgattgc agggatgctt gatactacta 12180
aaggacttat tcgagccagt atgtcaagag gtggtctgac atcttcactt gttttgaaat 12240
tgtcaacata tgattatcaa caatttagaa catgccttga atggctttat gcccctacca 12300
caggaatagc agtaagtgct gattcttgtt cagttttttt agccagagct attcgaaaaa 12360
ggatgtgggt tcacctgact aaaggaagag aaatttatgg cctagaagtg cctgatatat 12420
tagaatgtat gcagagcaat gtaattgttg atcatgaaga ttgttattca tgtattcaag 12480
gatcaagata ctacacatgg ttttttgtac cttctaattg tcagcttgat cagattaaca 12540
agtctacaaa ttctctacgg gttccttaca ttggctctac tacagaggaa agaagtgaca 12600
tgaaattatc atacgtcaga tcccctagta ggccacttaa ggcagcagtc cgaattgcag 12660
cagtctacac atgggcatac ggtgatgacg atctgtcttg gcgtgaggct tggtacttgg 12720
caaggactag ggcaaatgtt actttcgatg agcttaaatt agtaacaccc atagctacct 12780
ctactaactt ggcacataga ttaagggaca ggagtactca agttaagtat tcaggaactt 12840
cattggtaag agtggcacgc tatacaacaa tatccaatga taatatgtca tttgttatta 12900
atgacaaaaa ggtagatact aattttgtct atcaacaggg catgttattg ggtttgagta 12960
tcctagaata tatatttaga tactgtaaaa gtactggtca atcaaatact gtagttcact 13020
tgcatgcaga tgttaattgt tgcataatcc aaatgacaga tcaaccttat actccaagct 13080
taacgaaaaa attacctgag attaaaccta ttaataataa attgatttat gatccagctc 13140
ctataattga tactgatgca gctaggttat attctcagaa gtacttatca cacctgatag 13200
attttccaaa ttggtcaatg aatcagctaa atgtagtttt agcaaaagta gttgcaatat 13260
ctattgtgga cttgataact aaagcgagta aagatcatct caatgaaatt atggcagttg 13320
ttggagatga tgacattaat agctttataa cagaattttt gctagttgat ccgaggctat 13380
ttacattgta cttaggtcaa tacacgtcac ttcaatgggc atatgaaatt cattatcacc 13440
gacccgtagg caaataccag atggcagaag tgttacacac tttactgtca agagcaagta 13500
aaggtatatt taatatattg actaatgcct ttagtcatcc tagagtttac aaaagatttt 13560
gggaatgtgg attactggag cctatttatg gaccatacat agggagccaa aatttatata 13620
gtacagtaat tgattacctt tacaatgctt atataactta tttagatgct tatctatctg 13680
atcatatcga agatgcagac atagtaatat gtgagacaga agaaacttgt ctagctaata 13740
ggattgataa ctatcaaggt aggcatctcg ccgtacttat tgatctttat tgtgattcta 13800
ctaggtgtcc taatataaaa gggtcagaca caatcatgcg aaactcaatt ctcaaatctt 13860
ttattgataa tgagagaagg acaagtccat taggtctaac atggaatctt gatccattac 13920
tcatagatca tttcagttgt tcaattactt atctgaggag aggtattatt aaacagatta 13980
ggctaaggtt tgatccaaac atatctattg agttggttaa attggcaaaa cctgaagtga 14040
ttcatcaagg accaaaaata ccgtcttctt gggcccttat agatattaat cctgaggtca 14100
atgatcttaa tacagttttc ggagaattaa atagtaaatg gaaagatatt cctattggac 14160
aaattagaat tcaaaatttt gagatccatg cttaccgaag aattggagtt aattcaactg 14220
catgttataa agcattggaa atgctatctg tactaactcg gtttatgtct aacccagcag 14280
gagctttgtt tttaggagag ggtgcagggt caatgttagt tacctatcgt gcgtttatcc 14340
cgttcaagag aatttattat aatagtggag tttctataca aaatattcaa agccaaaggg 14400
aactaagtct atacccatct gaagtagcct tggtcgataa taaaaatcgt ttgaccagtg 14460
atcctgatat caaagtctta tttaatggca agccagaatc cacgtgggtt gggaatatag 14520
actgctttgc ttatattctg agtcatattg aaacttctag tttaacatta atccacagtg 14580
atattgaatc tagcttgagt aaaacaaaga ataagattct tgaggagctt tgccatattc 14640
tatcaatggc actgattcta ggaaagattg gatctgtatt agttattaag ctattaccac 14700
gggttggtga ctacacatat tcattttgca agtatgcgtc agaattctac caacagaatt 14760
tcttcatttt acctagattt agtaacatgt catcatctga aatttactac gttggagttc 14820
atttaaatac caatagactg gttgatccag ataggattgt gcaatatata atcaggaatc 14880
tccaatctac tccagtcact ttcttatctt acattttgga aactaaatat agaaataata 14940
tggttacaaa ttatgggctc tgtttgtctg atggacataa aagcgattac ttgtcatcaa 15000
tcaccaagat agaaaatgtt cttttatcat gtggattgga attgaatgga cctaagatta 15060
ttcagcaatt atctggacat gactacgcca atggagagat tagcttagaa tcaagtataa 15120
tggtactggt cagagaatat ctaaatgcaa ctatccaagg tcgagaaaca ctaggtcttt 15180
tttcacctta ccctgtgtta catgagagtc agttaagaga aattaacagg tgcattgcat 15240
tgaagtatgt tgtatattta cttttttact caacctctgt aggatctagt agacagatca 15300
tgagcaatct cagaaaagga gtattaatgt atgacttaag agatgagttt ttcatggaaa 15360
ggttatcaac aaatttcaag aaaaaaataa tgtcacaaga ggttaaaact acatggatct 15420
ttaatattga tgtaccaaca agaaaagctc tgtataaatt agttggttat tcacttatca 15480
ttaatcacgt ataacaagtg tattgagttg gtaatattct agatgaacaa gtataggttt 15540
atgtacagta agtgattaaa tattagattc aggtagataa acttcctaat agtgtatcct 15600
atagataacc taaggctatt tgatgttaga ttaattagaa aaaacttctt gaattatgat 15660
agacttcaac ccctggctaa gacttatcat ttaaaattat aaccaagttg tcctgataat 15720
atcagatctc attaattact tgatagcgta atataacagg tgcatgatga tcctttatta 15780
ctcatatacc tgttattaag ctcctgttca cattatcccc tatttaagtt gccttttaaa 15840
ttacctaata tgtttagtaa tgagaaacat tgatacatac aaagctaaag aagcctgatt 15900
ttatctaagg ttgtatctaa ttgttgtcaa tttataattc ggaatatctg ggccctaaac 15960
ctcctccaaa tatactaaaa ggttttaaaa aaacaaaaaa ggtttcttac ttattgtacg 16020
gacctatagc tttcttttgt ctggt 16045
<210> 9
<211> 519
<212> PRT
<213> Feline Paramyxovirus-Type 2
<220>
<223> Nucleocapsid protein, Strain TV25
<400> 9
Met Ala Ser Leu Leu Arg Ser Leu Ala Ala Phe Lys Lys His Arg Glu
1 5 10 15
Gln Pro Thr Val Pro Ser Gly Ser Gly Gly Thr Ile Lys Gly Leu Lys
20 25 30
Asn Thr Ile Ile Val Pro Val Pro Gly Asp Thr Val Ile Thr Thr Arg
35 40 45
Ser Asn Leu Leu Phe Arg Leu Val Tyr Ile Ile Gly Asn Pro Asp Thr
50 55 60
Pro Leu Ser Thr Ser Thr Gly Ala Ile Ile Ser Leu Leu Thr Leu Phe
65 70 75 80
Val Glu Ser Pro Gly Gln Leu Ile Gln Arg Ile Ala Asp Asp Pro Asp
85 90 95
Ala Val Phe Lys Leu Val Glu Val Val Pro Glu Val Gly Asn Pro Gly
100 105 110
Glu Leu Thr Phe Ala Ser Arg Gly Ile Asn Leu Asp Lys Gln Ala Gln
115 120 125
Gln Tyr Phe Arg Leu Ala Glu Lys Asn Asp Gln Gly Tyr Tyr Val Ser
130 135 140
Leu Gly Phe Glu Asn Pro Pro Asn Asp Asp Asp Ile Thr Ser Ser Pro
145 150 155 160
Glu Ile Leu Asn Tyr Ile Leu Ala Ser Val Leu Ala Gln Ile Trp Ile
165 170 175
Leu Leu Ala Lys Ala Val Thr Ala Pro Asp Thr Gly Gly Glu Ala Glu
180 185 190
Asn Arg Arg Trp Ile Lys Leu Met Gln Gln Arg Arg Val Asp Gly Glu
195 200 205
Leu Arg Leu Ser Lys Gly Trp Leu Asp Leu Val Arg Asn Lys Ile Ala
210 215 220
Ser Asp Ile Thr Ile Arg Arg Phe Met Val Ala Leu Val Leu Asp Ile
225 230 235 240
Lys Arg Ser Pro Gly Thr Arg Pro Arg Ile Ala Glu Met Ile Cys Asp
245 250 255
Ile Asp Asn Tyr Ile Val Glu Ala Gly Leu Ala Ser Phe Leu Leu Thr
260 265 270
Ile Lys Phe Gly Ile Glu Thr Arg Tyr Pro Ala Leu Ala Leu His Glu
275 280 285
Phe Ser Gly Glu Leu Ala Thr Ile Glu Gly Leu Met Lys Leu Tyr Gln
290 295 300
Ser Met Gly Glu Met Ala Pro Tyr Met Val Ile Leu Glu Asn Ser Ile
305 310 315 320
Gln Thr Arg Phe Ser Ala Gly Ser Tyr Pro Leu Leu Trp Ser Tyr Ala
325 330 335
Met Gly Val Gly Val Glu Leu Glu Arg Ser Met Ser Gly Leu Asn Phe
340 345 350
Thr Arg Ser Phe Phe Asp Pro Thr Tyr Phe Arg Leu Gly Gln Glu Met
355 360 365
Val Arg Arg Ser Ser Gly Met Val Asn Ser Ser Phe Ala Lys Glu Leu
370 375 380
Gly Leu Ser Glu His Glu Thr Gln Leu Val Ser Gln Ile Ile Asn Ser
385 390 395 400
Gly Gly Glu Ser Gly Ile Pro Lys Phe Asp Gly Phe Arg Ala Asn Pro
405 410 415
Thr Thr Phe Leu Gly Ala Lys Asp Asn Ile Thr Asp Arg Ser Glu Asp
420 425 430
Pro Leu Ile Ala Ile Pro Gly Ser Ser Gly Gln Pro Leu Pro Gly His
435 440 445
Asp Pro Asn Ile Ser Gly Asp Ser Tyr Arg Ile Asp Ser Ser Thr Lys
450 455 460
Asp Thr Asn Asn Ile Ser Asp Gly Gly Thr Asn Pro Ser His Asp Val
465 470 475 480
Ser Asn Ser Ala Met Glu Glu Leu Arg Arg Leu Val Glu Ser Thr Asn
485 490 495
Lys Ile Asp Thr Lys Lys Ser Glu Ser Pro Gly Ile Val Asn His Tyr
500 505 510
Asn Asp Thr Asp Leu Leu Arg
515
<210> 10
<211> 491
<212> PRT
<213> Feline Paramyxovirus-Type 2
<220>
<223> Phosphoprotein, Strain TV25
<400> 10
Met Ser Ala Glu Gln Ile Gln Gln Val Arg His Gly Leu Glu Ser Leu
1 5 10 15
Gln Glu Ile Lys Asn Asn Pro Pro Pro Ser Gln Asp Val Asn Leu Ala
20 25 30
Arg Glu Ile Tyr Glu Ser Ile Lys Gln Thr Gly Thr Pro Ser Thr Gln
35 40 45
Gly Gly Thr Ile Thr Gly Asn Asn Thr Thr Ser Gly Cys Asp Asn Tyr
50 55 60
Ser Met His Ser Gln Gly Ser Gly Pro Ser Val Ser Gly Ala Asp Lys
65 70 75 80
Asn Ile Glu Arg Leu Thr Gly Pro Asp Tyr Ser Glu Leu Trp Asp Pro
85 90 95
Glu Gly Asn Leu Cys Met Leu Phe Glu Ser Asp Asp Asp Asp Asn Asn
100 105 110
Tyr Ser Glu Ile Asn Gly Arg Ser Thr Ala Ile Glu Gly Leu Asp Glu
115 120 125
Gln Asn Asn Lys Asp Pro Gly Ile Lys Gln Ser Gly Asp Gln Cys Ser
130 135 140
Glu Gly Val Ser Lys Ile Asn Ser Ser Ser Ser Pro Gln Glu Ala Thr
145 150 155 160
Leu Ser Ser Gly Arg Ser Asp Ile Ser Gly Thr Gly Val Ser Pro Cys
165 170 175
Ala Ser Leu Asp Ile Thr Val Asn Glu Leu Glu Asp Ala Thr Val Lys
180 185 190
Asn Ser Asn Asn Met Lys Gly Asn Trp Pro Ile Pro Lys Leu Leu Val
195 200 205
Lys Pro Pro Pro Arg Met Lys Ser Leu Ser Asp Ser Val Thr Pro Leu
210 215 220
Lys Gly Ala Thr Asp Gly Lys Ser Val Leu Pro Gly Met Glu Ile Thr
225 230 235 240
Leu Ser Gly Lys Asn Gly Ala Thr Leu Pro Val His Pro Phe Thr Gln
245 250 255
Pro Val Lys Asp Ser Asn Ala Asp Val Ser Asn Val Arg Gln His Val
260 265 270
Pro Ser Val Thr Asp Gly Tyr Ser Asp Asp Asn Glu Glu Val Pro Gly
275 280 285
Leu His Lys Glu Thr Ile Asp Lys Ala Asp Leu Ser Met Gln Asp Ile
290 295 300
Tyr Asn Leu Ile Leu Gly Phe Lys Asp Asp Tyr Arg Lys Leu Ser Asn
305 310 315 320
Lys Leu Asp Met Ile Leu Glu Met Lys Gln Asp Ile Asp Asn Leu Lys
325 330 335
Lys Ser Ser Ala Lys Ile Gln Leu Ala Leu Ser Thr Ile Glu Gly His
340 345 350
Leu Ser Ser Val Met Ile Ala Ile Pro Gly Ser Gly Ile Asp Met Asn
355 360 365
Gln Asp Glu Lys Lys Asp Gln Leu Asn Ser Asp Leu Lys Pro Leu Leu
370 375 380
Gly Arg Asp His Cys Arg Ala Phe Arg Glu Val Thr Asn Pro Leu Asp
385 390 395 400
Glu Thr Ser Leu Thr Asn Ala Pro Thr Lys His Val Ala Lys Ile Asn
405 410 415
Lys Asn Cys Thr Leu Gln Lys Ile Asn Lys Asn Glu Thr Ser Ala Ile
420 425 430
Lys Phe Val Pro Asn Asp Ser Tyr Ala Ser Ile Ser Thr Ile Lys Ser
435 440 445
Ile Val Lys Ser Ser Asn Leu Asn Gln Glu Leu Lys Val Lys Leu Leu
450 455 460
Thr Ile Leu Ser Gln Ile Lys Gly Val Asp Asn Ile Lys Glu Phe Tyr
465 470 475 480
Glu Lys Val Met Ile Leu Ile Lys Asn Asn Asn
485 490
<210> 11
<211> 337
<212> PRT
<213> Feline Paramyxovirus-Type 2
<220>
<223> Matrix protein, Strain TV25
<400> 11
Met Thr Glu Ile Phe Asn Leu Asp Glu Ser Ser Trp Ser Val Lys Gly
1 5 10 15
Thr Leu Asp Pro Leu Thr Pro Asp Thr Tyr Pro Asp Gly Arg Leu Val
20 25 30
Pro Lys Ile Arg Val Ile Asp Pro Gly Leu Gly Asp Arg Lys Ser Gly
35 40 45
Gly Tyr Met Tyr Leu Leu Leu His Gly Val Ile Glu Asp Ser Glu Thr
50 55 60
Val Ile Asn Pro Lys Gly Arg Ala Phe Gly Ala Phe Pro Leu Gly Val
65 70 75 80
Gly Gln Ser Thr Glu Asn Pro Glu Asp Leu Phe Lys Glu Ile Leu Thr
85 90 95
Leu Asn Ile Val Thr Arg Arg Thr Ala Gly Phe Asn Glu Lys Leu Val
100 105 110
Tyr Tyr Asn Thr Thr Pro Leu Asn Leu Leu Thr Pro Trp Lys Lys Val
115 120 125
Leu Ala Tyr Gly Ser Ile Phe Thr Ala Asn Gln Val Cys Asn Asn Thr
130 135 140
Ser Ser Ile Pro Ile Asp Ile Pro Gln Lys Phe Arg Pro Val Tyr Leu
145 150 155 160
Thr Val Thr Lys Leu Ser Asp Asp Gly Tyr Tyr Gln Ile Pro Lys Met
165 170 175
Ile Gln Asp Phe Lys Ser Ser Asn Ser Val Ala Phe Asn Ile Leu Val
180 185 190
His Leu Ser Met Gly Thr Ile Leu Leu Asp Ser Ser Lys Gly Ser Arg
195 200 205
Val Gly Asn Pro Ala Glu Asn Leu Ile Thr Phe Met Ile His Ile Gly
210 215 220
Asn Phe Lys Arg Lys Asn Asn Lys Ala Tyr Ser Pro Glu Tyr Cys Lys
225 230 235 240
Arg Lys Ile Met Arg Leu Gly Leu Ile Phe Ser Leu Gly Ala Ile Gly
245 250 255
Gly Thr Ser Leu His Ile Arg Cys Thr Gly Lys Met Ser Lys Arg Leu
260 265 270
Gln Ala Tyr Leu Gly Phe Lys Arg Thr Leu Cys Tyr Pro Leu Met Tyr
275 280 285
Val Asn Glu Gly Leu Asn Lys Thr Leu Trp Arg Asn Glu Cys Arg Ile
290 295 300
Glu Lys Val Gln Ala Val Leu Gln Pro Ser Val Pro Asn Glu Phe Lys
305 310 315 320
Ile Tyr Asp Asp Ile Ile Ile Asp Asn Thr Asn Gly Leu Phe Lys Val
325 330 335
Lys
<210> 12
<211> 543
<212> PRT
<213> Feline Paramyxovirus-Type 2
<220>
<223> Fusion protein, Strain TV25
<400> 12
Met Tyr Lys Ile Lys Val Val Ile Met Gly Phe Leu Leu Leu Ser Asp
1 5 10 15
Ile Thr Phe Ala Gln Val Gly Trp Asp Asn Leu Thr Ser Ile Gly Val
20 25 30
Ile Ser Thr Lys Gln Tyr Asn Tyr Lys Ile Thr Thr Leu Asn Thr Asn
35 40 45
Gln Leu Met Val Ile Lys Met Val Pro Asn Ile Ser Ser Ile Ile Asn
50 55 60
Cys Thr Lys Leu Glu Leu Ala Lys Tyr Arg Glu Leu Ile Thr Gly Ile
65 70 75 80
Leu Arg Pro Ile Asn Glu Ser Leu Glu Leu Met Asn Ser Tyr Ile Asn
85 90 95
Met Arg Thr Gly Ser Glu Arg Phe Ile Gly Ala Val Ile Ala Gly Val
100 105 110
Ala Leu Gly Val Ala Thr Ala Ala Gln Ile Thr Ser Gly Ile Ala Leu
115 120 125
His Asn Ser Ile Met Asn Lys Lys Gln Ile Gln Glu Leu Arg Lys Ala
130 135 140
Leu Ser Thr Thr Asn Lys Ala Ile Asp Glu Ile Arg Ile Ala Gly Glu
145 150 155 160
Arg Thr Leu Ile Ala Val Gln Gly Val Gln Asp Tyr Ile Asn Asn Val
165 170 175
Ile Ile Pro Met Gln Glu Lys Leu Gln Cys Asp Ile Leu Ala Ser Gln
180 185 190
Leu Ser Ile Ala Leu Leu Arg Tyr Tyr Thr Asn Ile Leu Thr Val Phe
195 200 205
Gly Pro Ser Ile Arg Asp Pro Ile Thr Ser Thr Ile Ser Ile Gln Ala
210 215 220
Leu Ser Gln Ala Phe Asn Gly Asn Leu Gln Ala Leu Leu Asp Gly Leu
225 230 235 240
Gly Tyr Thr Gly Gln Asp Leu His Asp Leu Ile Glu Ser Arg Ser Ile
245 250 255
Thr Gly Gln Ile Ile His Ala Asp Met Thr Asp Leu Phe Leu Ile Leu
260 265 270
Arg Ile Asn Tyr Pro Ser Ile Thr Asp Met Gln Gly Val Val Ile Tyr
275 280 285
Glu Leu Asn Ser Ile Thr Tyr His Ile Gly Pro Glu Glu Trp Tyr Thr
290 295 300
Ile Met Pro Asn Phe Ile Ala Val Gln Gly Phe Leu Val Ser Asn Phe
305 310 315 320
Asp Glu Arg Lys Cys Ser Ile Thr Lys Thr Ser Ile Leu Cys Gln Gln
325 330 335
Asn Ser Ile Tyr Pro Met Ser Thr Glu Met Gln Arg Cys Ile Lys Gly
340 345 350
Glu Ile Lys Phe Cys Pro Arg Ser Lys Ala Ile Gly Thr Leu Val Asn
355 360 365
Arg Phe Ile Leu Ile Asn Gly Asn Leu Met Ala Asn Cys Leu Gly Ile
370 375 380
Ile Cys Arg Cys Tyr Thr Ser Gly Gln Ile Ile Thr Gln Asp Pro Asn
385 390 395 400
Lys Leu Ile Thr Ile Ile Ser Gln Glu Glu Cys Arg Glu Val Gly Val
405 410 415
Asp Gly Ile Arg Ile Met Val Gly Pro Lys Lys Leu Pro Asp Val Ile
420 425 430
Phe Asn Ala Arg Leu Glu Ile Gly Val Pro Ile Ser Leu Ser Lys Leu
435 440 445
Asp Val Gly Thr Asp Leu Ala Ile Ala Ser Ala Lys Leu Asn Asn Ser
450 455 460
Lys Ala Leu Leu Glu Gln Ser Asp Lys Ile Leu Asn Ser Met Ser Lys
465 470 475 480
Leu Asp Ser Leu Asn Ser Arg Ile Leu Gly Ser Val Phe Ile Met Met
485 490 495
Ile Ile Phe Val Ile Val Ile Val Ile Ile Trp Ile Ile Cys Lys Lys
500 505 510
Cys Arg Asn Lys Arg Asn Lys Leu Ser Ala Ser Ile Glu Pro Leu Tyr
515 520 525
Ile Pro Pro Ser Tyr Asn Ser Pro His Ser Ile Val Lys Ser Ile
530 535 540
<210> 13
<211> 595
<212> PRT
<213> Feline Paramyxovirus-Type 2
<220>
<223> Hemagglutinin, Strain TV25
<400> 13
Met Glu Ser Asn Asn Asn Lys Tyr Tyr Lys Asp Ser Asn Arg Tyr Phe
1 5 10 15
Ser Lys Ile Leu Asp Glu Asn Lys Thr Val Asn Asn His Leu Tyr Ser
20 25 30
Leu Ser Ile Arg Ile Ile Thr Val Ile Ala Ile Val Val Ser Leu Ile
35 40 45
Ala Thr Thr Ile Thr Ile Ile Asn Ala Ile Ser Gly Arg Thr Thr Leu
50 55 60
Asn Asn Asn Met Asp Met Leu Leu Asn Gln Gln Asp Lys Ile Asn Asn
65 70 75 80
Ile Lys Glu Met Ile Phe Asp Arg Ile Tyr Pro Leu Ile Asn Ala Met
85 90 95
Ser Thr Glu Leu Gly Leu His Ile Pro Thr Leu Leu Asp Glu Leu Thr
100 105 110
Lys Ser Ile Asp Gln Lys Ile Lys Ile Met Thr Pro Pro Leu Glu Thr
115 120 125
Thr Thr Ser Asn Leu Asn Trp Cys Ile Asn Pro Pro Asn Gly Ile Ile
130 135 140
Val Asp Pro Lys Gly Tyr Cys Glu Gly Leu Glu Leu Ser Lys Thr Tyr
145 150 155 160
Lys Leu Leu Leu Asp Gln Leu Asp Met Leu Arg Lys Lys Ser Leu Ile
165 170 175
Ile Asn Lys Lys Ser Ile Asn Gln Cys Arg Leu Val Asp Ser Ser Asn
180 185 190
Ile Ile Phe Ala Thr Val Asn Ile Gln Ser Thr Pro Arg Phe Leu Asn
195 200 205
Leu Gly His Thr Val Ser Asn Gln Arg Ile Thr Phe Gly Gln Gly Thr
210 215 220
Tyr Ser Ser Thr Tyr Ile Ile Thr Ile Gln Glu Asp Gly Leu Thr Asp
225 230 235 240
Val Gln Tyr Arg Val Phe Glu Ile Gly Tyr Ile Ser Asp Gln Phe Gly
245 250 255
Thr Phe Pro Ser Leu Ile Val Ser Arg Val Leu Pro Val Arg Met Val
260 265 270
Leu Gly Met Glu Ser Cys Thr Leu Thr Ser Asp Lys Phe Gly Gly Tyr
275 280 285
Phe Leu Cys Met Asn Ile Pro Thr Arg Ser Ile Tyr Asp Tyr Val Asn
290 295 300
Ile Arg Asp Leu Lys Ser Leu Tyr Val Thr Ile Pro His Tyr Gly Lys
305 310 315 320
Ile Asn Tyr Thr Tyr Phe Asn Phe Gly Lys Val Arg Ser Pro His Glu
325 330 335
Ile Asp Lys Ile Trp Leu Thr Ser Glu Arg Gly Gln Met Ile Ser Gly
340 345 350
Tyr Phe Ala Ala Phe Val Thr Ile Thr Ile Arg Asn Tyr Asn Asn Tyr
355 360 365
Pro Tyr Lys Cys Leu His Asn Pro Cys Leu Glu Arg Ser Glu Ser Tyr
370 375 380
Cys Lys Gly Trp Tyr Lys Asn Ile Thr Gly Thr Asp Asp Val Pro Ile
385 390 395 400
Leu Ala Tyr Leu Leu Val Glu Met Lys Asp Glu Glu Gly Pro Leu Ile
405 410 415
Thr Leu Val Glu Ile Pro Pro Tyr Asn Tyr Thr Ala Pro Ser His Asn
420 425 430
Ser Leu Tyr Tyr Asp Asp Lys Ile Asn Lys Leu Ile Met Thr Thr Ser
435 440 445
His Ile Gly Tyr Ile Gln Ile Asn Glu Val His Glu Val Ile Val Gly
450 455 460
Asp Asn Leu Lys Ala Ile Leu Leu Asn Arg Leu Ser Asp Glu His Pro
465 470 475 480
Thr Leu Thr Ala Cys Arg Phe Asn Gln Glu Ile Lys Glu Arg His Ile
485 490 495
Ser Asp Gly Leu Ile Ile Ser Asn Ser Ala Leu Ile Asp Ile Gln Glu
500 505 510
Arg Met Tyr Ile Thr Val Lys Ala Val Pro Pro Ile Gly Asn Tyr Asn
515 520 525
Phe Thr Val Glu Leu His Ser Arg Ser Asn Thr Ser Tyr Val Gly Leu
530 535 540
Pro Arg Gln Phe Asn Ala Arg Tyr Asp Lys Leu His Leu Glu Cys Phe
545 550 555 560
Ala Trp Asp Arg Ser Trp Trp Cys Ala Leu Ile Pro Gln Phe Ser Leu
565 570 575
Ser Trp Asn Glu Ser Leu Ser Val Asp Thr Ala Ile Phe Asn Leu Ile
580 585 590
Asn Cys Asn
595
<210> 14
<211> 2202
<212> PRT
<213> Feline Paramyxovirus-Type 2
<220>
<223> Polymerase, Strain TV25
<400> 14
Met Glu Gln Ser Asp Tyr Gln Asp Ile Leu Tyr Pro Glu Val His Leu
1 5 10 15
Asn Ser Pro Ile Val Ile Ser Lys Leu Val Gly Ile Leu Glu Tyr Ser
20 25 30
Lys Val Val His Asn Gln Gln Leu Ser Asp His Thr Ile Val Lys Asn
35 40 45
Ile Gln Phe Arg Leu Arg Asn Gly Phe Asn Ser Pro Arg Val Gln Thr
50 55 60
Leu Leu Val Met Gly Glu Ile Ile Asn Lys Ile Lys Asn Lys Tyr Pro
65 70 75 80
Asn Tyr Leu His Ile Pro Tyr Pro Glu Cys Asn Gln Lys Leu Phe Arg
85 90 95
Met Ala Asp Pro Glu Leu Thr Ser Lys Leu Glu Ala Leu Leu Asp Lys
100 105 110
Gly Asp Thr Leu Tyr Leu Lys Ile Lys Thr Glu Ile Ile Ala Cys Phe
115 120 125
Asp Lys Leu Lys Thr Lys Met Ser Ile Thr Asn Asp Leu Ile Ser Asp
130 135 140
Asn Arg Gln Leu Ile Ser Asp Leu Pro Leu Ile Val Lys Gly Ser Gln
145 150 155 160
Trp Phe Phe Pro Phe Leu Leu Trp Phe Ser Val Lys Thr Glu Thr Arg
165 170 175
Asn Cys Ile Arg Gln Asn Gln Lys Thr Arg Val Arg Ser Gln Tyr Arg
180 185 190
Pro His Leu Ser Glu Thr Lys Arg Ile Thr Leu Val Val Thr Pro Asp
195 200 205
Leu Ile Thr Ile Phe Asp His Val Asn Lys Cys Ile Tyr His Leu Thr
210 215 220
Phe Glu Met Leu Leu Met Tyr Cys Asp Val Val Glu Gly Arg Leu Met
225 230 235 240
Thr Glu Ala Ser Met Ser Leu Asp His Arg Phe Ile Asn Leu Leu Ser
245 250 255
Arg Val Gln Tyr Met Trp Asp Leu Leu Asp Gly Met Phe Glu Ser Leu
260 265 270
Gly Asn Gln Leu Tyr Ser Ile Ile Ala Leu Leu Glu Pro Leu Ser Leu
275 280 285
Ala Tyr Leu Gln Leu Met Asp Ala Asp Pro Gln Ile Arg Gly Thr Phe
290 295 300
Leu His His Cys Leu Ser Glu Leu Glu Glu Leu Leu Phe Ser Lys Ser
305 310 315 320
Pro Phe Asp Pro Val Ile Tyr Glu Asn Leu Ile Ser Gly Leu Asp Tyr
325 330 335
Ile Tyr Leu Thr Asp Asp Ile His Leu Thr Ala Glu Ile Phe Ser Phe
340 345 350
Phe Arg Ser Phe Gly His Pro Tyr Leu Glu Ala Gln Asn Ala Ala Ser
355 360 365
Asn Val Arg Lys Tyr Met Asn Gln Pro Lys Val Ile Ser Tyr Gln Thr
370 375 380
Leu Met Gln Gly His Ala Ile Phe Cys Gly Ile Ile Ile Asn Gly Phe
385 390 395 400
Arg Asp Arg His Gly Gly Thr Trp Pro Pro Val Glu Leu Pro His His
405 410 415
Ala Ser Ala Val Ile Arg Asn Ala Gln Leu Ser Gly Glu Gly Leu Thr
420 425 430
Pro Glu Gln Cys Ala Gln Tyr Trp Arg Ser Phe Cys Gly Phe Lys Phe
435 440 445
Lys Cys Phe Met Pro Leu Ser Leu Asp Ser Asp Leu Thr Met Tyr Leu
450 455 460
Arg Asp Lys Ala Leu Ser Pro Ile Lys Asn Glu Trp Asp Ser Val Tyr
465 470 475 480
Ala Lys Glu Tyr Leu Arg Tyr Asn Pro Gly Leu Pro Thr Ser Ser Arg
485 490 495
Arg Leu Val Asn Val Phe Leu Glu Asp Asp Lys Phe Asp Pro Tyr Glu
500 505 510
Met Ile Met Tyr Val Ile Asn Gly Asp Tyr Leu Arg Asp Asn Glu Phe
515 520 525
Asn Leu Ser Tyr Ser Leu Lys Glu Lys Glu Ile Lys Glu Val Gly Arg
530 535 540
Leu Phe Ala Lys Met Thr Tyr Lys Met Arg Ala Cys Gln Val Ile Ala
545 550 555 560
Glu Asn Leu Ile Ala Asn Gly Val Gly Lys Phe Phe Lys Asp Asn Gly
565 570 575
Met Ala Lys Asp Glu His Lys Leu Thr Lys Thr Leu His Lys Leu Ala
580 585 590
Ile Ser Gly Val Pro Lys Asp Asn Ser Gln Leu Tyr Leu Ser Glu Cys
595 600 605
Trp Glu Gln Val Val Glu Gln Cys Val Thr Ser Thr Gln Thr Lys Asn
610 615 620
Gln Ile Ile Ser Ser His Ser Gly Lys Ser Val Ala Ser Lys Phe Ser
625 630 635 640
Arg Ser Asn Pro Asn Asp Arg Gly Ile Leu Asn Ser Gly Arg His Leu
645 650 655
Asn Lys His Pro Lys His Pro Ser Asn Thr Glu Tyr Tyr Glu Thr Val
660 665 670
Ser Ser Phe Ile Thr Thr Asp Leu Lys Lys Tyr Cys Leu Asn Trp Arg
675 680 685
Tyr Glu Ser Ser Ser Val Phe Ala Glu Arg Leu Asn Glu Ile Tyr Gly
690 695 700
Leu Pro Gly Phe Phe His Trp Leu His Arg Ile Leu Glu Lys Ser Val
705 710 715 720
Leu Tyr Val Ser Asp Pro Ser Ser Pro Pro Asp Phe Asp Gln His Val
725 730 735
Asp Ile Asp Ser Val Pro Asn Asp His Ile Phe Ile Lys Tyr Pro Met
740 745 750
Gly Gly Ile Lys Gly Phe Cys Gln Lys Leu Trp Thr Ile Ser Thr Ile
755 760 765
Pro Phe Leu Tyr Leu Ala Ala Phe Asp Thr Gly Val Arg Ile Ser Ser
770 775 780
Leu Val Gln Gly Asp Asn Gln Ala Ile Ala Val Thr Lys Arg Val Pro
785 790 795 800
Ser Ser Trp Ser Tyr Ser Arg Lys Lys Glu Glu Ser Thr Lys Val Thr
805 810 815
Thr Gln Tyr Phe Leu Asn Leu Arg Gln Arg Leu His Asp Ile Gly His
820 825 830
Glu Leu Lys Ala Asn Glu Thr Ile Ile Ser Ser His Phe Phe Val Tyr
835 840 845
Ser Lys Gly Ile Tyr Tyr Asp Gly Ile Leu Leu Ser Gln Ser Leu Lys
850 855 860
Ser Ile Ala Arg Cys Val Phe Trp Ser Glu Thr Ile Val Asp Glu Thr
865 870 875 880
Arg Ser Ala Cys Ser Asn Ile Ser Thr Thr Leu Ala Lys Ala Ile Glu
885 890 895
Arg Gly Tyr Asp Lys Phe Val Ala Tyr Ala Ile Asn Ile Tyr Lys Thr
900 905 910
Ile His Gln Val Leu Ile Ala Leu Ser Phe Thr Ile Asn Pro Thr Met
915 920 925
Thr Pro Asp Ile Thr Glu Pro Phe Tyr Lys Ser Leu Asp Leu Leu Lys
930 935 940
Asn Leu Ile Leu Ile Pro Ala Pro Leu Gly Gly Met Asn Tyr Met Asn
945 950 955 960
Met Ser Arg Leu Phe Val Arg Asn Ile Gly Asp Pro Ile Thr Ala Ser
965 970 975
Phe Ala Asp Ile Lys Arg Met Ile Glu Cys Gly Leu Leu Gly His Asn
980 985 990
Val Leu Ser Gln Ile Met Tyr Gln Lys Cys Gly Thr Ser Lys Tyr Leu
995 1000 1005
Asp Trp Ala Ser Asp Pro Tyr Ser Ile Asn Leu Pro Tyr Ser Gln Ser
1010 1015 1020
Met Thr Lys Val Leu Lys Asn Ile Thr Ala Arg Tyr Val Leu Met His
1025 1030 1035 1040
Ser Pro Asn Pro Met Leu Lys Asp Leu Phe His Glu Lys Ser Gln Glu
1045 1050 1055
Glu Asp Glu Ile Leu Ala Glu Phe Leu Leu Asp Arg Gln Leu Ile Ile
1060 1065 1070
Pro Arg Ala Ala His Glu Ile Leu Ser Asn Ser Val Thr Gly Ala Arg
1075 1080 1085
Glu Ser Ile Ala Gly Met Leu Asp Thr Thr Lys Gly Leu Ile Arg Ala
1090 1095 1100
Ser Met Ser Arg Gly Gly Leu Thr Ser Ser Leu Val Leu Lys Leu Ser
1105 1110 1115 1120
Thr Tyr Asp Tyr Gln Gln Phe Arg Thr Cys Leu Glu Trp Leu Tyr Ala
1125 1130 1135
Pro Thr Thr Gly Ile Ala Val Ser Ala Asp Ser Cys Ser Val Phe Leu
1140 1145 1150
Ala Arg Ala Ile Arg Lys Arg Met Trp Val His Leu Thr Lys Gly Arg
1155 1160 1165
Glu Ile Tyr Gly Leu Glu Val Pro Asp Ile Leu Glu Cys Met Gln Ser
1170 1175 1180
Asn Val Ile Val Asp His Glu Asp Cys Tyr Ser Cys Ile Gln Gly Ser
1185 1190 1195 1200
Arg Tyr Tyr Thr Trp Phe Phe Val Pro Ser Asn Cys Gln Leu Asp Gln
1205 1210 1215
Ile Asn Lys Ser Thr Asn Ser Leu Arg Val Pro Tyr Ile Gly Ser Thr
1220 1225 1230
Thr Glu Glu Arg Ser Asp Met Lys Leu Ser Tyr Val Arg Ser Pro Ser
1235 1240 1245
Arg Pro Leu Lys Ala Ala Val Arg Ile Ala Ala Val Tyr Thr Trp Ala
1250 1255 1260
Tyr Gly Asp Asp Asp Leu Ser Trp Arg Glu Ala Trp Tyr Leu Ala Arg
1265 1270 1275 1280
Thr Arg Ala Asn Val Thr Phe Asp Glu Leu Lys Leu Val Thr Pro Ile
1285 1290 1295
Ala Thr Ser Thr Asn Leu Ala His Arg Leu Arg Asp Arg Ser Thr Gln
1300 1305 1310
Val Lys Tyr Ser Gly Thr Ser Leu Val Arg Val Ala Arg Tyr Thr Thr
1315 1320 1325
Ile Ser Asn Asp Asn Met Ser Phe Val Ile Asn Asp Lys Lys Val Asp
1330 1335 1340
Thr Asn Phe Val Tyr Gln Gln Gly Met Leu Leu Gly Leu Ser Ile Leu
1345 1350 1355 1360
Glu Tyr Ile Phe Arg Tyr Cys Lys Ser Thr Gly Gln Ser Asn Thr Val
1365 1370 1375
Val His Leu His Ala Asp Val Asn Cys Cys Ile Ile Gln Met Thr Asp
1380 1385 1390
Gln Pro Tyr Thr Pro Ser Leu Thr Lys Lys Leu Pro Glu Ile Lys Pro
1395 1400 1405
Ile Asn Asn Lys Leu Ile Tyr Asp Pro Ala Pro Ile Ile Asp Thr Asp
1410 1415 1420
Ala Ala Arg Leu Tyr Ser Gln Lys Tyr Leu Ser His Leu Ile Asp Phe
1425 1430 1435 1440
Pro Asn Trp Ser Met Asn Gln Leu Asn Val Val Leu Ala Lys Val Val
1445 1450 1455
Ala Ile Ser Ile Val Asp Leu Ile Thr Lys Ala Ser Lys Asp His Leu
1460 1465 1470
Asn Glu Ile Met Ala Val Val Gly Asp Asp Asp Ile Asn Ser Phe Ile
1475 1480 1485
Thr Glu Phe Leu Leu Val Asp Pro Arg Leu Phe Thr Leu Tyr Leu Gly
1490 1495 1500
Gln Tyr Thr Ser Leu Gln Trp Ala Tyr Glu Ile His Tyr His Arg Pro
1505 1510 1515 1520
Val Gly Lys Tyr Gln Met Ala Glu Val Leu His Thr Leu Leu Ser Arg
1525 1530 1535
Ala Ser Lys Gly Ile Phe Asn Ile Leu Thr Asn Ala Phe Ser His Pro
1540 1545 1550
Arg Val Tyr Lys Arg Phe Trp Glu Cys Gly Leu Leu Glu Pro Ile Tyr
1555 1560 1565
Gly Pro Tyr Ile Gly Ser Gln Asn Leu Tyr Ser Thr Val Ile Asp Tyr
1570 1575 1580
Leu Tyr Asn Ala Tyr Ile Thr Tyr Leu Asp Ala Tyr Leu Ser Asp His
1585 1590 1595 1600
Ile Glu Asp Ala Asp Ile Val Ile Cys Glu Thr Glu Glu Thr Cys Leu
1605 1610 1615
Ala Asn Arg Ile Asp Asn Tyr Gln Gly Arg His Leu Ala Val Leu Ile
1620 1625 1630
Asp Leu Tyr Cys Asp Ser Thr Arg Cys Pro Asn Ile Lys Gly Ser Asp
1635 1640 1645
Thr Ile Met Arg Asn Ser Ile Leu Lys Ser Phe Ile Asp Asn Glu Arg
1650 1655 1660
Arg Thr Ser Pro Leu Gly Leu Thr Trp Asn Leu Asp Pro Leu Leu Ile
1665 1670 1675 1680
Asp His Phe Ser Cys Ser Ile Thr Tyr Leu Arg Arg Gly Ile Ile Lys
1685 1690 1695
Gln Ile Arg Leu Arg Phe Asp Pro Asn Ile Ser Ile Glu Leu Val Lys
1700 1705 1710
Leu Ala Lys Pro Glu Val Ile His Gln Gly Pro Lys Ile Pro Ser Ser
1715 1720 1725
Trp Ala Leu Ile Asp Ile Asn Pro Glu Val Asn Asp Leu Asn Thr Val
1730 1735 1740
Phe Gly Glu Leu Asn Ser Lys Trp Lys Asp Ile Pro Ile Gly Gln Ile
1745 1750 1755 1760
Arg Ile Gln Asn Phe Glu Ile His Ala Tyr Arg Arg Ile Gly Val Asn
1765 1770 1775
Ser Thr Ala Cys Tyr Lys Ala Leu Glu Met Leu Ser Val Leu Thr Arg
1780 1785 1790
Phe Met Ser Asn Pro Ala Gly Ala Leu Phe Leu Gly Glu Gly Ala Gly
1795 1800 1805
Ser Met Leu Val Thr Tyr Arg Ala Phe Ile Pro Phe Lys Arg Ile Tyr
1810 1815 1820
Tyr Asn Ser Gly Val Ser Ile Gln Asn Ile Gln Ser Gln Arg Glu Leu
1825 1830 1835 1840
Ser Leu Tyr Pro Ser Glu Val Ala Leu Val Asp Asn Lys Asn Arg Leu
1845 1850 1855
Thr Ser Asp Pro Asp Ile Lys Val Leu Phe Asn Gly Lys Pro Glu Ser
1860 1865 1870
Thr Trp Val Gly Asn Ile Asp Cys Phe Ala Tyr Ile Leu Ser His Ile
1875 1880 1885
Glu Thr Ser Ser Leu Thr Leu Ile His Ser Asp Ile Glu Ser Ser Leu
1890 1895 1900
Ser Lys Thr Lys Asn Lys Ile Leu Glu Glu Leu Cys His Ile Leu Ser
1905 1910 1915 1920
Met Ala Leu Ile Leu Gly Lys Ile Gly Ser Val Leu Val Ile Lys Leu
1925 1930 1935
Leu Pro Arg Val Gly Asp Tyr Thr Tyr Ser Phe Cys Lys Tyr Ala Ser
1940 1945 1950
Glu Phe Tyr Gln Gln Asn Phe Phe Ile Leu Pro Arg Phe Ser Asn Met
1955 1960 1965
Ser Ser Ser Glu Ile Tyr Tyr Val Gly Val His Leu Asn Thr Asn Arg
1970 1975 1980
Leu Val Asp Pro Asp Arg Ile Val Gln Tyr Ile Ile Arg Asn Leu Gln
1985 1990 1995 2000
Ser Thr Pro Val Thr Phe Leu Ser Tyr Ile Leu Glu Thr Lys Tyr Arg
2005 2010 2015
Asn Asn Met Val Thr Asn Tyr Gly Leu Cys Leu Ser Asp Gly His Lys
2020 2025 2030
Ser Asp Tyr Leu Ser Ser Ile Thr Lys Ile Glu Asn Val Leu Leu Ser
2035 2040 2045
Cys Gly Leu Glu Leu Asn Gly Pro Lys Ile Ile Gln Gln Leu Ser Gly
2050 2055 2060
His Asp Tyr Ala Asn Gly Glu Ile Ser Leu Glu Ser Ser Ile Met Val
2065 2070 2075 2080
Leu Val Arg Glu Tyr Leu Asn Ala Thr Ile Gln Gly Arg Glu Thr Leu
2085 2090 2095
Gly Leu Phe Ser Pro Tyr Pro Val Leu His Glu Ser Gln Leu Arg Glu
2100 2105 2110
Ile Asn Arg Cys Ile Ala Leu Lys Tyr Val Val Tyr Leu Leu Phe Tyr
2115 2120 2125
Ser Thr Ser Val Gly Ser Ser Arg Gln Ile Met Ser Asn Leu Arg Lys
2130 2135 2140
Gly Val Leu Met Tyr Asp Leu Arg Asp Glu Phe Phe Met Glu Arg Leu
2145 2150 2155 2160
Ser Thr Asn Phe Lys Lys Lys Ile Met Ser Gln Glu Val Lys Thr Thr
2165 2170 2175
Trp Ile Phe Asn Ile Asp Val Pro Thr Arg Lys Ala Leu Tyr Lys Leu
2180 2185 2190
Val Gly Tyr Ser Leu Ile Ile Asn His Val
2195 2200

Claims (14)

1.一种分离的核酸分子,所述核酸分子具有任一种选自以下的核苷酸序列:(a)如SEQID NO:1或SEQ ID NO:8所示的核苷酸序列;(b) 编码具有如氨基酸序列SEQ ID NO:2所示的多肽的核苷酸序列;或者(c)(a)和(b)的所述核苷酸序列中的任一者的互补链。
2.一种副粘病毒(Paramyxovirus),所述副粘病毒的基因组由与如SEQ ID NO:1或SEQID NO:8所示的核苷酸序列互补的核糖核酸组成。
3. 一种以保藏编号CNCM I-5123保藏的副粘病毒(Paramyxovirus)。
4.一种载体,其包含如权利要求1的核酸分子。
5.一种宿主细胞,其包含如权利要求4的载体。
6. 一种分离的多肽,其具有如SEQ ID NO:2所示的副粘病毒的氨基酸序列。
7.一种免疫原性组合物或疫苗,其包含灭活形式的如权利要求3的副粘病毒,及可选地医药学上可接受的载剂或赋形剂。
8.如权利要求7的免疫原性组合物或疫苗,进一步包含佐剂。
9.如权利要求7或8的免疫原性组合物或疫苗在制备对猫进行免疫接种以抵抗猫中由副粘病毒引起的临床疾病的试剂盒中的用途。
10.如权利要求7或8的免疫原性组合物或疫苗在制备对猫进行免疫接种以降低猫中由副粘病毒引起的一或多个临床征象的发病率或严重程度的试剂盒中的用途。
11.如权利要求9的用途,其中所述由副粘病毒引起的临床疾病为猫泌尿生殖系统感染。
12.如权利要求10的用途,其中所述由副粘病毒引起的一或多个临床征象为猫泌尿生殖系统感染。
13. 一种试剂盒,其用于对猫进行疫苗接种以抵抗猫中由副粘病毒引起的临床疾病,该试剂盒包含:(a) 能够向猫施用疫苗的配送器;及(b) 如权利要求7或8的免疫原性组合物或疫苗,及(c) 可选的说明书小册子。
14. 一种试剂盒,其用于降低猫中由副粘病毒引起的一或多个临床征象的发病率或严重程度,该试剂盒包含:(a) 能够向猫施用疫苗的配送器;及(b) 如权利要求7或8的免疫原性组合物或疫苗,及(c) 可选的说明书小册子。
CN201780050005.7A 2016-08-25 2017-08-24 新颖的副粘病毒及其用途 Active CN109563491B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16185761.0 2016-08-25
EP16185761 2016-08-25
PCT/EP2017/071392 WO2018037100A1 (en) 2016-08-25 2017-08-24 New paramyxovirus and uses thereof

Publications (2)

Publication Number Publication Date
CN109563491A CN109563491A (zh) 2019-04-02
CN109563491B true CN109563491B (zh) 2024-02-13

Family

ID=56802335

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780050005.7A Active CN109563491B (zh) 2016-08-25 2017-08-24 新颖的副粘病毒及其用途

Country Status (13)

Country Link
US (2) US11173203B2 (zh)
EP (1) EP3504325B1 (zh)
JP (2) JP6868107B2 (zh)
KR (1) KR20190042062A (zh)
CN (1) CN109563491B (zh)
AR (1) AR110626A1 (zh)
AU (1) AU2017317572B2 (zh)
BR (1) BR112019003797A2 (zh)
CA (1) CA3031861A1 (zh)
EA (1) EA201990539A1 (zh)
MX (1) MX2019002134A (zh)
TW (1) TW201818961A (zh)
WO (1) WO2018037100A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3504325B1 (en) * 2016-08-25 2024-07-03 Boehringer Ingelheim Vetmedica GmbH New paramyxovirus and uses thereof
AU2019223768A1 (en) * 2018-02-23 2020-08-27 Boehringer Ingelheim Animal Health USA Inc. Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom
WO2023230598A2 (en) * 2022-05-27 2023-11-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Reverse genetics system for feline morbillivirus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013107290A1 (en) * 2012-01-20 2013-07-25 The Government of the Hong Kong Special Administrative Region of the People's Republic of China A novel paramyxovirus and uses thereof
JP2015198654A (ja) * 2014-04-01 2015-11-12 共立製薬株式会社 新規ネコモルビリウイルス株、不活化ワクチン製剤、並びにネコモルビリウイルス感染症予防方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1670508B1 (en) 2003-02-28 2012-10-24 Trustees Of The University Of Pennsylvania Compositions, methods and kits relating to poxvirus subunit vaccines
EP3504325B1 (en) 2016-08-25 2024-07-03 Boehringer Ingelheim Vetmedica GmbH New paramyxovirus and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013107290A1 (en) * 2012-01-20 2013-07-25 The Government of the Hong Kong Special Administrative Region of the People's Republic of China A novel paramyxovirus and uses thereof
CN104471064A (zh) * 2012-01-20 2015-03-25 中华人民共和国香港特别行政区政府 新型副粘病毒及其用途
JP2015198654A (ja) * 2014-04-01 2015-11-12 共立製薬株式会社 新規ネコモルビリウイルス株、不活化ワクチン製剤、並びにネコモルビリウイルス感染症予防方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Feline morbillivirus, a previously undescribed paramyxovirus associated with tubulointerstitial nephritis in domestic cats;Patrick C Y Woo et al.;《Proc Natl Acad Sci U S A》;20120403;第109卷(第14期);第5435页摘要,第5437页右栏最后4行和第5438页左栏前7行,第5438-5439页讨论第1-3段,表S5 *
Genetic diversity of feline morbilliviruses isolated in Japan;Shoichi Sakaguchi et al.;《Journal of General Virology》;20140701;第95卷(第7期);第1464-1468页 *
Genome characterization of feline morbillivirus from Italy;Maurilia Marcacci er al.;《Journal of Virological Methods》;20160504;第234卷;第160–163页 *
Park,E.S. et al..phosphoprotein [Feline morbillivirus] GENBANK ACCESSION NO. BAP74662.《GENBANK》.2014, *
Patrick C Y Woo et al..Feline morbillivirus, a previously undescribed paramyxovirus associated with tubulointerstitial nephritis in domestic cats.《Proc Natl Acad Sci U S A》.2012,第109卷(第14期), *
phosphoprotein [Feline morbillivirus] GENBANK ACCESSION NO. BAP74662;Park,E.S. et al.;《GENBANK》;20141009;第1页FEATURES *

Also Published As

Publication number Publication date
US11173203B2 (en) 2021-11-16
US20200268875A1 (en) 2020-08-27
CN109563491A (zh) 2019-04-02
EP3504325B1 (en) 2024-07-03
AU2017317572B2 (en) 2023-12-07
JP6868107B2 (ja) 2021-05-12
JP2021072793A (ja) 2021-05-13
WO2018037100A1 (en) 2018-03-01
BR112019003797A2 (pt) 2019-05-21
AR110626A1 (es) 2019-04-17
CA3031861A1 (en) 2018-03-01
KR20190042062A (ko) 2019-04-23
AU2017317572A1 (en) 2019-03-21
US20220125911A1 (en) 2022-04-28
TW201818961A (zh) 2018-06-01
JP2019532667A (ja) 2019-11-14
MX2019002134A (es) 2019-06-20
EA201990539A1 (ru) 2019-09-30
EP3504325A1 (en) 2019-07-03

Similar Documents

Publication Publication Date Title
Kraatz et al. Deletion mutants of Schmallenberg virus are avirulent and protect from virus challenge
Dargeviciute et al. Yeast-expressed Puumala hantavirus nucleocapsid protein induces protection in a bank vole model
EP2851428B1 (en) Porcine torque teno virus vaccines and diagnosis
US20220125911A1 (en) Paramyxovirus and uses thereof
CN110272473B (zh) 甲型流感通用型病毒样颗粒及其制备方法和应用
CN104471064B (zh) 副粘病毒及其用途
JP2012519471A (ja) 北米のイヌにおいて広まっているイヌジステンパーウイルスに基づく免疫原性組成物、ワクチンおよび診断法
Zhang et al. Glycoprotein E2 of classical swine fever virus expressed by baculovirus induces the protective immune responses in rabbits
CN109289047B (zh) 一种通用型h5亚型禽流感亚单位疫苗及其制备方法
Perez et al. A single dose of an MVA vaccine expressing a prefusion-stabilized SARS-CoV-2 spike protein neutralizes variants of concern and protects mice from a lethal SARS-CoV-2 infection
Joshi et al. Protective efficacy of an orf virus-vector encoding the hemagglutinin and the nucleoprotein of influenza A virus in swine
KR20220009960A (ko) 재조합 고전적 돼지 열병 바이러스
Guo et al. Protection of chickens against avian hepatitis E virus (avian HEV) infection by immunization with recombinant avian HEV capsid protein
WO2020128496A1 (en) Peste des petits ruminant virus (pprv) with chimeric n protein and corresponding vaccine
US9249192B2 (en) Infectious genomic DNA clone and serological profile of Torque teno sus virus 1 and 2
CN112111467A (zh) 一种基因vii型新城疫标记疫苗株及其制备方法与应用
CN106497951B (zh) 一种VP2融合基因、重组狂犬病病毒rHEP-rVP2株、构建方法及其应用
EA043331B1 (ru) Новый парамиксовирус и его применение
KR102365039B1 (ko) 부유세포 배양에 적응된 A/ASIA/Sea-97 유전형 구제역 바이러스 백신주 및 이의 제조방법
CA2737378C (en) Vaccines containing canine parvovirus genetic variants
KR101183251B1 (ko) A/Korea/CJ01/09 및 A/swine/Korea/CAN01/04의 유전자를 포함하는 재조합 돼지 신종인플루엔자 A 바이러스 및 이를 포함하는 돼지 인플루엔자 바이러스 백신
RU2708326C1 (ru) Штамм О N2344/Монголия/2017 вируса ящура Aphtae epizooticae типа О для изготовления биопрепаратов для диагностики и специфической профилактики ящура типа О
Tu et al. Construction of expression vectors of capsid proteins from goose parvovirus and investigation of the immunogenicity.
Yan et al. Application of ORF3 Subunit Vaccine for Avian Hepatitis E Virus. Vet. Sci. 2022, 9, 676
KR101753978B1 (ko) 고병원성 조류 인플루엔자(h5n1) 및 뉴캣슬병 바이러스 융합 바이러스 유사 입자 백신 및 이를 이용한 백신

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant